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Among potential value-added fuels and chemicals, fatty acid-based chemicals are 
important due to their wide use in industrial processes and in daily life. Fatty acids 
produced from microbial systems could provide a sustainable supply to replace the 
current costly and unsustainable process using plant oil or animal fat. The oleaginous 
yeast Yarrowia lipolytica naturally possesses moderate lipid production capacity and 
grows on different kinds of biomass and organic waste. However, fatty acid production 
from native, un-engineered strains is not economically viable. Therefore, this work 
develops strategies inspired from synthetic biology and metabolic engineering to expand 
the engineering potential of Y. lipolytica — helping to establish this organism as a 
premier platform for industrial-level, high lipid production as well as providing a 
platform for uncovering novel understanding of lipogenesis.  
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To do so, first, novel synthetic promoters and high expression plasmid were 
necessary to achieve the ability to tune gene expression levels inside the cell. We 
developed a hybrid promoter engineering strategy to create a promoter library exhibiting 
a range of more than 400-fold in terms of mRNA levels as well as engineered plasmids 
with regulated centromeric function to achieve a 2.7 fold expression range. Next, a 
rational and evolutionary metabolic engineering approach was coupled with genomic and 
transcriptomic studies to both engineer and understand underlying lipogenesis in this 
organism. Through the engineering efforts, we successfully increased the lipid production 
titer to over 40 g/L in bioreactor as well as identified novel lipogenic enhancers and 
mechanisms. In addition, we identified and characterized a mutant mga2 protein with 
superior lipogenesis enhancing capacity, which can regulate fatty acid desaturation and 
carbon flux inside the cells. Collectively, these studies have facilitated the utilization of Y. 
lipolytica as an industrially relevant microbial lipid production platform and supplied 
novel understanding of its lipogenesis process. The methods and concepts developed here 
can also be adapted to other oleaginous microbes and serve as a template for enabling 
value-added chemical production in other nonconventional organism. 
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Chapter 1: Introduction and Background 
 
1.1 Value-added chemical production in yeast 
Fungal systems possess an extensive track record in biotechnological applications 
such as ethanol fermentation and enzyme production (1-2). Although metabolic 
engineering endeavors over the past 20 years have focused primarily on diverse chemical 
production in Escherichia coli (3-6), this organism is not always an ideal fermentation 
host since it demonstrates relatively low stress tolerance (7), limited post-translational 
modifications, difficulty in expressing complex enzymes such as P450s (2), and a lack of 
subcellular compartments.  In contrast, yeasts often lack these inherent flaws and possess 
favorable attributes such as larger cell sizes (thus simplifying separation),  lower growth 
temperatures, higher pH and by-product tolerances (8), and immunity to phage 
contamination.  Collectively, these advantageous traits encourage the use of yeasts for 
industrial-scale chemical and fuel production. 
 Contemporary metabolic engineering relies on bypassing native feedback 
inhibition, constructing heterologous pathways and general optimization and rewiring of 
metabolic flux. This approach has developed fungal platforms for the production of new 
chemicals such as alcohols, sugar derivatives, organic acid, fats, terpenes, aromatics and 
polyketides (9). This dissertation demonstrates a reproducible methodology used to 
develop a nonconventional yeast, Yarrowia lipolytica, into a premier value-added 
chemical (lipid) production platform. In particular, this feat is accomplished through 
expanding the control over gene expression (Chapters 2 and 3), rational and evolutionary 
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metabolic engineering (Chapters 4 and 5) as well as probing novel regulators of 
metabolism (Chapter 6). Chapter 7 provides a brief review of major findings and future 
study recommendations and Chapter 8 contains comprehensive description of materials 
and methods.  
Figure 1.1 Metabolic map for value-added chemical production in yeast 
Examples of value-added chemicals produced in yeast production systems showing with 
simplified biosynthesis pathways. 
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1.2 Metabolic engineering for microbial production  
The goal of metabolic engineering is to rewire metabolic flux inside cells toward 
desired phenotype, typically using recombinant DNA technology. Since native 
microorganisms often inefficiently produce value added chemicals or consume different 
types of feedstock like lignocellulose, metabolic engineering can be used to enhance 
these capabilities or even create novel functions. This methodology has enabled the 
microbial production of various value-added chemicals such as short chain alcohols  (10), 
fatty acids (11), terpenoids (12), opioids (13) and artemisinic acid precursors (14). There 
are two basic requirements to successfully apply metabolic engineering for value-added 
chemical production: (1) the ability to manipulate gene expressions and (2) a basic 
understanding of the biosynthesis process. There are still numerous challenges associated 
with both requirements currently, especially when working with non-model organisms or 
poorly understood biosynthetic pathways.  
 
1.2.1 Promoter and plasmid engineering for gene expression 
Manipulation of cellular gene expression can be achieved by using genetic 
toolboxes, which can be used to facilitate engineering efforts.  Genetic engineering 
techniques such as genomic integrations, gene-knockouts, and gene-knockdowns as well 
as engineering of genetic components such as plasmids, promoters, and terminators 
enable control over gene expression. Specifically in this work, we used promoter and 
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plasmid engineering to develop effective means for manipulating gene expression in Y. 
lipolytica. 
Promoter engineering is an efficient means to tune gene expression since 
endogenous promoters do not fully sample the complete continuum of transcriptional 
control (15). Synthetic control of gene expression is critical for metabolic engineering 
efforts since precise control of key pathway enzymes (heterologous or native) can help 
maximize product formation. To this end, several studies have developed techniques for 
engineering promoters for desired expression characteristics. For instance, mutagenesis-
based promoter engineering has been used to create a library of mutants that could be 
screened for those with desirable expression levels (16). Recently, a hybrid-promoter 
engineering strategy was developed which paired multiple UAS sequences from one 
native promoter with a different core promoter (17). Moreover, novel design of synthetic 
yeast promoters has also been accomplished by tuning promoter sequences to alter 
nucleosome architecture (18). These methods enabled the creation of different promoters 
with a wide range of strength and properties. However, most of these promoters were 
developed for model organisms such as S. cerevisiae. In order to unleash the microbial 
production potential of non-conventional yeasts like Y. lipolytica, such tools need to be 
developed for use in those organisms. In the work presented in Chapter 2, a hybrid 
promoter engineering strategy was developed and implemented in Y. lipolytica to greatly 
expand the ability for tuning gene expression in this yeast. 
In addition to engineering of promoters, altering plasmid design can function as a 
convenient means for tuning expression. In S. cerevisiae, plasmid-based control of gene 
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expression is achieved by using varieties of plasmids such as centromeric (CEN) 
plasmids (low copy), 2-micron plasmids (high copy), and autonomously replicating 
sequence (ARS) plasmids (high copy) (19-21) that possess different properties. However, 
in Y. lipolytica, there is only CEN plasmid available. In the work presented in Chapter 3, 
an alternative route to enable plasmid level gene expression control in Y. lipolytica was 
enabled through developing a high expressing plasmid by repressing centromeric 
function. This tuning ability on plasmid added another level of control over gene 
expression in this yeast. 
 
1.2.2 Rational and evolutionary metabolic engineering 
Rational metabolic engineering refers to such engineering efforts which select 
enzymes, transporters, or regulatory proteins as targets for genetic manipulation based on 
available information regarding the pathways, enzymes, and regulation associated with 
generating the product of interest. Rational metabolic engineering has been fairly 
successful in various applications including the production of antimalarial drug precursor 
artemisinic acid (14), the industrially versatile commodity chemical phenol (22), and 
medically essential opioids (13). Common strategies used in rational metabolic 
engineering include by-product elimination, precursor enrichment, rerouting metabolic 
pathways and cofactor optimization (5). These approaches have been very efficient when 
utilized to enable the production of various chemicals in different microbial hosts (23-26). 
By engineering the precursor biosynthesis pathways, riboflavin production was 
significantly improved in Ashbya gossypii (27). In addition, optimization of co-factor 
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supply and precursor production enabled α-santalene overproduction in S. cerevisiae (28). 
Furthermore, inhibition of hydrocarbon accumulation in cyanobacteria has led to 
improved production of fatty alcohols in these organisms (29). Chapter 4 describes our 
efforts to utilize rational metabolic engineering techniques to systematically engineer Y. 
lipolytica for high lipid production, which achieved a genetic background capable of at a 
titer of over 25 g/L. 
Although rational metabolic engineering has demonstrated successful in 
numerous applications, manipulating only rational targets can be less successful than 
predicted or even demonstrate detrimental effects. This arises due to an incomplete 
understanding of the complex global metabolic network, which prevents the anticipation 
of every consequence of a genetic modification. Evolutionary metabolic engineering, 
often associated with multiple cycles of random genetic perturbation and selection, can 
be very effective in overcoming this challenge by identifying phenotypically 
advantageous variants (30-32). This approach has been successfully implemented to 
rapidly provide strains with complex desired phenotypes such as improved galactose and 
xylose catabolism in S. cerevisiae (30, 33), increased isobutanol, succinate, and L-
tyrosine production in E. coli (31, 34-35),  as well as riboflavin production in Candida 
famata (36). If a working selection method accompanied with techniques for screening 
and/or enrichment has been developed, evolutionary engineering can provide a powerful 
complimentary method to rational metabolic engineering. In the work presented in 
Chapter 5, an evolutionary metabolic engineering strategy was developed and successful 
implemented which further increased lipid production in Y. lipolytica. This provided a 
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strain able to achieve a lipid titer of over 40 g/L, which represents a 60% improvement 
over the strain generated using rational metabolic engineering alone, without sacrificing 
productivity or yield. Moreover, implementing inverse metabolic engineering with strains 
developed using evolutionary metabolic engineering to identify the genetic basis for the 
differing phenotypes provided novel understandings as well as additional engineering 
targets. This can be achieved by using next generation sequencing to resolve strain 
differences that arise from evolutionary engineering.  
  
1.2.3 Next generation sequencing analysis in metabolic engineering 
 Analysis of evolutionary engineering efforts through next generation sequencing 
(NGS) can reveal the detailed genomic and transcriptomic information within these 
strains. This can then be utilized to identify beneficial mutations and identify novel 
underlying cellular mechanisms. The rapid advances in next generation sequencing 
technology has greatly enhanced genomic approaches, providing new potential for 
evolutionary engineering and inverse metabolic engineering successes (37). NGS usually 
refers to non-Sanger-based high-throughput DNA sequencing technologies including 
Illumina sequencing, Roche 454 sequencing, SOLiD sequencing, etc. Millions or billions 
of DNA strands can be sequenced in parallel, substantially improving sequencing 
throughput and minimizing the need for fragment-cloning methods that are often 
necessary for sequencing genomes using Sanger sequencing (38). Illumina sequencing is 
the most popular sequencing technique used for omic studies such as whole genome 
sequencing (WGS) and RNA-Seq. Utilization of both of these techniques can be very 
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informative in the application of metabolic engineering for microbial production of 
value-added chemicals.  
 WGS provides access to the information coded in the genome of a 
microorganism, which enhances our understanding of the organism, enabling metabolic 
engineering endeavors. This information is commonly used for genome mining to 
identify novel enzymes and pathways. Additionally, this can probe genotype-phenotype 
linkage to identify changes at the genome level present in strains demonstrating a 
superior phenotype, which can be used for identifying targets for inverse metabolic 
engineering. A recent WGS study revealed the enriched difference in cAMP pathway 
genes by comparing a model stain for modern industrial biotechnology, S. cerevisiae 
CEN.PK113-7D, with another strain S288C. Moreover, beneficial mutations have been 
identified through WGS approaches with improved galactose utilization as well as 
improving heat tolerance in S. cerevisiae (39-40). The work presented in Chapters 5 and 
6 describes the implementation of WGS analysis to identify beneficial mutations, which 
arose from evolutionary engineering and random mutation, to enhancing understanding 
of lipogenesis in Y. lipolytica. 
Although WGS reveals detailed genomic information, RNA-Seq experiments can 
analyze the cellular transcriptome which provides substantial information regarding to the 
cellular metabolic state. RNA-Seq is especially useful when working with non-
conventional microorganisms since standard microarrays are not available for many of 
these organisms. More importantly, RNA-Seq supplies more information compared to 
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traditional methods such as alternative splicing (41), differential isoform expression (42), 
and promoter usage (43). It can also enable a more precise comparison of the expression 
level of different genes within samples in addition to the differential gene expression 
resulting from different samples/conditions. A recent study using RNA-Seq analysis to 
investigate host-strain dependency for xylose utilization in recombinant S. cerevisiae 
strains identified important transcription factors (44). Another study of Hansenula 
polymorpha transcriptome identified abundant and highly upregulated expression of 40% 
of the genome in methanol grown cells, and revealed alternative splicing events (45). 
Chapters 5 and 6 describe transcriptomic analysis employed to unveil relevant 
mechanisms present in high lipogenic strains. 
  
1.3 Yarrowia lipolytica as a microbial production host for lipid production 
Recently, there has been a surge in the types of microbially-derived oleochemicals 
produced (46-48), including alkanes (46), alkenes (49-50), fatty alcohols (51), and fatty 
esters (25, 51)  as well as polyunsaturated fatty acids (52). However, most of these efforts 
still suffer from low titers largely in part from the choice of the cellular host, typically E. 
coli. Alternatively, oleaginous organisms, such as the fungus Y. lipolytica, could serve as 
a more ideal host due to higher innate lipogenesis potential. Y. lipolytica is increasingly 
being recognized as promising hosts for the production of valuable compounds (53). It is 
a unique host for biochemical production and heterologous protein excretion on account 
of its abilities to accumulate high levels of lipids (54-56), overproduce organic acids (23-
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24, 57-58), utilize hydrophobic and waste carbon sources (59-61), and secrete native and 
heterologous proteins at high levels (62-64). The availability of Y. lipolytica’s genome 
sequence (65-66) along with basic genetic tools such as transformation methods (67-69), 
gene knockouts (70), and both episomal (68, 71-73) and integrative expression cassettes 
(74-75) enable metabolic engineering approaches.  
 
1.3.1 Lipid biosynthesis in Y. lipolytica 
Lipid biosynthesis in Y. lipolytica starts from taking glucose into the cells 
followed by glycolysis pathway and TCA cycles. After that, accumulated citrate in 
mitochondria gets transported out into cytosol and then feed into fatty acid/lipid 
biosynthesis pathways (Figure 1.2). Lipid biosynthesis here is thought to be initiated by 
the activity of four enzymes - AMP deaminase (AMPD), ATP-citrate lyase (ACL), malic 
enzyme (MAE) and acetyl-CoA carboxylase (ACC) - that collaboratively divert carbon 
flux from central carbon metabolism towards fatty acid biosynthesis (56, 76). Previous 
efforts to increase lipid accumulation have shown promise in Y. lipolytica. Deletion of β-
oxidation enzymes coupled with enhancing glycerol synthesis substantially increases ex 
novo lipid accumulation (56, 76), and deletion of the pex10 peroxisomal biogenesis gene 
greatly increases eicosapentaenoic acid yield (24).  Although there is success from the 
previous engineering efforts, the resulted production is still below the ideal performances. 
The de novo lipid content in this organism has been limited to below around 60% by dry 
cell weight (23). Therefore, further action is required to develop Y. lipolytica for higher 
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lipid production. In the work presented in Chapters 4, 5 and 6, we successfully increased 
the lipid production metrics in Y. lipolytica.  
 
Figure 1.2 Simplified scheme of lipid metabolism in Y. lipolytica 
 
Simplified lipid metabolism in Y. lipolytica showing carbon flux through glycolysis, TCA cycles 
and fatty acid and lipid biosynthesis. 
 
1.3.2 Current challenges for high lipid production in Y. lipolytica 
As a nonconventional oleaginous yeast, Y. lipolytica presents an exciting starting 
point to be developed into a microbial lipid production host. However, the lack of control 
over gene expression, the insufficient lipid production performance and the incomplete 
understanding over its lipogenesis processes significantly hampered its industrial 
potential. In the work, we first used promoter and plasmid engineering efforts to enable a 
high level control over gene expression in Y. lipolytica (Chapters 2 and 3). Then we 
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employed rational and evolutionary metabolic engineering to develop Y. lipolytica into a 
high lipid production host and in the same time, we supplied novel understanding over 
lipogenesis process (Chapters 4 and 5). Lastly, we identified and analyzed a novel 
lipogenesis regulator, a mutant mga2 protein, which expand the limited knowledge of 
complex regulation of lipid production (Chapter 6).  
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Chapter 2: Hybrid promoter engineering in Yarrowia lipolytica
1
 
2.1 Chapter summary 
 The development of strong and tunable promoter elements is necessary to enable 
metabolic and pathway engineering applications for any host organism. In this chapter, 
we have expanded and generalized a hybrid promoter approach to produce libraries of 
high-expressing, tunable promoters in the nonconventional yeast, Yarrowia lipolytica to 
enable the gene expression manipulation in this yeast. These synthetic promoters are 
comprised of two modular components—the enhancer element and the core promoter 
element. By exploiting this basic promoter architecture, we have overcome native 
expression limitations and provided a strategy for both increasing native promoter 
capacity and producing libraries for tunable gene expression in a cellular system with ill-
defined genetic tools.  In doing so, the work presented in this chapter has created the 
strongest promoters ever reported in Y. lipolytica. Furthermore, we have characterized 
these promoters at the single-cell level through the use of a developed fluorescence based 
assay as well as at the transcriptional and whole-cell level. The resulting promoter 
libraries exhibited a range of more than 400 fold in terms of mRNA levels, and the 
strongest promoters in this set had eight-fold higher fluorescence levels compared with 
typically used endogenous promoters. These results suggest that promoters in Y. 
lipolytica are enhancer limited and this limitation can be partially or fully alleviated 
                                                          
1
 Portion of this chapter has been published previously in AEM, 77(22), 7905-7914 with JB, LL, HR, HA designed and carried the 
experiments. 
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through the addition of tandem copies of upstream activation sequences (UAS).  Finally, 
the results from this chapter illustrates that tandem copies of UAS regions can serve as 
synthetic transcriptional amplifiers that may be generically used to increase the 
expression level of promoters.  
 
2.2 Introduction 
Developing and establishing a comprehensive suite of promoter elements in 
organisms with poorly defined genetic tools is essential for enabling metabolic and 
pathway engineering applications. To this end, the oleaginous yeast Yarrowia lipolytica 
has received attention as a potential biofuels producing host, yet lacks genetic tools for 
tunable and high level gene expression. In other organisms, prior attempts of promoter 
engineering relied on modifying the expression range of endogenous promoters through 
point mutations.  As an example, error-prone PCR of the native Saccharomyces 
cerevisiae TEF promoter yielded a library of mutant promoters with a nearly seventeen-
fold range in relative expression strength (77). A similar approach in E. coli led to a 
nearly eighteen-fold range in relative expression strength based on the heterologous Pl-
lambda promoter (16).   An alternative strategy aimed at tuning intergenic regions in 
heterologous Escherichia coli operons enabled a seven-fold improvement in pathway 
throughput and was used to prevent the accumulation of a toxic intermediate (78).  While 
successful, these methods and applications are quite limited by: (1) their reliance on a 
strong, well-defined starting core promoter and (2) the tendency of alterations to result in 
15 
 
expression levels lower than these baselines.  These limitations present a challenge for 
creating a dynamic range of promoters with similar regulation in a novel organism 
without highly characterized strong promoter elements. 
Beyond point mutations, the generation of hybrid promoters has been previously 
successful in significantly augmenting promoter architecture and function (79-81).  Most 
of these approaches attempt to create synthetic hybrid promoters by fusing an upstream 
activating sequence (UAS) to a separate (often minimal) core promoter region.  The 
result is a functional UAS-core promoter chimera.  In this construct, the UAS regulatory 
site enhances gene expression by localizing trans-acting regulatory elements 
(transcription factors). As a result, this approach raises the possibility to uniquely 
engineer promoters as two independent, synthetic parts—activating regions and core 
regions. In this chapter, we present a generalizable approach of hybrid promoter 
engineering for the construction of both very high-strength promoters and tunable 
promoter libraries in the non-conventional, oleaginous yeast host Y. lipolytica. 
 Although Y. lipolytica is a promising production host, many of the methods in 
this organism rely on ill-defined genetic elements (60) especially in the area of promoters.  
One of the strongest promoters in Y. lipolytica, the XPR2 promoter (pXPR2) has complex 
requirements for induction that hinders its industrial applications (82). Nevertheless, this 
promoter has been functionally analyzed to reveal a 105 base pair distal UAS fragment 
named UAS1B (83-84). Previously, between one to four tandem UAS1B copies were 
fused to a core minimal LEU2 promoter to create four increasingly strong hybrid chimera 
promoters, named hp1d through hp4d (82).  As a result, the hp4d promoter has become a 
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commonly used tool for heterologous protein expression in Y. lipolytica.  A further re-
analysis of these four promoters revealed a linear increase of promoter strength as a 
function of number of tandem UAS1B elements which raises the possibility of further 
improvements.   
Specifically, in this chapter, we describe the development of a generic, hybrid 
promoter approach for creating synthetic, tunable promoters.  Furthermore, these results 
demonstrate that the activating regions and core regions can act as independent synthetic 
parts to create a hybrid promoter.  In particular, we construct and characterize two 
libraries of synthetic hybrid promoters: a UAS1B-leum library in which between one and 
thirty two UAS1B elements are fused to the minimal LEU2 promoter region and an 
UAS1B8/16-TEF library in which eight or sixteen tandem UAS1B elements are fused to 
varying sized TEF promoter regions.  In doing so, this work creates the strongest 
characterized promoters in Y. lipolytica and the first ever reported capacity for tunable 
gene expression in this system.  Moreover, this work establishes synthetic hybrid 
promoter construction as a generic approach for promoter engineering to expand and 
enhance the strength of engineered promoters in a manner not accessible through 
traditional promoter engineering applications.   
 
2.3 Results  
2.3.1 Characterization of endogenous promoters at the single-cell level 
Prior studies of promoter strength in Y. lipolytica have relied on assaying whole 
cultures for protein expression level (using reporters such as β-galactosidase) (62, 82).   It 
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is commonly known that these methods can mask potential bimodal “on/off” distributions 
within the population.  Thus, to avoid this complication, we sought to utilize a 
fluorescence-based assay using the Y. lipolytica plasmid pSl16-Cen1-1(227) (85).  All 
results generated in this chapter, except where indicated, employed derivatives of this 
replicative, ARS-CEN based plasmid. Since codon biases are known to limit translation 
in Y. lipolytica (86) and no fluorescent reporter protein has been previously used in Y. 
lipolytica to gauge promoter strength, we initially evaluated several available fluorescent 
reporter proteins. The TEF promoter was coupled to four different fluorescence genes 
including yECitrine, EGFP, hrGFP and mStrawberry and flow cytometry was performed 
to determine reporter functionality.  Of these variants, only hrGFP imparted detectable 
fluorescence (Figure 2.1a).  This gene, optimized for expression in mammalian cells, has 
the highest Codon Adaptation Index for Y. lipolytica of the four fluorescence genes (87),  
indicating the closest compatibility with codon usage frequencies for this organism.  
As a result, the hrGFP reporter gene was used to evaluate the promoter strength of 
seven previously identified endogenous Y. lipolytica promoters—TEF, EXP, FBA, GPAT, 
GPD, YAT, and XPR2 (Table 2.1, Figure 2.1b) (62, 88-89).  Based on this analysis, the 
relative ordering of promoters strengths is EXP > TEF > GPD > GPAT > YAT > XPR2 > 
FBA.  The low mean fluorescence values of even the strongest of these native promoters, 
EXP and TEF, highlight that even strong endogenous promoters in Y. lipolytica may be 
too low for metabolic engineering purposes.  When each of these promoters was used in a 
plasmid-based construct, a bimodal fluorescence distribution was seen.  Based on prior 
reports to further improve the expression strength, a consensus four nucleotide “caca” 
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sequence 5’ of the +1 ATG codon was included (86, 90-92); however, this inclusion was 
found to be detrimental to expression levels in most cases (data not shown).  The 
differential regulation patterns and small dynamic range of these endogenous promoters 
require a novel approach to enable metabolic engineering applications in this organism. 
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Figure 2.1 Fluorescence based assay for endogenous promoter characterization   
Figure 2.1a 
 
Figure 2.1b 
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Figure 2.1 cont. 
 
(A) The relative fluorescence levels of yECitrine, mStraw, EGFP and hrGFP driven by the TEF 
promoter in Yarrowia lipolytica were tested with flow cytometry and mean fluorescence from 
different fluorescent protein were presented for comparison.  These results indicate that hrGFP 
was the only functional fluorescent protein for this system.  (B)  Endogenous promoters including 
EXP, TEF, GPD, GPAT, YAT, XPR2, and FBA were used to drive the expression of hrGFP.  
The mean fluorescence data was collected with flow cytometry analysis for comparison. Error 
bars represent standard deviation from biological replicates.  The EXP and TEF promoters were 
identified as the strongest among this tested set. 
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Table 2.1 Promoter elements used in hybrid promoter engineering 
Promoter 
element name 
Open reading frame regulated YALI number Basepair 
range 
Reference 
number 
EXP1 Export protein YALI0C12034p -999 to -1 (89) 
GPAT Glycerol-3-phosphate 
dehydrogenase 
YALI0C00209p -1130 to -1 (89) 
GPD Glyceraldehyde-3-phosphate 
dehydrogenase 
YALI0C06369p -931 to -1 (89) 
TEF Translation elongation factor EF-1α YALI0C09141p -406 to -1 (89) 
YAT1 Ammonium transporter YALI0E27203p -775 to -1 (89) 
FBA Fructose-bisphosphate aldolase YALI0E26004p -830 to 
+171 
(89) 
XPR2 Alkaline extracellular protease YALI0E26719p -947 to -1 (82) 
TEF(136) Translation elongation factor EF-1α YALI0C09141p -136 to -1 This chapter 
TEF(203) Translation elongation factor EF-1α YALI0C09141p -203 to -1 This chapter 
TEF(272) Translation elongation factor EF-1α YALI0C09141p -272 to -1 This chapter 
TEF(504) Translation elongation factor EF-1α YALI0C09141p -504 to -1 This chapter 
TEF(604) Translation elongation factor EF-1α YALI0C09141p -604 to -1 This chapter 
TEF(804) Translation elongation factor EF-1α YALI0C09141p -804 to -1 This chapter 
TEF(1004) Translation elongation factor EF-1α YALI0C09141p -1004 to -1 This chapter 
Leum β-isopropylmalate dehydrogenase YALI0C00407p -92 to +25 (82) 
UAS1B Alkaline extracellular protease YALI0E26719p -805 to -
701 
(82) 
 
 
2.3.2 Creating and characterizing a hybrid promoter series using the UAS1B 
element and minimal leucine core promoter 
To bypass the limitations of endogenous promoters in Y. lipolytica, we evaluated 
the generalizable nature of hybrid promoters comprised of fused upstream activating 
sequences with a minimal core promoter.  In prior work, a nearly perfect positive linear 
correlation was detected between the number of tandem UAS1B sequences and promoter 
outputs in the hp1d to hp4d promoter series (82).  This observation led to our hypothesis 
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that these minimal core promoters and potentially other Y. lipolytica full-length, native 
promoters are enhancer limited.  To address this limitation, we created an expanded 
series of hybrid promoters by fusing between one and thirty two tandem UAS1B 
enhancer sequences to the leucine minimal promoter (Leum) to form promoters UAS1B1-
Leum through UAS1B32-Leum (Figure 2.2a). The newly constructed UAS1B-Leum 
promoter series was tested with hrGFP based flow cytometry analysis.  The fluorescence 
data displayed several domains for correlation between output fluorescence and the 
number of upstream UAS elements.  Initially, an exponential increase in fluorescence 
was seen as UAS1B sequence count increased from one to eight.  This trend became 
linear through nineteen tandem repeats (a total of 1995 bp of upstream activating 
sequences upstream of the core promoter).  Finally, the output fluorescence seemed to be 
saturated through 32 tandem UAS1B repeats (Figure 2.2b).  This data strongly 
conformed to a Hill Cooperative Binding model (correlation coefficient of 0.95) and 
exhibited a high Hill Constant (3.889) which indicates a strong amount of binding 
cooperativity of the enhancer elements (Figure 2.2b).  Specifically, this data was fit to 
the equation: 
 
 with the resulting coefficients of  a= 0.794, Hill Coefficient= 3.889, and c= 10.146.  As 
with the prior tests using endogenous promoters, these plasmid-based expression 
cassettes showed a bimodal distribution of fluorescence levels.  However, when these 
cassettes were integrated into the genome, these promoters gave a singular, high 
expression peak which indicates that the bimodal nature was conceivably due to episomal 
tCoefficien HilltCoefficien Hill
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expression issue related to this organism.  These integrative expression cassettes 
generated roughly two-fold higher fluorescence values than their corresponding 
replicative-based cassettes (data not shown). 
2.3.3 Transcriptional analysis of the UAS1B-leum hybrid promoter series 
A transcriptional analysis was performed to confirm that the observed effect in 
fluorescence was indeed manifested at the transcriptional level.  To do so, qRT-PCR 
analysis was employed using the hrGFP mRNA of select promoter constructs (Leum, 
UAS1B4-Leum, UAS1B8-Leum, UAS1B16-Leum, UAS1B24-Leum, and UAS1B32-Leum) 
(Figure 2.2c).  Expression values were normalized to the mRNA level seen with only the 
minimal leucine promoter used to drive hrGFP.  Indeed, the increase in mean 
fluorescence levels was strongly correlated with the increase in relative mRNA levels.  
The relative mRNA levels increased and likewise plateaued for constructs with a high 
number of UAS1B repeats.  Moreover, these results demonstrate an extraordinary range 
of promoter strength in this series with more than a 400 fold dynamic range of transcript 
level between the minimal promoter and strongest promoters in this set.  
2.3.4 Utility and stability of the UAS1B-leum hybrid promoter series 
To ensure that the observed effect was independent of reporter gene, we sought to 
provide a further characterization of the UAS1B-Leum promoter series with a separate 
reporter gene, the β-galactosidase gene encoded by E. coli lacZ.  Select promoter 
constructs (including the endogenous TEF, EXP, and XPR2 promoters as well as hybrid 
UAS1B-leum constructs containing 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 28, and 32 UAS1B 
copies) were used to construct expression cassettes with lacZ in place of hrGFP.  β-
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galactosidase assays were performed as described previously (93-94) with a maximum 
value of 1198 miller units generated by the UAS1B28-leum construct (Figure 2.2d).  
Promoter strength increased with increasing UAS1B copy number up through 32 UAS1B 
repeats unlike in the hrGFP assay. However, the β-galactosidase assay results matched 
well with the hrGFP analysis and the data showed a strong positive statistical correlation 
(r
2
=0.85).  These results demonstrate that the UAS1B-leum hybrid promoter series 
developed here is a generic tool for obtaining tuned gene expression in Y. lipolytica.   
 These hybrid promoters rely on a high number of tandem repeats, thus, genetic 
stability was evaluated.  To accomplish this, selected promoter constructs (with 12 or 16 
repeated UAS1B elements) were tested on the basis of sequence fidelity after non-
selective serial subculturing.  These strains were subcultured for a total of 36 generations.  
After this process, cells were harvested and plasmids were isolated and sequenced to 
assess gene construct stability.  In total, 20 separate plasmids containing the UAS1B12-
Leum and 20 containing the UAS1B16-Leum promoters were evaluated.  17 out of 20 
UAS1B12-Leum and 20 out of 20 UAS1B16-Leum were positively sequence and 
restriction enzyme digest confirmed after 36 doublings.  Thus, these promoters are 
suitably stable in Y. lipolytica for long-term expression and use.   Collectively, this data 
suggests that the expression output from hybrid promoters can be altered by changing the 
number of activating regions with a given core promoter region.  Next, we sought to 
address the ability to alter the core promote region of this construct. 
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Figure 2.2 Developing and characterizing a UAS1B-Leum hybrid promoter set 
Figure 2.2a 
 
 
 
 
 
 
Figure 2.2b 
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Figure 2.2 cont. 
Figure 2.2c 
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Figure 2.2 cont. 
Figure 2.2d 
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Figure 2.2 cont. 
 
(A) A schematic diagram for UAS-enabled hybrid promoter engineering illustrates that these 
promoters were created from two distinct parts—the core promoter and upstream activation 
sequence (UAS) elements. By inserting tandem copies of UAS upstream to the core promoter, 
fine-tuned promoter sets with the strongest expression levels seen in Y. lipolytica were created.  
(B) The tandem insertion of 1 to 32 copies of UAS1B sequences upstream of a minimal LEU 
promoter enabled construction of the UAS1B1-Leum to UAS1B32-Leum promoters. Error bars 
represent standard deviation from biological triplicates. The relative promoter strengths of 
UAS1B-Leum promoters were fit to the Hill equation:  
  
 
resulting in a= 0.794, Hill Coefficient= 3.889, c= 10.146 and r
2
= 0.9495 using Polymath Software 
(Willimantic, CT).  (C) Transcriptional profiling of select promoter constructs was used to 
calculate mRNA levels relative to the minimal Leum promoter.  Expression profiles matched 
fluorescence data.  Error bars represent standard deviation from biological triplicates.  (D) 
Endogenous and hybrid promoters were tested with a β-galactosidase reporter gene, yielding 
similar results to the hrGFP assay. Error bars represent standard deviation from biological 
triplicates. 
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2.3.5 Generalizing the hybrid promoter approach by switching the core promoter 
region 
 As discussed above, a hybrid promoter has two potential independent elements—
activating regions and core promoter region.  The data above suggests that tandem UAS 
elements may serve as movable, synthetic expression amplifiers for a given promoter.  
Next, we sought to test the hypothesis that even native promoters in Y. lipolytica are 
enhancer limited and can be strengthened by adding additional UAS elements.  To do so, 
we constructed new hybrid promoters containing either eight tandem UAS1B sequences 
(UAS1B8) or sixteen tandem UAS1B sequences (UAS1B16) inserted 5’ upstream of a 
series of different TEF-based core promoters.  Specifically, we amplified eight different 
regions of the TEF promoter spanning 136 bp and 1004 bp upstream of the ATG starting 
site from PO1f (82) genomic DNA (Table 2.1).  Included in this set is the consensus 404 
bp TEF promoter for Y. lipolytica as well as lengthened and truncated versions of this 
promoter.  These eight core TEF promoters and their corresponding UAS1B8 and 
UAS1B16 hybrid promoters were tested and compared with the Leum, UAS1B8-Leum 
and UAS1B16-Leum constructs. 
 This new series of hybrid promoters was assayed via hrGFP fluorescence by flow 
cytometry.  In the absence of UAS elements, it can be seen that the fluorescence value 
decreases for truncated promoters below the consensus TEF size as expected.  Moreover, 
the full length (and larger) TEF promoters have more strength than the minimal leucine 
promoter (Figure 2.3a).  The UAS1B8 and UAS1B16 enhancer fragments in isolation do 
not confer any promoter activity (data not shown).  When these enhancer fragments were 
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fused with the TEF promoter elements, a substantial increase in the net promoter strength 
was seen regardless of the TEF variant utilized.  The enhancement provided by UAS1B8 
was roughly half the value obtained by using UAS1B16.  Moreover, these enhancements 
were seen for both more minimal and full length TEF promoter elements, even with the 
existence of naturally occurring UAS elements in the consensus and longer TEF 
promoters.  Thus, this data suggests that even strong endogenous promoters like TEF are 
enhancer limited in Y. lipolytica and their expression capacity can be increased through 
additional UAS elements.   
 The amplification of expression imparted by the UAS1B8 and UAS1B16 enhancer 
elements was not even for all promoters.  The fold increase of the constructs relative to 
the UAS-free TEF core promoters is plotted in (Figure 2.3b).  In general, the largest 
improvement is obtained when the UAS elements are placed most closely 5’ of a core 
promoter region.  This fold improvement trend is rationalized in terms of a mechanism of 
proximity and localization of enhancer elements.  However, it is interesting to note that 
the total promoter size (with 16 activating sequences and a core region) totals upwards of 
3 kbp for many of these promoters—a region that is quite large for typical yeast 
constructs.  In addition, many of these larger constructs were the best performing 
promoters.  Specifically, nearly all of these promoters proved to be stronger than the 
corresponding UAS1B8-Leum and UAS1B16-Leum promoters, demonstrating the fitness 
of the TEF-based core promoter regions for strong hybrid promoter engineering.  In this 
regard, this work demonstrates that tandem UAS elements serve to synthetically amplify 
the expression level imparted by the core promoter element chosen.   
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Figure 2.3 Expanding the hybrid promoter approach by altering the core promoter 
element 
 
Figure 2.3a 
 
Figure 2.3b 
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Figure 2.3 cont.  
 
(A)  The characterization of relative promoter strengths for the core TEF promoters (blue), 
UAS1B8-TEF promoters (red) and UAS1B16-TEF promoters (green) using flow cytometry.  This 
data was compared with the UAS1B8-Leum and UAS1B16-Leum promoters.  (B) The tuning 
ability of UAS1B8 and UAS1B16 decreases as a function of core promoter length.  
33 
 
2.4 Discussion and conclusion 
The work presented in this chapter establishes a synthetic approach for tuning 
gene expression using a hybrid promoter approach.  Moreover, this approach is unique in 
its capacity to up-regulate the expression of the baseline starting promoter unlike most 
traditional approaches that typically generate promoters of decreased expression.  In 
doing so, this work created the strongest known promoters in the oleaginous yeast 
Yarrowia lipolytica and allows for fine-tuned gene expression in this organism.  The 
general strategy developed in this chapter employing tandem UAS repeat elements could 
potentially be applied to other organisms and further generalized by using other UAS 
regions.  Finally, these results have the biological implication that the expression capacity 
for promoters (at least in Y. lipolytica) is enhancer limited.  In this regard, this approach 
expands the quantity and quality of parts available for systems biology research (95-96).   
Using the hrGFP-enabled single-cell analysis, this work observed bimodal 
fluorescence distributions for all the data collected using plasmid based expression.  
These results strongly suggest an “on/off” switch mechanism resulting from the low copy 
CEN-based plasmid used in the study.  It is interesting to note that this bimodal 
distribution was absent when using integrated expression cassette instead.  As a result, 
this work highlights an important consideration for using plasmids in a Y. lipolytica 
system. Nevertheless, the hrGFP analysis allowed for a characterization of endogenous Y. 
lipolytica promoters and identified EXP and TEF as strong promoters among the set 
tested.  Furthermore, this analysis led to the creation of several series of promoter 
elements capable of high-level expression.   
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The magnitude of these hybrid promoters can be seen by the relative mRNA 
range of more than 400 fold between the core promoter (Leum) and the maximum of 
UAS1B24-Leum. The strongest UAS1B-Leum hybrid promoter exhibited a more than 
eight fold increase in promoter strength in terms of Miller units compared to the strong 
endogenous promoters tested in this chapter.  It should be noted that the expression of the 
UAS1B4-Leum reported here were substantially lower than previously reported.  These 
comparisons are difficult due to the slight differences in restriction sites used to create 
these hybrid promoters, the use of rich media in prior reports, and the use of replicative 
plasmids here compared with integrated plasmids in other studies.  Even with these 
difference and discrepancies, this work still presents up to a fourfold increase in 
performance compared with the best reported endogenous promoters or previously 
constructed hybrid promoters (82, 97).  This illustrates that multiple tandem repeats of 
the UAS1B enhancer element activate transcription to levels far stronger than those 
previously described and that this enhancer activation can occur at regions more than 
2000 nucleotides upstream of the start codon (for UAS1B16-32-Leum).   
 The UAS1B8 and UAS1B16 elements were shown to behave as synthetic 
amplifiers when tested with various TEF-based promoters.  In this regard, we 
demonstrated that the ability of a UAS1B element to amplify expression is independent 
of the core promoter element.  However, the magnitude of this amplification was 
dependent on the core promoter used.  Thus, both the choice of tandem enhancer element 
and core promoter element contribute to the collective strength of hybrid promoters.  This 
observation raises the possibility of rationally designing hybrid promoters with specified 
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expression strength.  The drastic increase in expression levels by both of the UAS1B8 and 
UAS1B16 elements across this series demonstrates that these genetic elements are 
portable, modular components that can generically alleviate native enhancer-limitation 
without disrupting endogenous regulation. The modularity of the UAS1B insert and the 
strength of the UAS1B-Leum and UAS1B-TEF series advocate the use of hybrid 
promoter engineering as generic approach towards building stronger, fine-tuned promoter 
libraries with interchangeable, modular components. 
Collectively, these results give credence to the theory that Y. lipolytica promoters 
are enhancer-limited, and we have shown that this limitation can be effectively overcome 
through hybrid promoter engineering.  Tandem UAS elements help bypass the enhancer 
limited nature of promoters by serving as transcriptional amplifiers.  Cells containing the 
strong hybrid promoters developed in this chapter did not exhibit any growth defects.  
Therefore, transcription factor availability does not seem to be limiting for these cells as 
these promoters did not seem to deplete or starve cells of transcription factors.  In this 
regard, transcription factor binding is posited to serve as a major rate limiting step for 
transcription at promoter sites with addition of upstream activating sites alleviating this 
limitation.  Thus, it is possible for us to control transcriptional activity by indirectly 
modulating transcription factor localization or affinity through the choice of enhancer and 
core elements in a hybrid promoter. 
The generic approach of hybrid promoter engineering described in this chapter is 
an important, generic synthetic biology tool enabling the construction of high-level and 
fine-tuned promoters with interchangeable promoter parts.  This approach is one of the 
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first to rationally amplify the expression output of a given promoter element.  By utilizing 
this approach, we have expanded the metabolic engineering toolbox in Y. lipolytica and 
developed several novel promoter series - UAS1B1-32-Leum, UAS1B8-TEF, and 
UAS1B16-TEF.  Heterologous protein expression requires strong promoters to obtain 
high protein expression level, while metabolic pathway engineering necessitates strictly 
controlled, fine-tuned promoters set to optimize pathways.  The generic hybrid promoter 
approach described here accomplished both of these tasks.  Moreover, these results 
demonstrate that the expression from Y. lipolytica native promoters is enhancer limited, 
which may be a generic phenomenon across other yeast organisms. Finally, given the 
results in this chapter, it is possible to conceive of novel combinations of upstream 
activation sequences with various promoter elements to achieve both fine-tuned 
expression and controlled regulation.  
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Chapter 3: Increasing expression level and copy number of a Yarrowia 
lipolytica plasmid through regulated centromere function
2
 
3.1 Chapter summary 
Beyond the promoter engineering strategies described in Chapter 2, manipulating 
gene expression using different types of plasmids (centromeric, 2-micron, and 
autonomously replicating sequence) can expand expression levels and enables a quick 
characterization of combinations, both of which are highly desired for metabolic 
engineering applications. However, for the powerful potential industrial workhorse 
Yarrowia lipolytica, only a low-copy CEN plasmid is available.  As presented in this 
chapter, we engineered the CEN plasmid from Y. lipolytica by fusing different promoters 
upstream of the centromeric region to regulate its function and expand its range.  By 
doing this, we successfully improved the copy number and gene expression at plasmid 
level by 80% and enabled a dynamic range of nearly 2.7 fold.  This improvement was 
seen to be independent from both the promoter and gene used in the expression cassette.  
These results present a better starting point for more potent plasmids in Y. lipolytica.  
 
 
 
 
                                                          
2 Portion of this chapter has been published previously in FEMS Yeast Research 14(7), 1124-1127 with LL, PO, AP, HA designed 
and carried the experiments 
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3.2 Introduction 
  The ability to tune gene expression is essential for the success of metabolic 
engineering efforts. To this end, previous work including endogenous promoter 
characterization (98), hybrid promoter engineering as described in Chapter 2, and multi-
copy integration (99) have increased the capacity to engineer Yarrowia lipolytica. 
However, this tuning capacity has not been matched at the plasmid level, a convenience 
that would enable quick characterization of genetic constructs through a simple 
transformation and also a tool that can enable fundamental studies of replication and 
segregation (100). 
In the widely used baker’s yeast Saccharomyces cerevisiae, plasmid-based gene 
expression control is enabled by several varieties of plasmids including centromeric 
(CEN) plasmids (low copy), 2-micron plasmids (high copy), and autonomously 
replicating sequence (ARS) plasmids (high copy) (19-21). However, for the case of Y. 
lipolytica, a suitable 2-micron has not been identified and the CEN and ARS elements 
cannot be separated (68, 72, 85) leaving only low copy CEN-based plasmids. In S. 
cerevisiae, it has been reported that a CEN plasmid can be converted into an ARS-like 
plasmid by fusing a promoter upstream of the centromeric region leading to increase in 
copy number and gene expression (101).  In the work presented in this chapter, we sought 
to invoke a similar strategy for a Y. lipolytica CEN plasmid to both increase copy number 
and expression level (Figure 3.1a). 
 
3.3 Results  
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To accomplish this task, we first selected various endogenous promoters and 
synthetic variants (P-GPD, P-EXP, P-POT1, P-MET2, P-TEF and truncated P-TEF: P-
TEF(272) and P-TEF(136) with 272 bp and 136 bp upstream of the ATG starting site  (98, 
102-103) as well as two cell-cycle dependent promoters (P-CDC2 and P-YOX1) to 
regulate the centromere function in Y. lipolytica (all promoters were amplified with 50bp 
from the coding region). Previous studies in S. cerevisiae suggested CDC2 and YOX1 
exhibit cell-cycle dependent expression patterns and express in G1-phase and mid G1 to 
early S phase respectively (104-106). Whereas the promoter fused to the CEN region was 
altered in each plasmid, each construct contained a strong hybrid promoter (P-UAS1B16-
Leum) upstream of hrGFP, a green fluorescence protein. Through the use of flow 
cytometry, we found that altering the promoter upstream of the centromere region in Y. 
lipolytica leads to similar phenotype found in S. cerevisiae. As a result, it was possible to 
alter the expression level via regulated centromere function (Figure 3.1b). For the case of 
P-TEF(272), P-CDC2, P-POT1 and P-EXP based engineered plasmid, fluorescence was 
increased by at least 50% compared to the control plasmid construct and up to 80% for 
the case of P-TEF(272). Interestingly, the P-MET2 promoter upstream of the CEN region 
resulted in a decreased expression by 30%. Collectively, a nearly 2.7 fold dynamic range 
was achievable through this strategy. 
Next, we replaced the hrGFP gene with a β-galactosidase reporter gene for two of 
the plasmids (containing the promoters P-POT1 and P-CDC2 upstream of CEN) to test 
the generalizability of this approach. Both plasmids showed a similar improvement of 
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roughly 50% in the β-galactosidase activity as seen with the hrGFP (Figure 3.1c).  In 
addition, the increase in expression is preserved when a lower strength native promoter 
(P-EXP) is used to drive the expression of β-galactosidase, thus indicating that the 
approach is independent of reporter protein and promoter driving the expression cassette 
(Figure 3.1d).  
To confirm that the increased protein expression level was the result of increases 
in plasmid copy number, we employed a relative copy number assay based on RT-PCR 
using a total genomic DNA extract (19, 107).  The copy number in the augmented 
plasmids was found to be increased by roughly 80% compared to the initial plasmid 
construct (Figure 3.1c). Thus, these engineering efforts successfully increased the copy 
number as well as the expression level from Y. lipolytica plasmids. 
One commonly observed feature of these Y. lipolytica plasmids is a bimodal 
distribution of fluorescence signal as mentioned in Chapter 2 (103). The improvement in 
expression seen in this chapter was the cumulative result of both an increase in the signal 
as well as a mild increase of the size of the positive subpopulation (Figure 3.1e).  In an 
effort to further understand this bimodal phenotype, we separated the positive and 
negative subpopulations through cell sorting and cultivated the sorted populations. 
Whereas the positive population reverted back to the bimodal distribution, the negative 
population was unable to be grown in selective growth conditions. This data suggests a 
biased plasmid segregation occurs in Y. lipolytica CEN-based plasmids which can be 
attributed to the nature of the plasmid as well as the size (about 9.5kb). 
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Figure 3.1 Improving expression level and copy number of plasmid in Yarrowia 
lipolytica with regulated centromere function 
 
Figure 3.1a 
 
Figure 3.1b 
 
Promoter 
for CEN 
Promoter for 
hrGFP 
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Figure 3.1 cont. 
Figure 3.1c 
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Figure 3.1 cont. 
Figure 3.1d 
 
Figure 3.1e 
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Figure 3.1 cont. 
 
 (A) A schematic of the engineered plasmids with regulated centromere function. (B) Promoters, 
including P-MET2, P-GPD, P-TEF, P-TEF(136), P-YOX1, P-EXP, P-POT1, P-CDC2, P-
TEF(272), were used to regulate centromere function.  Mean fluorescence data collected by flow 
cytometry analysis was used to compare expression at a time point of 48 h in minimal medium. 
(C) Relative plasmid copy number and β-galactosidase activity with P-POT1 and P-CDC2 based 
engineered plasmid and control plasmid with P-UAS1B16-Leum driving expression of β-
galactosidase. The data was collected by RT-PCR and Gal-Screen™ β-Galactosidase Reporter 
Gene Assay System for Yeast or Mammalian Cells (life technologies) at a time point of 48 h in 
minimal medium. (D) Relative β-galactosidase activity with P-POT1 and P-CDC2 based 
engineered plasmids and control plasmid with promoter P-EXP driving expression of β-
galactosidase. The data was collected by Gal-Screen™ β-Galactosidase Reporter Gene Assay 
System for Yeast or Mammalian Cells (life technologies) at a time point of 48 h in minimal 
medium. (E) Histogram of fluorescence signal showing the bimodal distribution with P-POT1 
(blue), P-EXP (red) based engineered plasmids with the control plasmid (yellow). The data was 
collected by flow cytometry analysis to compare P-POT1, P-EXP based engineered plasmids with 
the control plasmid at a time point of 48h in minimal medium: P-POT1 based plasmid contains 
46.1%, P-EXP based plasmid contains 46.2% and the control plasmid contains 36.6% positive 
subpopulations. The graph was made using FlowJo software (Tree Star Inc., Ashland, OR). In all 
graphs, error bars represent standard deviations from biological replicates. 
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3.4 Discussion and conclusion 
From the data presented in this chapter, the improvements in expression and copy 
number at the plasmid level are highly dependent on the characteristics of the promoters 
repressing centromere function. Both of the strength and the expression pattern of the 
promoters affect the turning ability with the engineered plasmids. For instance, the 
decreased signal with promoter MET2 based plasmid could be resulted from the 
expression pattern of MET2 is not in favor of plasmid stability.  The different expression 
levels exhibited with plasmids of constitutive promoter EXP, GPD and TEF series could 
be due to different strengths possessed by different promoters. Moreover, the increase of 
both positive population and mean fluorescence suggested a more stable plasmid 
behavior in the engineered plasmids. This stability could be a result of increased copy 
number inside the cells. The tuning ability achieved through this plasmid engineering 
strategy can largely facilitate the metabolic engineering and microbiological studies in Y. 
lipolyitica, since it supplies an opportunity to alter the gene expression level without 
changing genetic components such as promoter and terminator, thus, enables the 
preservation of native regulation pattern. In this chapter, we reported the improvement in 
expression level and copy number at the plasmid level in Y. lipolytica through altering its 
centromere function. These efforts resulted in over 80% improvement of plasmid copy 
number and expression and also enabled a dynamic range of nearly 2.7 fold. This 
improvement was seen to be independent of both the promoter and gene in the expression 
cassette. Although the improvement is significantly less comparing with other expression 
tuning strategies such as hybrid promoter engineering in this yeast (Chapter 2), the 
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method presented here can be applied in addition to the promoter engineering strategy to 
further increase the expression level. Specifically, with eight fold improvement in the 
term of fluorescence signal described in Chapter 2 and the 80% improvement described 
here, an over 14 fold total increment of gene expression on plasmid could be achieved.  
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Chapter 4: Rational metabolic engineering Yarrowia lipolytica for high 
lipid production
3
 
4.1 Chapter summary 
Economic feasibility of biosynthetic fuel and chemical production hinges upon 
harnessing metabolism to achieve high titer and yield.  Once we gained the ability of 
manipulating gene expression in Yarrowia lipolytica as described in Chapters 2 and 3. 
We performed a thorough genotypic and phenotypic optimization of an oleaginous 
organism to create a strain with significant lipogenesis capability based on rational 
combinatorial metabolic engineering strategies described in this chapter. Specifically, we 
rewire Y. lipolytica’s native metabolism for superior de novo lipogenesis by coupling 
combinatorial multiplexing of lipogenesis targets with phenotypic induction. We further 
complete direct conversion of lipid content into biodiesel. Tri-level metabolic control 
results in saturated cells containing upwards of 90% lipid content and titers exceeding 25 
g/L lipids, a 60-fold improvement over parental strain and conditions.  Through this 
rewiring effort, we advance fundamental understanding of lipogenesis, demonstrate 
noncanonical environmental and intracellular stimuli, and uncouple lipogenesis from 
nitrogen starvation.  The high titers and carbon-source independent nature of this 
lipogenesis in Y. lipolytica in this chapter highlight the potential of this organism as a 
platform for efficient oleochemical production.   
                                                          
3 Portion of this chapter has been published previously in Nature Comm 5:3131 with JB, LL, HA designed the experiments, JB, AH, 
LL, RK, JM, AP, PO carried the experiments and JB, HA wrote the manuscript. 
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4.2 Introduction 
Microbial biosynthesis of fuels (such as ethanol and biodiesel) and industrial 
chemical precursors provides a renewable means to reduce dependence on petroleum 
feedstock (3, 5, 108-110).   In particular, bio-based production of oils and lipids provides 
a unique platform for the sustainable production of biodiesel and other important 
oleochemicals (46, 110).  Most efforts for developing such a platform involve either 
rewiring E. coli or cultivating cyanobacteria.  These attempts suffer from low titers (less 
than 7 g/L) and variable lipid content (ranging between 10 and 87%), with the highest of 
these levels typically occurring in non-tractable, slow growing hosts cultivated in oil 
containing media (i.e., ex novo lipid incorporation instead of de novo  lipogenesis) (51, 
108, 110-114).   
As an alternative, several groups have explored oleaginous organisms such as the 
fungus Yarrowia lipolytica, but total oil content and titers are still limited (23, 55, 57, 76, 
115-116).  Yet, the genetic tractability of Y. lipolytica (9, 65, 68, 70, 74, 102-103) 
coupled with its modest, innate de novo lipogenesis (~10-15% lipid content in wildtype 
(23, 55-56, 117-118)) make it a potential candidate as a platform organism for superior 
lipid production.   
Lipid biosynthesis is primarily initiated by the activity of four enzymes - AMP 
Deaminase (AMPD), ATP-Citrate Lyase (ACL), Malic Enzyme (MAE) and Acetyl-CoA 
Carboxylase (ACC) - that cooperatively divert carbon flux from central carbon 
metabolism towards fatty acid precursors (56, 76).  AMPD inhibits citric acid cycle flux 
to promote the accumulation of citrate, which is then cleaved into acetyl-CoA by ACL.  
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Fatty acid synthesis is further encouraged by carboxylation of acetyl-CoA to malonyl-
CoA fatty acid building blocks by ACC and by an increased NADPH supply generated 
by MAE or the pentose phosphate pathway (56, 76, 119) (Figure 4.1a). Leucine 
biosynthetic capacity has also been implicated as an effector of lipogenic ability in 
oleaginous organisms (117, 120), and a putative acetyl-CoA generating leucine 
degradation pathway was recently identified through a comparative genomics analysis of 
non-oleaginous and oleaginous yeast strains (121). In this regard, Y. lipolytica also 
possesses homologs for every enzyme and enzymatic subunit necessary for acetyl-CoA 
generation through isoleucine degradation (>45% similarity to Homo sapiens enzymes) 
(66, 122).  Previous efforts to increase lipid accumulation have shown promise in Y. 
lipolytica.  In particular, deletion of β-oxidation enzymes coupled with enhancing 
glycerol synthesis substantially increased ex novo lipid accumulation (56, 76), and 
deletion of the pex10 peroxisomal biogenesis gene greatly increased eicosapentaenoic 
acid yields (24).  However, these studies have been limited by their breadth of metabolic 
control and their comprehensiveness of genotypic and phenotypic sampling towards 
complete redirection of metabolic flux towards lipid accumulation (23, 55, 76, 117).  
Moreover, de novo lipid content in this organism has been limited to below around 60% 
by dry cell weight (23).   
In the work presented here, we undertake a large scale engineering effort - 
multiplexing genomic engineering of lipogenesis targets with phenotypic induction - and 
create a Y. lipolytica strain with significantly improved lipogenesis capability.  
Simultaneous perturbation of five lipogenic targets (affecting three disparate metabolic 
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pathways) results in lipid-saturated cells, culminating in the highest reported lipid content 
(~90%) and lipid titer (25.3 g/L).  The latter milestone represents a more than 60-fold 
improvement over parental strain and conditions. Through this rewiring effort, we 
describe several non-canonical facets of lipogenesis, including that lipogenesis is 
dependent on absolute environmental carbon content, that rare odd-chain fatty acids 
pathways are naturally activated by high lipogenesis, that lipid accumulation phenotypes 
are dependent on leucine-mediated signaling, and that high lipogenesis can be un-coupled 
from nitrogen starvation and entails a reduction in citric acid cycling.  We further 
demonstrate that these lipids can be easily converted into FAMEs (fatty acid methyl 
esters) suitable for biodiesel.  This work demonstrates, and capitalizes upon, the lipogenic 
potential of Y. lipolytica, utilizing its amenable metabolism to realize high titers and 
carbon-source independent lipid accumulation. 
 
4.3 Results 
4.3.1 Combinatorial genomic rewiring for improved lipogenesis 
 In this work, we investigate a combinatorial, multiplexing of targets spanning 
fatty acid, lipid, and central metabolism through the overexpression of five lipogenesis 
enzymes in four genomic backgrounds marked by differential fatty acid catabolic 
capacity (Table 4.1, Figure 4.1a).  Specifically, AMPDp, ACLp, and MAEp 
overexpression were investigated for their potential to increase acetyl-CoA and NADPH 
supply (ACCp overexpression has not been reported to significantly improve lipogenesis 
and was excluded (23)) and DGA1 and DGA2p (acyl-CoA:diacylglycerol 
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acyltransferases isozymes I and II) were included for their potential in catalyzing the 
ultimate step in triglyceride synthesis (123).  These overexpression targets were 
multiplexed with deletions that served to reduce fatty acid catabolism by reducing one or 
both of β–oxidation (via mfe1 deletion) (55, 76) and peroxisome biogenesis (via pex10 
deletion) (117, 124) (Table 4.1).  We have previously demonstrated that restoration of a 
complete leucine biosynthetic pathway increased lipid accumulation more than 
alleviation of uracil auxotrophy in a PO1f base strain (117).  Thus, we included the 
complementing of leucine and uracil biosynthetic capacity both singly and in tandem as 
targets for this multiplexing.  Integrated expression cassettes were driven by our high 
strength synthetic UAS1B16-TEF constitutive hybrid promoter developed in Chapter 2.  
Collectively, the combinatorial multiplexing of enzyme overexpressions, fatty-acid 
inhibition knockouts, and other biosynthetic pathways resulted in 57 distinct genotypes 
that were analyzed for lipogenesis capacity compared to the wild-type strain (Figure 
4.1b).  Initially, a Nile Red based fluorescence assay coupled with flow cytometry (125) 
was used to efficiently determine relative lipid content and assess critical genotype 
synergies.  Across the resulting lipogenesis metabolic landscape, we observed a 
significant range in lipid accumulation that spanned a 74-fold improvement in 
fluorescence over unmodified Y. lipolytica PO1f (Figure 4.1b).  Using fluorescence 
microscopy, it is evident that cells become larger and visibly more saturated with lipid 
content across the resulting lipogenic continuum in this landscape (Figure 4.1c).   
 Three dominant genetic targets exhibited cooperativity towards enhancing 
lipogenesis—pex10 deletion, DGA1 or DGA2 overexpression, and restoration of a 
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complete leucine biosynthetic pathway (leucine
+
 genotype) (Figure 4.1b).  Each of these 
targets independently improved Nile Red based fluorescence by more than threefold, and 
DGA1 overexpression outperformed that of DGA2 (Figure 4.1b). Overexpression of 
MAE and AMPD were positive effectors of lipogenesis, but offered no cooperative 
advantage when combined into the pex10 leucine
+
 DGA1 overexpression background, 
potentially by unbalancing metabolic flux towards lipid production through the 
overproduction of fatty acid synthesis precursors (Figure 4.1b).  Deletion of the mfe1 
gene was not seen to alter total Nile Red based lipid fluorescence measurements, but its 
removal reduces fatty acid degradation in carbon starvation conditions (76, 117).  
Similarly, the uracil
+
 genotype had minimal effect on fluorescence, but improved growth 
rate and permitted cultivation in a pure minimal medium composition.  Thus, the pex10, 
mfe1, leucine
+
, uracil
+
, DGA1 overexpression genotype, the strain with the highest 
lipogenesis potential in terms of fluorescence, was selected as our most advantageous 
strain.  We extracted and measured lipid content to confirm Nile Red-based flow 
cytometry assessment of lipid content (Figure 4.1d,e,f).  In small scale, test-tube 
cultivations, the final engineered strain outperformed all others, yielding 6.00 g/L lipids 
with 74% lipid content, a nearly 15-fold improvement over control (0.41 g/L lipid and 
16.8% lipid content).  
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Figure 4.1 Combinatorial strain engineering for high lipid production in Yarrowia 
lipolytica 
 
Figure 4.1a 
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Figure 4.1 cont. 
Figure 4.1b 
 
Figure 4.1c 
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Figure 4.1 cont. 
Figure 4.1d 
 
Figure 4.1e 
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Figure 4.1 cont. 
Figure 4.1f 
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Figure 4.1 cont. 
 
(A) A schematic illustrating the pathways rewired in Y. lipolytica’s metabolism to drastically 
increase lipogenesis capacity.  (B) Nile Red fluorescence analysis of the strains constructed in  
this chapter.  Strain names include strain background (POlf, pex10, mfe1, pex10 mfe1), 
auxotrophies relieved (leucine
+
 or uracil
+
), and enzymes overexpressed.  “Epi” denotes episomal 
overexpressions.  Lipogenesis is induced as pex10 deletion is coupled with leucine biosynthetic 
capacity and DGA1 overexpression – generally from front left to back right of the 3D contour 
heat map representation.  Error bars represent the standard deviation of technical triplicates.(C) 
Fluorescence light microscopy images of six strains increasing in lipid content (white) from left 
(unmodified POlf) to right (pex10 mfe1 leucine
+
 DGA1). (D, E) Increases in lipid titer and lipid 
content realized by engineering POlf to create the pex10 mfe1 leucine
+
 uracil
+
 DGA1 strain and 
then optimizing fermentation conditions in a bioreactor.  Error bars represent standard deviations 
of technical triplicates.  (F) Four strains were analyzed for percent lipid content (g lipids/g dry 
cell weight) after cultivation in 80 g/L glucose, 6.7 g/L Yeast Nitrogen Base w/o amino acids 
(1.365 g/L ammonium),  and 0.79 g/L CSM supplement – POlf, pex10 mfe1 leucine+ uracil+ 
AMPD MAE, pex10 mfe1 leucine
+
 DGA1, and pex10 mfe1 leucine
+
 uracil
+
 DGA1.  The pex10 
mfe1 leucine
+
 uracil
+
 DGA1 strain yielded the highest percentage lipid content (74%), a more 
than 4-fold improvement over PO1f control (16.8% lipid content). 
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Table 4.1 List of genes and enzymes for rational metabolic engineering for high lipid 
production 
 
Genomic backgrounds 
Name Genotype  and (function of knockout) 
POlf MatA, leucine
-
, uracil
-
, no extracellular proteases 
pex10 POlf-Δpex10 (prevents peroxisome biogenesis) 
mfe1 POlf-Δmfe1 (prevents β-oxidation) 
pex10 mfe1 
POlf-Δpex10 Δmfe1 (prevents peroxisome 
biogenesis and β-oxidation) 
Enzymatic overexpressions 
Name Function 
AMPD Inhibits TCA cycle, increasing citric acid level 
ACLsubunit1 Cleaves citric acid to acetyl-CoA 
ACLsubunit2 Cleaves citric acid to acetyl-CoA 
MAE Increases NADPH cofactor supply 
DGAisozyme1 Catalyzes lipid synthesis step 
DGAisozyme2 Catalyzes lipid synthesis step 
Auxotrophic markers 
Name Utilized for expression 
Leucine
+/-
 Episomally and chromosomally 
Uracil
+/-
 Chromosomally 
  
AMPD = Adenosine monophosphate deaminase; ACL = ATP-Citrate Lyase; MAE = Malic 
Enzyme; DGA = acyl-CoA:diacylglycerol acyltransferases.  ACL is a heterodimeric protein so 
only dual overexpressions of the ACLsubunit1 and ACLsubunit2 were constructed and tested. 
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4.3.2 Lipogenic induction through nutrient level optimization 
 We next sought to understand the complex relationship between de novo lipid 
accumulation and nutrient levels. Previous studies generally accepted that lipogenesis 
capacity is highly dependent on the ratio of available carbon and nitrogen (C:N ratio) and 
that lipogenesis induction requires a nitrogen starvation mechanism (118, 126).  
However, no definitive, quantitative relationship between genotype and lipogenesis 
induction has been determined.  Thus, we analyzed the effect of nitrogen starvation and 
carbon availability on lipogenesis for unmodified Y. lipolytica PO1f and eleven 
engineered strains spanning the lipogenesis landscape.  Cultivation of these twelve strains 
in thirteen media formulations containing between 10 g/L and 160 g/L glucose and 0.055 
g/L and 1.365 g/L ammonium revealed that absolute glucose level, rather than generally 
accepted C:N ratio, is crucial towards inducing lipid synthesis, and high lipid producers 
realized optimal accumulation in higher glucose media (Figure 4.2).  In particular, 
unmodified Y. lipolytica PO1f and other low performing strains were most strongly 
induced by a lower carbon level (20 g/L glucose and 0.273 g/L ammonium), but 
responded poorly at similar C:N ratios with higher glucose and ammonium 
concentrations (Figure 4.2a).  Moderate lipid accumulators were highly induced at 
intermediate glucose levels but again responded poorly at similar C:N ratios (Figure 
4.2b).  The highest accumulators, including the pex10 mfe1 leucine
+
 DGA1 
overexpression genotype, were induced most intensely by higher levels of carbon and 
nitrogen (80 g/L glucose and 1.365 g/L ammonium) (Figure 4.2c).  Thus, the current 
paradigm asserting the necessity of nitrogen starvation and that similar C:N ratios beget 
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similar induction irrespective of overall carbon and nitrogen levels is incorrect. Instead, a 
defined amount of carbon content ultimately controls lipid synthesis, and this favorable 
carbon level increases in strains capable of superior lipogenesis. Increasing carbon and 
nitrogen levels only improves lipogenesis to a certain extent, as lipid yield decreases 
when glucose levels are increased to 160 g/L (Figure 4.2c), and cultivation of various 
engineered strains in media containing 320 g/L glucose drastically reduced growth rate, 
most likely due to osmotic stress (127). 
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Figure 4.2 Genotypic dependency towards lipid induction phenotype with selected strains 
Figure 4.2a 
 
Figure 4.2b 
 
Figure 4.2c 
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Figure 4.2 cont. 
 
Heat maps of Nile Red stained lipid fluorescence for the (A) POlf low lipid accumulating strain, 
(B) POlf leucine
+
 uracil
+
 moderate lipid accumulating strain, and (C) pex10 mfe1 leucine
+
 DGA1 
high lipid accumulating strain demonstrate a decoupling of lipogenesis and nitrogen starvation as 
well as the implication of absolute carbon content as a lipogenesis effector.  Fluorescence data is 
shown for each strain after cultivation and staining in twelve media formulations containing 
between 20 g/L and 160 g/L glucose and 0.055 g/L and 1.365 g/L ammonium.  Lipogenesis is 
dependent on absolute environmental carbon content, and low lipid accumulators (A) require less 
carbon for optimal lipogenic induction than moderate (B) or high (C) lipid accumulating strains.  
In highly lipogenic strains (C), high lipogenesis is un-coupled from nitrogen starvation.  These 
studies were conducted with technical duplicates. 
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4.3.3 Controlled fermentation enables superior lipogenesis 
 Taken together, these dominant lipogenesis targets and nutrient levels 
(specifically, 80 g/L glucose and 1.365 g/L ammonium) enabled an optimization of 
fermentation conditions for the pex10 mfe1 leucine
+
 uracil
+
 DGA1 overexpression strain 
to maximize lipid accumulation in a bioreactor setting.  We cultivated this fully 
prototrophic strain in an inexpensive minimal media formulation consisting of only 
glucose, ammonium sulfate, and yeast nitrogen base.  By additionally controlling pH, 
temperature, and dissolved oxygen levels, we observed significantly improved lipid titer 
to 16.1 g/L with cells containing up to 88% lipid cellular content (Figure 4.3a).  This 
represents a 5.4 fold increase over a POlf leucine
+
 uracil
+
 control and 63% of the 
theoretical stoichiometric yield with a specific productivity approaching 0.2 g/L hr
-1
 
(Figure 4.3).  Lipogenesis continues in the engineered strain throughout the six day 
fermentation despite complete depletion of glucose and cessation of biomass production 
within three days (Figure 4.3a).  Moreover, this engineered strain exhibits reduced citric 
acid and biomass production to enable heightened flux towards lipid synthesis (Figure 
4.3a,c). In contrast, excess carbon flux in the control strain accumulates as citric acid 
(dispersed throughout the supernatant) before reabsorption and incorporation into 
biomass (Figure 4.3c).  Thus, the engineered strain’s metabolic processes are in stark 
contrast to a central tenet of lipid accumulation in oleaginous organisms – that lipid 
accumulation requires prior production of citric acid (128-130).  We hypothesize that our 
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re-engineered metabolism enables temporary carbon storage in secondary metabolites 
more amenable to direct incorporation into elongating fatty acids.   
Doubling nutrient availability to 160 g/L glucose and 2.73 g/L ammonium further 
increased lipid titer to 25.3 g/L, the highest reported titer to date (Figure 4.1d).  This 
represents an increase in specific productivity to 0.21 g/L/h, but a decrease in cellular 
lipid content to 71% and a decrease to 44% of theoretical stoichiometric yield.  This 
further demonstrates the need to fully optimize carbon and nitrogen content to maximize 
lipogenic efficiency.  These extremely high lipogenesis levels correlated with a metabolic 
shift to maintain homeostatic, steady state ammonium levels not seen in the low lipid 
accumulation background (Figure 4.3b,d).  Specifically, after an initial drop, engineered 
cells re-buffered the nitrogen level within the media, thus illustrating a newfound, 
decoupled relationship between lipogenesis and nitrogen starvation. The control and 
engineered strain both exhibit similar intracellular protein degradation during the final 
four days of fermentation (Figure 4.3e).  However, the control strain produces 4.9 g/L 
biomass containing ~11% nitrogen content (thus utilizing 0.54 g/L nitrogen) (131), while 
the engineered strain re-buffers supernatant nitrogen levels to ~0.5 g/L.  A simple mass 
balance indicates that the nitrogen replenishment afforded by engineered cells is 
originating from protein degradation.  Interestingly, the purely lipogenic phase (after 
biomass accumulation) in the engineered cells corresponds to a reduction in oxygen 
utilization, evidenced by a large, prolonged spike in dissolved oxygen content in 
bioreactor run, suggesting that both nitrogen and oxygen utilization are down regulated to 
reduce metabolite utilization for cell growth to enable enhanced lipogenesis. 
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Figure 4.3 Fermentation profiles of pex10 mfe1 leucine+ uracil+ DGA1 and POlf 
leucine+ uracil+ 
 
Figure 4.3a 
 
Figure 4.3b 
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Figure 4.3 cont. 
Figure 4.3c 
 
Figure 4.3d 
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Figure 4.3 cont. 
Figure 4.3e 
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Figure 4.3 cont. 
 
Time courses of the 1.5L scale batch fermentation of the pex10 mfe1 leucine
+
 uracil
+
 DGA1 (A,B) 
and POlf leucine
+
 uracil
+
(C,D) strains in 80 g/L glucose, 6.7 g/L YNB (no amino acids, 1.365 g/L 
ammonium) are shown, including production of biomass, lipids, and citric acid (left axis a,c), 
consumption of glucose (right axis a,c), and ammonium level (B,D).  (A)  During the pex10 mfe1 
leucine
+
 uracil
+
 DGA1 fermentation, negligible citric acid was produced, and lipid product 
accumulated during and after biomass production phases.  This fermentation was run three times 
in identical conditions, reaching final yields of 15.25 g/L lipids and 20.3 g/L biomass (75% lipid 
content), 14.96 g/L lipids and 20.6 g/L biomass (73% lipid content), and 16.9 g/L lipids and 
19.21 g/L biomass (88% lipid content).  Most time points show average values from the former  
Figure 4.3 cont. 
 
two fermentations (75% and 73% final lipid content), while endpoints represent averages from all 
three final values.  Error bars represent standard deviations of these technical replicates.  Glucose 
and ammonium substrate were fully consumed after 72 hours, but surprisingly, (B) ammonium 
level was replenished to a steady state level of ~0.5 g/L, almost 40% of the original starting level.  
(C) During the POlf leucine
+
 uracil
+
 fermentation, citric acid accumulated to more than 14 g/L 
after 72 hours before quickly reducing to 4 g/L.  Lipid production did not trend with biomass 
production, reaching a final yield of only 3 g/L lipids, compared to 30 g/L biomass, and glucose 
was again consumed within 72 hours.  (D) Ammonium was fully consumed after 72 hours with 
no replenishment as observed in the mutant strain. (E) Ammonium is fully utilized by both the 
pex10 mfe1 leucine
+
 uracil
+
 DGA1 and POlf leucine
+
 uracil
+
 strains after 72 hours of bioreactor 
batch fermentation.  However, during pex10 mfe1 leucine
+
 uracil
+
 DGA1 fermentation, 
ammonium levels are replenished.  We tested if this could be a result of intracellular protein 
degradation, by analyzing protein content before, during, and after this dip in ammonium 
concentration.  However, protein concentration decreases in both pex10 mfe1 leucine
+
 uracil
+
 
DGA1 cells and in POlf leucine
+
 uracil
+
 cells.  Thus, the metabolic shift to sustain steady state 
nitrogen levels observed in pex10 mfe1 leucine
+
 uracil
+
 DGA1 fermentation is not solely the 
result of protein degradation.  This experiment was conducted with individual samples. 
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4.3.4 High lipogenesis with alternative carbon sources 
 We further tested this engineered strain on alternative carbon sources to assay for 
carbon-source independent lipogenesis. We observed that the pex10 mfe1 leucine
+
 uracil
+
 
DGA1 overexpression strain exhibited superior production in nearly all carbon sources, 
establishing these lipogenesis targets as essential in rewiring this organism into an 
oleochemical platform strain (Figure 4.4). 
 
Figure 4.4 Lipid accumulation on alternative carbon sources 
   
The pex10 mfe1 leucine+ uracil+ DGA1 strain effectively generates high lipid content in a 
carbon-source independent manner.  Error bars represent standard deviations of biological 
triplicates. 
 
4.3.5 Lipid analysis and conversion into soybean-like biodiesel 
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 We analyzed lipid content with GC and saw predominantly C16:0, C16:1, C18:0, 
C18:1, and C18:2 fatty acids (very similar to soybean), making these lipid reserves ideal 
feedstock for biodiesel synthesis (Figure 4.5a) (132).  Moreover, we observed 127 mg/L 
accumulation of C17 fatty acids, a very rare metabolite in cells (Figure 4.5b).  We 
hypothesize that extremely active lipogenesis enables less favored odd chained synthesis 
and such high titers permit detection and characterization.  Finally, a standard methanol 
transesterification reaction with bioreactor-extracted lipids demonstrated de novo 
biodiesel production (Figure 4.5c).  Thus, the microbial production of high lipids in this 
host can facilitate a renewable biodiesel production process with profiles similar to 
conventional plant-derived oils.    
 
Figure 4.5 Fatty acid profile characterization and biodiesel conversion 
Figure 4.5a 
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Figure 4.5 cont. 
Figure 4.5b 
 
Figure 4.5c 
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Figure 4.5 cont. 
 
(A) Fatty acid profiles of lipid extract from pex10 mfe1 leucine
+
 uracil
+
 DGA1 and POlf leucine
+
 
uracil
+
 strains after six day bioreactor batch fermentations are shown.  We observed 
predominantly C16 and C18 fatty acid content, as expected, with a noticeable amount of C17 
accumulation.  We observed C18:2 (linoleic acid) accumulation in the pex10 mfe1 leucine
+
 uracil
+
 
DGA1 but not in the POlf leucine
+
 uracil
+
 control.  Error bars represent standard deviations of 
technical triplicates. (B) GC-MS analysis of pex10 mfe1 leucine
+
 DGA1 lipid content.  Lipid 
extract from the pex10 mfe1 leucine
+
 DGA1 strain was analyzed with GC (top panel) and MS 
(bottom two panels).  Coinciding with the C17:0 standard retention time, C17:0 was present 
between 12.16-12.23, and MS analysis showed the expected mass of 327 m/z (bottom panel).  
C17:1 was present on the GC between 11.79 and 11.86, and analysis with MS (middle panel) 
revealed the expected mass of 325 m/z, which corresponds to C17:0 losing two hydrogen atoms 
as it is unsaturated to C17:1. (C) Image of transesterified lipid content (FAMEs/biodiesel).  Lipid 
content from pex10 mfe1 leucine
+
 uracil
+
 DGA1 cells fermented in a bioreactor was 
transesterified with methanol to form FAMEs (biodiesel).  Shown is a picture of ~1500 μL 
sample of biodiesel in a 15 mL Falcon tube against a white backdrop.   
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4.5.6 Probing the link between leucine and lipogenesis 
 Finally, we sought to explain the lipogenic benefit bestowed by leucine 
biosynthetic capacity by comparing leucine supplementation to genetic complementation.  
Leucine supplementation mimicked genotypic complementation in leucine
-
 strains but 
did not affect leucine
+
 backgrounds (Figure 4.6a,b). Isoleucine supplementation had no 
effect, insuring that this leucine-mediated response was not a result of amino acid 
catabolism (Figure 4.6a,b). Leucine supplementation or genetic complementation 
enabled a pronounced alteration in steady state nitrogen concentration that correlated 
with lipogenesis in small scale cultivations (Figure 4.6c,d).  These results implicated 
leucine as an intracellular trigger to stimulate lipogenesis while regulating nitrogen 
availability.  In this regard, the yeast and mammalian TOR complexes (TORC1) promote 
cell anabolic processes, such as growth, proliferation, and protein synthesis, in response 
to amino acid availability and growth factor stimuli (133-134).  The leucyl-tRNA 
synthetase has recently been implicated as an intracellular sensor of amino acid 
availability for the TORC1, providing a potential link between leucine stimulation and 
lipogenesis (135-136).  To probe this interaction further, we inhibited Y. lipolytica TOR 
kinase activity with rapamycin, revealing a complex TOR-regulated lipogenic phenotype, 
in which leucine stimulation and TOR inhibition coupled to facilitate lipogenesis in low 
lipid production backgrounds but reduced lipogenesis in high production strains (Figure 
4.6e).  Thus, we demonstrated here that leucine-mediated lipogenic induction is affected 
by TOR regulation.  
74 
 
 
Figure 4.6 Leucine supplementation recovers leucine+ phenotype 
Figure 4.6a 
 
Figure 4.6b 
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Figure 4.6 cont. 
Figure 4.6c 
 
Figure 4.6d 
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Figure 4.6 cont. 
Figure 4.6e 
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Figure 4.6 cont. 
 
The ability of leucine or isoleucine supplementation to complement the leucine
+
 phenotype in the 
(A) pex10 mfe1 leucine
-
 uracil
+ 
DGA1 and the (B) PO1f leucine
-
 uracil
+ 
backgrounds was tested.  
1.6 g/L leucine supplementation complemented the leucine
+
 phenotype in both the pex10 mfe1 
leucine
-
 uracil
+ 
DGA1 and the PO1f leucine
-
 uracil
+ 
backgrounds.  Leucine supplementation had 
no effect on the pex10 mfe1 leucine
+
 uracil
+ 
DGA1 background or the PO1f leucine
+
 uracil
+ 
backgrounds, demonstrating the leucine biosynthetic capacity generates enough leucine to 
stimulate lipogenesis.  Isoleucine had no effect on lipogenesis in either the leucine
+
 or leucine
-
 
backgrounds.  Thus, the benefit of leucine towards lipogenesis is not a result of leucine 
catabolism for carbon and nitrogen use.  Error bars represent standard deviations of biological 
triplicates. (C)  The steady state ammonium concentration of PO1f and pex10 mfe1 leucine
+
 
DGA1 Epi strains were measured during cultivations in 30 mL media containing 80 g/L glucose, 
6.7 g/L Yeast Nitrogen Base w/o amino acids (1.365 g/L ammonium), and 0.79 g/L CSM 
supplement.  The engineered pex10 mfe1 leucine
+
 DGA1 Epi strain maintains a lower steady state 
ammonium concentration than the unmodified POlf low lipid production strain.  This experiment 
was conducted with individual samples. (D) In addition to effecting higher lipogenesis, leucine 
biosynthetic capacity results in lower ammonium levels in the pex10 mfe1 leucine
+
 uracil
+
 DGA1 
strain than in the pex10 mfe1 leucine
-
 uracil
+
 DGA1 strain.  Once again, leucine supplementation 
of the leucine
-
 strain complements the phenotype observed in the leucine
+
 by reducing ammonium 
levels.  Leucine supplementation has no effect on ammonium levels for the leucine
+
 strain.  Thus, 
leucine biosynthetic capacity, lipogenesis, and nitrogen availability are linked in high lipid 
accumulating strains of Y. lipolytica.  Error bars represent standard deviations of biological 
triplicates. (E) 2 μg mL-1 rapamycin was used to inhibit Y. lipolytica TOR activity. Coupling 
TOR inhibition with leucine biosynthetic capacity stimulates lipogenesis in the low lipid 
accumulating PO1f leucine
+
 background.  As this strain has leucine biosynthetic capability, it is 
unaffected by leucine supplementation. TOR inhibition and leucine supplementation are 
necessary to induce lipogenesis in the PO1f leucine
-
 background. Thus, TOR inhibition coupled 
with leucine-mediated signaling enables high lipogenesis in low accumulation backgrounds. TOR 
inhibition tends to decrease lipogenesis in the lipogenic pex10 mfe1 uracil
+
 DGA1 background, 
except when leucine biosynthetic capacity and supplementation are absent: TOR inhibition can 
increase lipogenesis in this instance. Error bars represent standard deviations of biological 
triplicates. 
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4.4 Discussion and conclusion 
Lipogenic organisms offer ideal platforms for biodiesel and oleo-chemical 
synthesis.  To this effect, we rewired Y. lipolytica’s native metabolism via a 
combinatorial multiplexing to effect superior de novo lipid accumulation.  Our analyses 
revealed that high lipogenesis can be un-coupled from nitrogen starvation, is dependent 
on leucine-mediated signaling and absolute environmental carbon content, and is 
adversely affected by citric acid and nitrogen cycling.  For the majority of our moderate 
or highly lipogenic strains, optimal lipid accumulation was enabled in nitrogen-
permissive, high carbon conditions.  In contrast, low performing strains were optimally 
induced by low carbon levels, indicating central carbon metabolisms ill-equipped to 
utilize energy-dense media formulations.  Thus, genomic rewiring quickly eliminates the 
requirement of induction through nitrogen starvation and necessitates a re-optimization of 
environmental stimulus after each metabolic perturbation. During bioreactor 
fermentation, a lowly lipogenic strain diverted excess carbon to production of 
extracellular citric acid before assimilation into biomass (simultaneously utilizing 
nitrogen derived from protein degradation).  In contrast, a highly lipogenic strain avoided 
citric acid accumulation and prevented incorporation of nitrogen into biomass.  In this 
manner, our final engineered strain mentioned in this chapter maintained nitrogen levels 
optimal for high lipogenesis and prevented extracellular carbon flux, promoting easier 
lipid accumulation.   
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The work from this chapter reports the novel link between leucine signaling and 
lipogenesis in Y. lipolytica. Specifically, we contrasted the effects of leucine and 
isoleucine supplementation on lipogenesis and demonstrated that only leucine acts to 
promote lipogenesis.  As Y. lipolytica possesses degradation pathways for both leucine 
and isoleucine to acetyl-CoA fatty acid precursors (66, 121-122), leucine must act as an 
intracellular signal to permit lipid production, rather than as a carbon source.  This is 
further established by the leucine-dependent TOR-inhibition phenotype of the PO1f 
leucine
-
 uracil
+
 and PO1f leucine
+
 uracil
+
 strains. Thus, a complex signaling scheme is 
implicated for high lipid titers in this organism. 
 In summary, we conducted the largest rewiring of an oleaginous organism, and 
successfully engineered and enhanced de novo lipid accumulation in Y. lipolytica by 
more than 60 fold comparing to the starting strain.  In doing so, we identified several 
unique features of lipogenesis, demonstrated that lipid accumulation approaching 90% of 
cell mass is possible, determined dominant genotype- phenotype dependencies, 
decoupled lipogenesis and nitrogen starvation, illustrated carbon-source independence, 
and demonstrated the feasible conversion of these lipids into FAMEs.  We further 
presented evidence that two central tenets of lipogenesis, the necessity for nitrogen 
starvation and citric acid cycling, are not universal.  The work presented in this chapter 
reports a high lipid titers to date at 25 g/L and it can be used as starting point for further 
evolutionary metabolic engineering as described in the next chapter (Chapter 5).
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Chapter 5: Evolutionary metabolic engineering for high lipid 
production in Yarrowia lipolytica 
5.1 Chapter summary 
Through rational metabolic engineering efforts described in Chapter 4, 
lipogenesis titers in Yarrowia lipolytica were significantly enhanced.  However, the 
improvement still suffered from decreased biomass generation rates.  Here, we attempted 
to employ a rapid evolutionary metabolic engineering approach linked with a floating cell 
enrichment process to improve lipogenesis rates, titers, and yields.  Through this iterative 
process, we were able to ultimately improve yields from our prior strain by over 60% to 
achieve production titers of 40.5 g/L with upwards of 79% of the theoretical maximum 
yield of conversation. Isolated cells were saturated with up to 89% lipid content.  An 
average specific productivity of 0.55 g/L/h was achieved with a maximum instantaneous 
specific productivity of 0.86 g/L/h during the fermentation. Genomic sequencing of the 
evolved strains revealed a link between a decrease/loss of function mutation of succinate 
semialdehyde dehydrogenase, uga2, suggesting the importance of gamma-aminobutyric 
acid assimilation in lipogenesis.  This linkage was validated through gene deletion 
experiments.  This chapter presents an improved host strain that can serve as a platform 
for efficient oleochemical production.   
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5.2 Introduction 
 Metabolic engineering of a highly oleaginous strain of Y. lipolytica capable of 
producing titers exceeding 25 g/L in bioreactors has been achieved as described in 
Chapter 4. Nevertheless, even in this organism, improvements in all metrics 
(productivities, titers, and yields) are essential to make microbial production of chemicals, 
and especially commodity chemicals and biofuels, economically viable. Thus, here, we 
take an evolutionary approach to further improve lipogenesis rates. 
One particular challenge of rational metabolic engineering is the competition 
between product titers and yields (137). To this end, improved lipid production is usually 
accompanied by a decrease in cell growth (138). Specific for engineering lipogenesis in Y. 
lipolytica, rational approaches have mainly produced strains with increased lipid 
production at the cost of decreased biomass production (23, 139) . Thus, a more balanced 
evolutionary approach may access a middle ground for these two competing factors.  
Evolutionary metabolic engineering of bio-based production of oils and lipids is 
challenging due to the lack of developed enrichment and selection schemes. Prior work 
has coupled random mutagenesis with anti-metabolites such as cerulenin screening to 
evolve oleaginous yeast Lipomyces starkeyi (140). However, the improvement was rather 
limited probably due to the lack of full enrichment and the high specificity of cerulenin 
screening. An alternative strategy based on physiology has been employed in the case of 
identifying high lipid containing mutants from a transposon library of S. cerevisiae 
whereby a gradient centrifugation selection step was used (141).  However, these 
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approaches can be quite sensitive to conditions of the selection, yet demonstrate the 
potential for an evolutionary approach. 
Here, we designed and performed a simple, evolutionary metabolic engineering 
approach for improving lipogenesis in a pre-engineered starting strain using random 
mutagenesis and an observed buoyancy property of lipid-filled cells. Specifically, by 
repeating the process of error generation and floating-based selection, we were able to 
ultimately improve yields from our prior strain by over 60% to achieve production titers 
of 40.5 g/L with upwards of 79% of the theoretical maximum yield of conversation and 
average specific productivities reaching 0.55 g/L/h with a maximum instantaneous 
productivity of 0.86 g/L/h. More importantly, these improvements simultaneously 
increase both biomass and titer. Whole genome sequencing reveals a novel lipid 
production enhancer (uga2) and provides important insight into the relationship between 
glutamate degradation and lipogenesis.  Thus, this chapter presents a metabolically 
evolved, novel platform with substantial lipogenesis potential.   
  
5.3 Results 
5.3.1 High-lipid content cells can be identified via floating cells 
By coupling combinatorial multiplexing of lipogenesis targets with phenotypic 
induction, we successfully rewired Y. lipolytica’s native metabolism for high de novo 
lipogenesis through the identification of three dominant genetic targets – pex10 deletion, 
DGA1 overexpression and restoration of a complete leucine biosynthetic pathway 
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(leucine
+
 phenotype) and created an engineered strain PO1f pex10 mfe1 leucine
+
 uracil
+ 
DGA1 with production titer exceeding 25 g/L in bioreactor (139). During these 
engineering efforts, we successfully identified a subpopulation of cells with extremely 
high buoyancy property: these cells can float on top of the medium once the culture 
settled while normal cells would settle down to the bottom of the tube (Figure 5.1).  At 
times, this “floating” subpopulation can even survive conditions of mild centrifugation 
(e.g. 100 x g).  We then examined the lipid bodies inside both cell populations using 
fluorescence microscopy with Nile Red staining (a dye straining lipid bodies showing 
yellow-green fluorescence when excited with blue light (125)) and observed that the 
floating cells were full of lipids whereas cells that settled were not (Figure 5.1, this strain 
is further characterized in Chapter 6). Thus, we concluded that higher lipid containing 
cells would possess a higher buoyancy property and can be separated based on this 
“floating” phenotype.  Here, we sought to utilize this observation as a method to isolate 
cells with high lipid content cells by coupling this floating selection with random 
mutagenesis and evolutionary engineering. 
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Figure 5.1 High-lipid content cells can be identified via floating cells 
A non-floating strain (left) and culture with a floating subpopulation strain (right) was cultured in 
high glucose media and then allowed to settled for 4 hours in room temperature in culture tubes to 
demonstrate the observed floating cell phenotype.  Representative fluorescence microscopic 
pictures show lower lipids content inside the cells staining with Nile Red from the non-floating 
population (left bottom) than from the floating subpopulation (right top).  
 
5.3.2 Random mutagenesis linked with floating cell transfer can identify improved 
lipogenesis traits 
Based on the observations described above, we opted to invoke an iterative, 
evolutionary metabolic engineering approach using our prior engineered strain of Y. 
lipolytica  PO1f pex10 mfe1 leucine
+
 uracil
+ 
DGA1 (Chapter 4) as a starting point.  
Overall, this process consists of generating a random mutagenesis library using Ethyl 
methanesulfonate (EMS), enriching for mutants with higher lipid content by sequentially 
transferring the floating cells, screening individual colonies on Nile Red plates, and 
finally testing for lipid content and cell growth (Figure 5.2).  The best lipid producer was 
tested in a bioreactor to evaluate the overall lipid production performance and was 
Floating 
cells 
Non-floating 
cells 
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characterized with whole genome sequencing to identify the causative mutations leading 
to the enhanced lipogenesis genotype.  Moreover, this process can be iterated to further 
evolve the strain toward an optimal lipogenesis phenotype (Figure 5.2). Following this 
process, early stationary phase cells (our previously engineered strain, PO1f pex10 mfe1 
leucine
+
 uracil
+ 
DGA1) were first treated with EMS to generate mutations resulting in a 
library size of approximately 10
8
 cells (142).  A sample not treated with EMS was used 
as a control for this experiment to evaluate the impact of spontaneous mutations during 
the selection process.  Next, the floating subpopulation in this library was subjected to 
serial transfer in culture tubes for five rounds after which the culture was plated for 
screening using Nile Red plates to isolated individual colonies with high lipogenesis 
potential.  In total, 31 colonies from the EMS library (named E1 to E31), and 5 colonies 
from the non-EMS treated control were selected from the plates based on high visual 
fluorescence.  These colonies were then cultured along with the engineered strain at the 
test tube level to further characterize lipid accumulation level by using the metric of 
Mean Nile Red fluorescence*OD600 as a reference for lipid production performance and 
a means of rank-ordering the mutants (Figure 5.3a).  All of the selected strains exhibited 
a clear improvement over the engineered strain.  Moreover, while spontaneous 
mutagenesis through the serial transfer process could lead to enhanced lipogenesis, 
mutation generation was beneficial for the isolation of higher performing strains.  Next, 
we selected the top two strains (E13 and E26, Figure 5.3a) as they both exhibited a 
nearly 3.5 fold-increase over the engineered strain.  These two mutants showed both an 
increase of around 60% improvement based on absolute Nile Red staining (Figure 5.3b) 
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as well as an over 60% increase in the final OD600 (cell growth).  Whole genome 
sequencing (described in 5.3.5) revealed that these two mutant strains were highly similar 
genetically, thus we selected E26 for further characterization.  The fluorescence 
micrograph of the E26 mutant clearly illustrated the enhanced lipogenesis with this strain 
when compared to the parental, engineering strain (Figure 5.3c).  Specifically, the empty 
edge without lipid in the engineered stain disappeared in the E26 strain and was engulfed 
with lipid instead.   
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Figure 5.2 Overall schematic for the iterative, evolutionary metabolic engineering 
approach used to enhance lipogenesis in Yarrowia lipolytica 
 
   
High lipid producing strains were created through first inducing random mutations by EMS, using 
serial transfer of floating cells, screening colonies on Nile Red plates, and characterizing resulting 
mutants through both whole genome sequencing and bioreactor production. 
 
5.3.3 High lipid production through bioreactor fermentation with E26 
To more accurately quantify the improvement achieved through this evolutionary 
metabolic engineering approach, we cultivated the E26 strain in an inexpensive minimal 
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media formulation consisting of only glucose (160 g/L), ammonium sulphate (10 g/L) 
and yeast nitrogen base while controlling pH, temperature and dissolved oxygen levels at 
set points we previously found optimal (Figure 5.3d).  In our previous efforts described 
in Chapter 4, the engineered strain produced 25.2 g/L lipid with an average productivity 
of 0.21g/L/h under these condition. After the evolutionary engineering, the E26 strain 
derived from this engineered host exhibited a significantly improved lipid titer reaching 
40.5 g/L with cells containing 89% lipid cellular content (Table 5.1).  This value 
represents the highest reported titer of lipid to the date.  Moreover, this represents a 61% 
increase in titer over the engineered strain.  This strain achieved 79% of the theoretical 
stoichiometric yield and had an average specific productivity approaching 0.51 g/L/h (a 
2.5-fold increase over the engineered strain).  The increased lipid titer was the combined 
effect of both increase cellular lipid content as well as a higher overall biomass.  For the 
parental, engineered strain, the main period of lipogenesis occurred in the later parts of 
fermentation (through 144 hours) after glucose depletion and biomass formation (139).  
In contrast, for the evolved E26 strain, lipogenesis occurred during the biomass 
accumulation stage and was completed within 96 hours.  Thus, the evolved strain’s 
metabolic processes are in clear contrast to the parental, engineered strain and presented 
improvements in rate, titer, and yield.  
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Figure 5.3 Random mutagenesis linked with floating cell transfer can identify improved 
lipogenesis strains.   
 
Figure 5.3a 
 
Figure 5.3b 
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Figure 5.3 cont. 
Figure 5.3c 
 
Figure 5.3d 
 
Engineered 
strain 
E26 strain 
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Figre 5.3 cont. 
 
(A) Comparison of lipid production using engineered strain (green), non-EMS evolved strain 
(light blue), and EMS evolved strain (dark blue) using Mean Nile Red fluorescence*OD600 as 
ranking metric.  Selected strains E13 and E26 are highlighted by a red circle.  (B) Enhanced 
lipogenesis among the isolated evolved strains E13 and E26 were characterized using flow 
cytometry and compared with the parental, engineered strain.  (C) Comparison of lipids stained 
with Nile Red between the engineered strain and evolved E26 strain using fluorescence 
microscopy. (D) Batch bioreactor fermentation profile of the E26 strain for lipid production. 
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Table 5.1 Bioreactor metrics with E26 and E26E1 strains 
 Titer Biomass Average specific 
productivity 
Overall 
yield 
Lipid 
content 
Engineered 
strain 
25.3 g/L 35.0 g/L 0.21 g/L/h 0.158 g/g 71% 
E26 strain 40.5 g/L 45.3 g/L 0.51 g/L/h 0.253 g/g 89% 
E26E1 
strain 
40.4 g/L 47.3 g/L 0.55 g/L/h 0.253 g/g 85% 
 
Performance metrics for lipid production in batch bioreactor fermentation with the engineered 
strain (Chapter 4), E26 strain and E26E1 strain.  
 
5.3.4 Assemble and analysis of draft genome of PO1f 
To enable the SNP analysis described in 5.3.5, we first sequenced and analyzed 
the genome from control strain PO1f. Although a high quality genome sequence of Y. 
lipolytica strain CLIB122 (E150) has been available (65), this strain is not the most 
popular for metabolic engineering applications. Specifically, Y. lipolytica strain W29 
(CLIB 89) and its derivatives such as PO1f  have been more widely used, especially in 
metabolic engineering studies for value-added chemical production (23, 76, 117, 139, 
143-144), therapeutic protein production (145-146) and fundamental microbiology 
studies (55, 147-148).  As one of the parental strains of the French inbred lines, the wild-
type haploid strain, W29, was originally isolated from sewage material (118). A 
preliminary sequencing effort was conducted with only 4.9 Mb  available (149). In the 
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work here, we assembled a draft genome of PO1f and analyzed the SNPs through its 
genome using CLIB122 genome as reference. 
The genome of Y. lipolytica PO1f was sequenced using the illumina HiSeq DNA 
sequencing platform (PE2X100). The raw sequence data comprises a total of 8,740,022 
reads that together provide very high sampling coverage of the genome (43.7-fold 
coverage). The reads were assembled using Velvet with k-mer size of 55 (150). This led 
to a genome assembly containing 669 contigs (each at length >= 500 bp). The total length 
of the genome assembly is 20,282,994 bp with N50 equals 58kbp. The reads were also 
assembled using A5 pipeline (151) and closed gaps with IMAGE (152) to 348 contigs 
(each at length >=500 bp) and further scaffolded based on genome sequence of strain 
CLIB122 using ABACAS (153). Total 19,922,824 bp were placed to the final 6 scaffolds. 
The final de novo assembled genome was analyzed to assign open reading frames (ORF) 
with Augustus (154) trained with Y. lipolytica CLIB122 data. A total of 6,420 putative 
ORFs were identified and 4,096 were annotated with Blast2Go (155). The genome 
sequences of PO1f and strain CLIB122 are very similar in nature. By mapping the 
Illumina reads to the CLIB122 genome using BWA (156) and analyzing using Samtools 
(156) and BEDTools (157), a total of 24,675 single nucleotide variations were called in 
PO1f genome sequences (QUAL>=30; DP>=10). Moreover, LTR-retrotransposon 
elements are confirmed being absent in stain PO1f, matching prior information about this 
strain (149). There is one large deletion in chromosome A with four ORF missing. Two 
of them are weakly similar to the SMC5/6 complex (YALI0A01562p and 
YALI0A01602p), which are related to double strand break repairing and homologous 
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recombination (158). These absences may give rise to differences in homologous 
recombination efficiencies in this strain. 
5.3.5 Whole genome sequencing revealed enhanced lipogenesis genotype  
To establish a genotype-phenotype linkage in our evolved strains, we performed 
whole genome sequencing for isolated strains E13 and E26 using an Illumina platform.  
An average of 65X coverage over the genome was obtained and a single nucleotide 
polymorphism (SNP) analysis was performed by mapping the sequences to the CLIB122 
genome (65) and comparing with SNPs identified from our recent draft genome sequence 
of the PO1f strain described in 5.3.4.  The SNPs identified in both E13 and E26 are 
highly similar suggesting both successful enrichment of the enhanced lipogenesis 
subpopulation as well as a co-occurrence of common mutations within this population.  
After filtering the sequences (QUAL>30), a total of 182 SNPs were identified in E13 and 
179 SNPs in E26 with 93 of them in common between the two strains.  Using the IGV 
genome browser (159), a total of 16 SNPs in E13 and 19 SNPs in E26 were determined to 
be in coding regions.  Further analysis taking into account read quality revealed that E13 
and E26 shared 9 authentic coding region mutations (Table 5.2). Out of these 9 coding 
regions, three of these ORFs had linkages with lipogenesis, namely YALI0A02354g 
(YOX1), YALI0E20449g (OSH6) and YALI0F26191g (UGA2). YOX1 encodes for a 
homeobox transcriptional repressor and has been suggested to bind with leucine tRNA 
genes in Y. lipolytica, which could affect the leucine synthesis regulation (141).  OSH6, a 
member of the oxysterol-binding protein family, is associated with the activity of the 
TOR (target of rapamycin) complex 1 (160). Both leucine and TOR were demonstrated to 
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be linked with lipogenesis in our prior engineering efforts (139).  Finally, UGA2 encodes 
for succinate semialdehyde dehydrogenase (SSADH) and participates in the GABA 
(gamma-aminobutyric acid) assimilation pathway, converting succinate semialdehyde to 
succinate following 4-aminobutyrate aminotransferase (161).  Further analysis and 
investigation into the non-coding mutations may also be necessary to fully investigate the 
genotype-phenotype linkage. 
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Table 5.2 Authentic SNP shared in coding region in genome of E13 and E26 with their 
annotation 
 
Chrom Position Base changes  Annotation 
Yali0A 297474 G A YALI0A02354g similar to S. cerevisiae OSH6; member of an 
oxysterol-binding protein family 
Yali0C 138994 T C YALI0C01001g no similarity 
Yali0C 139014 A G YALI0C01001g no similarity 
Yali0C 953493 G A YALI0C07150g similar to S. cerevisiae IRC20; E3 ubiquitin 
ligase and putative helicase 
Yali0C 2966661 C T YALI0C22231g weakly similar to Schizosaccharomyces pombe 
RNA polymerase III Transcription factor 
(TF)IIIC subunit 
Yali0C 3047264 G A YALI0C22726g no similarity 
Yali0D 1576990 G A YALI0D12628g similar to Fusarium solani cutinase 
transcription factor 1 alpha 
Yali0E 2424790 T G YALI0E20449g weakly similar to S. cerevisiae YOX1 
Yali0F 3369592 C T YALI0F26191g similar to S. cerevisiae UGA2 
 
SNP analysis in isolated strains.  Authentic SNPs shared in coding region in genome of E13 and 
E26 with their annotation. (All are missense mutations except mutation in YALI0C22231g is a 
silence mutation) 
 
5.3.6 uga2 pro209ser may play a critical role for improving lipid production 
 As an initial test, we sought to investigate whether individual overexpression of 
these mutants in the engineered strain background would elicit a dominant lipogenesis 
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phenotype.  To this end, no significant improvements were achieved through these efforts. 
We were particularly intrigued by the uga2 mutant as it was functionally related to 
nitrogen metabolism and relatively well studied (161-162). The identified mutation site in 
uga2, Proline 209 is a highly conserved residue based on sequence alignment using 
Geneious software (Figure 5.4a).  Through the use of the i-tasser protein structure 
prediction server (163) and structural analysis to a homologue (Synechococcus sp. 
succinic semialdehyde dehydrogenase, PDB 3VZ3), Pro209 sits at a starting point of a 
helix and is in close proximity to a hydrogen bond forming serine that provides critical 
binding to the cofactor NADP
+
 (164) (Figure 5.4b).  Thus, we hypothesized that the 
mutation from proline to serine could distort the helix, decrease enzyme function, and 
thus alter the GABA assimilation pathways. To test whether the uga2 P209S was a 
reduced function allele, we cultivated the E26 strain and the engineered strain with either 
GABA or NH4
+
 as the sole nitrogen source and tested the ratio of cell densities as a 
measurement of the GABA assimilation function.  E26 showed reduced growth and thus 
a significant decrease in GABA assimilation (Figure 5.4c). To further link uga2 
mutations to increased lipogenesis, we knocked out the UGA2 gene from the engineered 
strain. This modification improved lipogenesis as measured by an over 30% increase in a 
Nile Red staining assay (Figure 5.4d).  Collectively, this data suggests the uga2 mutation 
identified from genome sequencing is indeed a beneficial mutation for enhanced 
lipogenesis.  
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Figure 5.4 Functional and structural analysis of uga2 as an elicitor of lipogenesis 
Figure 5.4a 
 
Figure 5.4b 
 
 
 
209 206 Position 
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Figure 5.4 cont. 
Figure 5.4c 
 
Figure 5.4d 
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Figure 5.4 cont. 
 
(A) Alignment of Y. lipolytica uga2 amino acid sequence with different species to demonstrate 
the conservation of the proline 209 residue.  (B) Structural illustration of the conserved 
proline209 residue. The proline 209 is positioned at the starting point of a helix which harbors 
serine that has a key interaction with co-factor NADP’s phosphate residue.  Illustration is made 
using PyMOL.  (C) Growth of the E26 strain and the engineered strain using GABA or NH4
+
 as 
sole nitrogen source. The ratio of OD (GABA) / OD (NH4
+
) represents the ability of using 
GABA as sole nitrogen source.  (D) Evaluation of uga2 deletion on lipogenesis using a Nile Red 
staining assay. 
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5.3.7 Iterative evolutionary engineering to further improve lipogenesis rates 
The first round of evolutionary metabolic engineering produced strains such as 
E26 that exhibited improved rates, titers, and yields of lipids. Thus, we sought to iterate 
this process using E26 as the parental strain to further enhance lipogenesis rates. In this 
round, we opted to carry out the floating selection using flasks instead of culture tubes in 
hopes of obtaining strains that were better suited for bioreactor conditions. After five 
rounds of enrichment, screening and selection, we first characterized 34 isolated mutants 
from this round and chose the top candidate, E26E1, for further testing (Figure 5.5a).  
E26E1 had a 31% increase of our lipid ranking metric (OD600*Nile Red mean 
fluorescence) compared to the E26 strain and a 97% increase compared to the engineered 
strain.  Visualization of the E26E1 strain using fluorescence microscopy showed fully 
saturated cells (Figure 5.5b).  To further evaluate the lipid production performance of 
E26E1, we cultivated this strain in a bioreactor with the same conditions as for E26 and 
the engineered strain (Figure 5.5c).  Overall, E26E1 showed an improved lipogenesis 
capacity with a titer of 40.4 g/L and an average specific productivity of 0.55 g/L/h (a 
slight increase over E26).  The final lipid content reached 85% with a yield of 0.253 g/g 
glucose (Table 5.1).  More interestingly, between 48 and 72 hours of fermentation, the 
instantaneous specific productivity reached 0.86 g/L/h, a 20% increase over the E26 
strain.  Thus, this further evolved strain could benefit from fed-batch fermentation 
operation.   
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Figure 5.5 Iterative evolutionary engineering can further improve lipogenesis rates 
Figure 5.5a 
 
Figure 5.5b 
 
 
 
 
 
E26E1 
strain 
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Figure 5.6 cont. 
Figure 5.5c 
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Figure 5.6 cont. 
 
(A) Overall performance of iterative evolutionary metabolic engineering using Mean Nile Red 
fluorescence * OD 600 as metric to rank the strains. Green: the engineering strain; light blue: non 
EMS mutagenized control strains; dark blue: isolated EMS mutants. The selected mutant, E26E1 
is circled in red.  (B) Fluorescence microscopy pictures of the E26E1 strain stained with Nile Red 
to visualize lipids.  (C) Batch bioreactor fermentation profile of the E26E1 strain for lipid 
production. 
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5.3.8 RNA-Seq analysis revealed the importance of glutamate degradation and 
DHAP biosynthesis  
To further exam the transcriptome level changes in the high lipogenesis strain, we 
performed RNA-Seq analysis with E26 stain and the control strain (PO1f leu
+
 ura
+
). Due 
to the identified beneficial mutation in uga2 from E26 and E13, we first took a look into 
the glutamate degradation pathway genes and compared their expression (based on log2 
fold change) to their expression in PO1f leu+ ura+. There are two metabolic pathways for 
glutamate degradation in Y. lipolytica. The first pathway (along with expression fold 
changes) uses glutamate decarboxylase (GAD1, YALI0F08415g, -0.82 and 
YALI0F16753g, -0.37), GABA transaminase (UGA1, YALI0F18238g, no significant 
change) and succinate semialdehyde dehydrogenase (UGA2, YALI0F26191g, -0.27).  
The second pathway (along with expression fold changes) uses glutamate dehydrogenase 
(GDH2, YALI0F17820g, +0.20).  These transcriptional changes suggest a downregulated 
glutamate decarboxylase pathway and a slightly upregulated glutamate dehydrogenase 
pathway.  In the glutamate decarboxylase pathway, degradation costs one 2-oxoglutarate 
and generates one succinate, however, the glutamate dehydrogenase pathway generates 
one 2-oxoglutarate. From this analysis, it is again possible that the glutamate 
dehydrogenase pathway can lead to an unbalanced TCA cycle and subsequently lead to 
increased citrate secretion from mitochondria. Interestingly, glutamate dehydrogenase 
also releases one ammonia molecule during the reaction and we indeed found 
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accumulation of ammonia in the medium as characterized in the high lipid production 
strain described in Chapter 4. 
To gain a more holistic, global view of gene expression changes in the evolved 
strain, we also sought to examine the top overexpressing genes in the E26 strain. Several 
of the most highly expressed genes are related to important aspects of lipogenesis such 
YCF1 (YALI0E08969g) for antioxidation, SPS19 (YALI0F01650g) for denoyl-CoA 
reductase, ACP1 (YALI0D24629g) for acyl-carrier protein. Interestingly, 
dihydroxyacetone kinase (YALI0E20691g) was also upregulated.  This enzyme generates 
dihydroxyacetone phosphate (DHAP), a backbone precursor for triacylglycerol synthesis, 
which could be a very important molecule in lipogenesis. Interestingly, further analysis of 
DHAP biosynthesis related gene expression demonstrates that both transketolase and 
transaldolase were downregulated in E26 (-0.77 and -0.38). This data suggested a 
reduced exchange between PPP and glycolysis, which could lead to an accumulation of 
glyceraldehyde 3-phosphate (G3P) that can then be converted to DHAP or continue 
through glycolysis. The reversible reaction between DHAP and G3P could be an 
important regulatory node for lipogenesis, since the carbon flux can go to DHAP (for 
lipid biosynthesis), PPP (for generating NADPH and pentose) or continue into glycolysis 
to TCA cycle (for most biosynthetic pathway including fatty acid biosynthesis).  
 
5.4 Discussion and conclusion 
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Evolutionary metabolic engineering strategies have been successfully applied to 
improve production of molecules such as lactic acid, L-ornithine and isobutanol (31, 165-
166).  Here we developed a floating based selection scheme that was able to significantly 
increase: (1) lipid titers from 25 g/L to over 40 g/L, (2) average specific productivity 
from 0.21 g/L/h to 0.55 g/L/h and (3) overall yield from 0.158 g/g to 0.253 g/g.  
Moreover, we were able to achieve maximum instantaneous productivities of 0.86 g/L/h 
during the fermentation.  Previous rational engineering efforts resulted in unbalanced 
strains with increased lipid production at the cost of decreased biomass production and 
fitness.  In contrast, the floating cell enrichment scheme used here resulted in concurrent 
enhanced lipogenesis and biomass formation. Thus, we have efficiently resolved the 
competition between product titers and yields by evolutionary engineering following our 
rational engineering approach.  
The balance of lipogenesis and biomass generation developed here could serve as 
a key for industrialized and economically viable production of oleochemcials using Y. 
lipolytica.  The titer of over 40 g/L is the highest titer reported to the date for this 
organism.  Furthermore, this evolved strain exhibits lipid accumulation during the cell 
growth phase without the need for extensive nitrogen starvation.  The result is 
improvements in all three metrics for a process: rate, titer, and yield. 
In addition to the improvements in lipid production, whole genome sequencing of 
the evolved strain produced critical information about the underlying metabolism.  
Among the many SNPs identified in this analysis, a major contributing factor to the 
observed phenotype was a reduced/loss of function mutation in the uga2 allele. Uga2p 
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functions in the GABA assimilation pathway, which serves as one of two pathways for 
glutamate degradation and thus related to nitrogen assimilation, a key factor for 
triggering lipogenesis in Y. lipolytica (56).  Moreover, previous studies suggest that 
nitrogen sources, especially glutamate, can be a critical factor for lipid accumulation 
inside the cells (167).  In Saccharomyces cerevisiae, uga2 null mutants result in an 
accumulation of α-ketoglutarate (168) as well as a decrease in succinic acid (more than 5 
fold decrease) (169).  Moreover,  reductive glutamine metabolism has been suggested as 
a function of the α-ketoglutarate to citrate ratio in cells (170).  Collectively, this 
information suggests the decrease of GABA assimilation could lead to large changes in 
carbon flux and result in an imbalance of TCA cycle intermediates which then stalls the 
TCA cycle allowing for more flux through to fatty acid biosynthesis.  In this regard, this 
rewiring may be similar to the function of AMP deaminase as proposed before (56).  It is 
also likely that decreased GABA assimilation can alter the nitrogen metabolic flux during 
the protein degradation stage and also lead to increased lipogenesis.  Beyond both carbon 
and nitrogen flux, it is known that the glutamate metabolic node is critical in many 
processes and can act to buffer redox changes in the cell (171).  Furthermore, the relation 
between GABA metabolism and the TOR pathway, an important signaling pathway for 
lipid accumulation (139), has been suggested (172-173).  Thus, it is likely that the overall 
rewiring achieved through this evolutionary approach is quite complex.  Beyond the 
GABA target, two additional notable mutations, YOX1 and OSH6, were also closely 
related to known lipogenesis elicitors (i.e. leucine biosynthesis, TOR pathway) (139).  
While the overexpression of these mutant alleles did not immediately improve phenotype, 
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they merit further investigation and can likely be novel engineering targets in the future. 
Further analysis of the evolved strain E26 with RNA-Seq supported the beneficial effect 
of uga2 mutation and revealed the potential importance of DHAP in high lipogenesis. 
Overall, as described in this chapter, we developed an evolutionary metabolic 
engineering approach that successfully enhanced lipogenesis of a previously engineered Y. 
lipolytica strain to achieve lipid titers of 40.5 g/L with an average specific productivity 
reaching 0.55 g/L/h, both representing the highest to the date in this organism. Moreover, 
cells were saturated with upwards of 89% lipid content in bioreactors.  Through whole 
genome sequencing and RNA-Seq, we were able to provide a link between GABA 
assimilation and lipogenesis. This evolutionary metabolic engineering approach linked 
with a simple floating enrichment to enrich high lipogenesis potential presents a platform 
for engineering a number of other oleaginous systems including potentially microalgae to 
increase lipid production without compromising cell growth.  The resulting strains 
developed in this chapter should serve as a stepping stone towards creating a robust, 
efficient engineering platform for converting carbon sources into value-added 
oelochemical and biofuels. 
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Chapter 6: A mutant mga2 protein confers improved lipogenesis in 
Yarrowia lipolytica 
6.1 Chapter summary 
 Lipogenic organisms represent great starting points for engineering high lipid 
production. While previous engineering efforts were able to significantly improve 
lipogenesis in Yarrowia lipolytica (Chapters 4 and 5), understanding of its lipogenesis 
process was rather limited. In this chapter, we started from a superior lipid accumulation 
strain, L36, and employed whole genome sequencing and inverse metabolic engineering 
to identify a mutant mga2 protein conferring improved lipogenesis.  Phenotypic 
characterization revealed this mutant’s newly-acquired role in regulating the profile of 
unsaturated fatty acids. Furthermore, transcriptomic analysis suggested that this mutant 
enhancer operates by redirecting the net carbon flux difference from an upregulated 
glycolysis pathway and a downregulated TCA cycle into an upregulated fatty acid 
synthesis pathway.  
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6.2 Introduction 
In Chapters 4 and 5, we described our efforts of exploring the metabolic 
landscape of lipogenesis through rational and evolutionary engineering, thus driving 
production to titers exceeding 40 g/L in bioreactors. This exploration can also be done in 
other ways, such as combining systems and combinatorial engineering of metabolic 
enzymes (174), engineering the sensor-regulator system (175) or metabolic switches (11) 
as well as engineering global transcriptional regulators (176-177). The landscape scanned 
by these approaches contains overlapping phenotypes despite the fact that these 
engineering efforts targeted different enzymes and pathways, illustrating the complex 
regulation and crosstalk inherent to this system.   
Lipogenesis is regulated in a complex manner (178). This complexity can lead to 
a disconnection between the expected and actual results of rational engineering. 
Regulators play a key role in the lipogenesis regulatory network. Thus, identification and 
engineering of global regulators related to lipogenesis could potentially de-bottleneck 
lipid production, enriching our understanding over the process and enhancing our 
engineering ability. A recent study of SNF1 (179), a regulator for lipid accumulation, 
showed that deletion of SNF1 conferred a 2.6 fold improvement to lipid production . 
Moreover, results from studies of UBX2 (180) and MIG1 (181) also indicated important 
function as regulators of lipogenesis. 
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In this chapter, we report the identification and characterization of a mutant mga2 
protein functioning as a lipogenesis enhancer from the L36 mutant strain. In doing so, we 
further engineered the strain into a high lipid producer and explored the altered 
transcriptomic landscape caused by the mutation. Specifically, we identified a mutant 
mga2 exhibiting a similar regulatory effect on unsaturated fatty acid biosynthesis as the 
mga2 knockout but which is better able to enhance lipogenesis in Y. lipolytica. 
Transcriptomic analysis suggested that a carbon flux imbalance was created by the 
upregulation of glycolysis and the downregulation of TCA cycle, leading to upregulated 
biosynthesis of acetyl-CoA/acyl-CoA from pyruvate and hence fatty acid production. 
 
6.3 Results 
6.3.1 Isolation and whole-genome sequencing of a high lipid producer revealed a 
mutant mga2 
During the course of metabolic engineering approach to improve lipid production 
through construction genomic library (overexpression library on plasmid) and following 
screening, we isolated mutant strain (L36) exhibiting a dark purple color when grown on 
solid media containing Nile Red, indicative of high lipid content. Strikingly, during 
growth in liquid media, this strain settled at the liquid surface while cells from the parent 
strain remained at the bottom, indicating a reduced mass density in the mutant, consistent 
with increased lipid production.  Indeed, Nile Red staining of the mutant strain followed 
by fluorescence microscopy indicated almost nothing but lipid inside the cells (Figure 
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5.1, Chapter 5).  Furthermore, TLC plate analysis of cell extracts indicated that the 
majority of accumulated lipids were in the form of triacylglycerol (Figure 6.1a). 
However, this significant improvement is not due to the plasmid the strain contained due 
to no beneficial effect was detected when the plasmid was transformed into a control 
strain. 
In order to identify the mechanism underlying this superior lipid accumulation 
phenotype, we isolated genomic DNA and performed whole-genome sequencing with 
strain L36 using the Illumina HiSeq platform yielding 2x100bp reads. A 47x coverage 
was obtained and single nucleotide polymorphism (SNP) analysis was performed by 
mapping the sequences to the CLIB122 genome (65) and comparing these to the SNPs 
identified from the draft genome sequence of the PO1f strain (Chapter 5). After filtering 
the sequences (Q>30), a total of 259 SNPs were identified in L36. Manual curation using 
the IGV genome browser (159) revealed that there is only one coding region mutation in 
L36: YALI0B12342g (g1927a), corresponding to MGA2 (g1927a). Mga2 has been well-
studied as regulator for multiple cellular processes. It is known to be proteolytically 
processed on the ER membrane before translocation into the nucleus to function as a 
transcriptional regulator for delta-9 desaturase gene expression with its homolog spt23 
(182-185).  Overexpression of mga2 can also influence the chromatin accessibility (186). 
Mga2 has also been associated with hypoxia as well as with glucose sensing (187-188). 
Its linkage with lipogenesis has also been studied in S. cerevisiae, showing that 
overexpression of mga2 was accompanied by the appearance of large lipid particles due 
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to accumulation of unsaturated triacylglycerol (189). To understand the potential impact 
of the isolated mutation on mga2 function, we first analyzed the mga2 protein sequence 
from Y. lipolytica using the Simple Modular Analysis Research Tool (SMART) (190). 
This analysis revealed the presence of putative functional domains which were identical 
and arranged similarly to other mga2 proteins: an IPT domain (DNA-binding domain), an 
ankyrin-like domain (protein binding domain) and a transmembrane (TM) domain. The 
isolated mutation occurs in the middle of the DNA-binding domain and the protein 
binding domain at position amino acid 643, changing a glycine into arginine 
(mga2G643R).  
 
6.3.2 MGA2 (g1927a) leads to superior lipogenesis compared with MGA2 deletion 
We sought to test the importance of the mga2G643R mutation using inverse 
metabolic engineering. We first knocked out the mutant mga2 gene from L36.  The lipid 
accumulation from the resulting strain L36 Δmga2(g1927a) leu+ was dramatically 
decreased compared with L36 leu
+
, confirming the importance of this SNP to the superior 
lipogenesis phenotype in L36 (Figure 6.1b). Subsequently, we deleted wild-type mga2 
from the parent strain PO1f (PO1fΔmga2 leu+) and then integrated the mutant mga2 
(including 1000bp upstream of the start codon to preserve native expression/regulation) 
to test whether this SNP is the dominant mutation causing a superior lipogenesis 
phenotype.  The resulting strain PO1fΔmga2 MGA2(g1927a) leu+ exhibits an almost, if 
not all, restored phenotype compared to L36 leu
+
 (Figure 6.1b,c).  In particular, knockout 
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of mga2 from PO1f resulted in an over 2 fold increase in Nile Red signal, and 
introduction of mutant mga2 restored the superior lipogenesis phenotype as characterized 
by Nile Red straining (Figure 6.1b) as well as the floating phenotype (Figure 6.1c). 
Hence, mga2 is an important lipogenesis regulator in Y. lipolytica. While knockout can 
improve lipogenesis, the mutant mga2 identified here functions as a superior lipogenesis 
enhancer. Collectively, these results suggest that this mutant mga2 protein results in a 
gain-of-function in the context of lipogenesis.  
 
Figure 6.1 MGA2 (g1927a) leads to superior lipogenesis and is better than an MGA2 
deletion 
Figure 6.1a 
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Figure 6.1 cont. 
Figure 6.1b 
 
Figure 6.1c 
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Figure 6.1 cont. 
(A) TLC plate analysis showing that majority of lipid accumulated in L36 is in the form of 
triacylglycerol. (B) Nile Red staining characterized with flow cytometry for strains through 
inverse metabolic engineering process. (C) Floating phenotype exhibited with L36 leu
+
 and 
PO1fΔmga2 MGA2(g1927a) leu+ after cultivation. 
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6.3.3 Metabolic engineering of strain L36 for high lipid production  
While L36 showed promising lipid accumulation traits, its lipid production 
potentials were not yet fully explored. To further enhance its lipid production capacity, 
we sought to introduce two previously identified lipogenesis enhancers: PEX10 
(pexisome biogenesis factor 10) knockout and DGA1(diacylglycerol acyltransferase 1) 
overexpression, as identified in Chapter 4. We first integrated DGA1 into L36 with 
leucine and uracil biosynthesis capacity, improving Nile Red fluorescence by 13% 
(Figure 6.2a). Intriguingly, knockout PEX10 significantly decreased lipid accumulation 
inside the cells (Figure 6.2a). To further examine the lipid production performance of the 
engineered mutant strain, cultivation in a bioreactor was undertaken (Figure 6.2b). The 
lipid titer reached 25 g/L with a specific productivity of 0.142 g/L/h, suggesting its 
potential for use as an industrial production host. Both measures are comparable to those 
from the rational metabolic engineering efforts described in Chapter 4.  
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Figure 6.2 Metabolic engineering lipid production in strain L36 
Figure 6.2a 
 
Figure 6.2b 
 
(A) Lipogenesis among control strain, L36 leu
+
 ura
+
, engineered strains L36 DGA1 leu
+
 ura
+
 and 
L36 Δpex10 leu+ ura+ were characterized using flow cytometry with Nile Red strained cells. (B) 
Fed batch bioreactor fermentation profile of the L36 DGA1 leu
+
 ura
+
 strain for lipid production. 
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6.3.4 Rag- phenotype and elevated unsaturated fatty acid levels associated with 
mga2 
To further understand this mutant mga2 protein, we cultivated PO1f leu
+
, L36 
leu
+, PO1fΔmga2 leu+ and PO1fΔmga2 MGA2 (g1927a) leu+ on solid media containing 
YPD, GAA (a rich glucose medium supplemented with the mitochondrial inhibitor 
antimycin A) and GAA+UFA (GAA with unsaturated fatty acids). All strains grew well 
on YPD plates, while only PO1f leu
+
 could grow on GAA plates.  The addition of 
unsaturated fatty acids (GAA+UFA) was required to rescue the growth of L36 leu
+
, 
PO1fΔmga2 leu+ and PO1fΔmga2 MGA2 (g1927a) leu+ (Figure 6.3a). These phenotypes 
are comparable to what has been reported for S. cerevisiae and Kluyveromyces lactis 
during mga2 knockout (187-188). This impaired growth on GAA plates is known as the 
Rag
-
 phenotype (191) and is usually ascribed to defective glycolysis and/or fermentation. 
Interestingly, this phenotype can be rescued by UFA, suggesting a functional correlation 
mediated by mga2 between UFA biosynthesis and defective growth, which is similar to 
observations in K. lactis. Following this, we studied the fatty acid profile changes in these 
strains. In Y. lipolytica, both the knockout and the mutant mga2 protein led to an increase 
in C16:1 and C18:1 fatty acid production at the cost of C16:0 and C18:0 (Figure 6.3b). 
These results stand in contrast to results from S. cerevisiae and K. lactis, suggesting a 
different function of mga2 in regulating desaturase gene expression in Y. lipolytica. The 
elevated C16:1 and C18:1 production from the knockout strain indicated an upregulation 
of delta-9 desaturase gene (OLE1), suggesting that mga2 functions as a repressor for 
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OLE1 expression in Y. lipolytica. The results demonstrated here, which show similar 
Rag
-
 phenotype and UFA profile from the mga2 deletion and mutant mga2 protein 
expression, suggest that the mutant functions similarly to a deletion in terms of regulating 
glycolysis/fermentation and UFA biosynthesis. However, the improved lipogenic 
capacity of the mutant mga2 protein confirmed that there are preserved functions in this 
mutant which are important for lipid accumulation. 
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Figure 6.3 Mga2 is related to Rag- phenotype and unsaturated fatty acid level 
Figure 6.3a 
 
Figure 6.3b 
  
(A) Plate growth assay with different inverse metabolic engineering strains on YPD, GAA and 
GAA-UFA plates. (B) Fatty acid profile from GC analysis with different inverse metabolic 
engineering strains. 
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6.3.5 Link the mga2G643R with phenotype using RNA-Seq 
 To further probe the mechanisms underlying the phenotypic changes resulting 
from mga2G643R, we performed RNA-Seq analysis with PO1f leu
+
 and PO1fΔmga2 
MGA2 (g1927a) leu
+
. Overall, we identified 429 upregulated and 467 downregulated 
genes (> 1-fold change) with edgeR (192). Due to changes in the fatty acid profile, we 
first examined the expression of desaturase genes. Indeed, the expression of delta-9 
desaturase (YALI0C05951g) and delta-12 desaturase (YALI0B10153g) were upregulated 
in the inverse engineered strain, explaining the increased level of C16:1/C18:1 and C18:2 
fatty acids.  
 Due to the importance of acetyl-CoA/malonyl-CoA and glycerol-3-phosphate 
(G3P) in lipid biosynthesis, we also examined the expression of genes related to their 
biosynthesis (Figure 4). We found that while most of the genes involved in glycolysis 
were significantly upregulated in the mutant strain, genes related to TCA cycles were not, 
especially the genes close to citrate biosynthesis. This observation raises the possibility 
that the improved lipogenesis in the inverse engineered strain results from the generation 
of extra carbon flux due to an imbalance between increased glycolysis and reduced TCA 
cycle. This net carbon flux could then be funneled into acetyl-CoA biosynthesis through 
the upregulated pyruvate dehydrogenase and citrate synthase. However, it is also 
interesting to note that pyruvate decarboxylase, another possible route to generate acetyl-
CoA from pyruvate, is downregulated. While pyruvate dehydrogenase yields one NADH 
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to generate an acetyl-CoA, pyruvate decarboxylase costs one, indicating a substantial 
benefit for the cell to use pyruvate dehydrogenase instead of pyruvate decarboxylase. The 
acetyl-CoA in mitochondria can be converted into citrate, exported efficiently through the 
upregulated citrate transporters, and converted into acetyl-CoA with the upregulated ATP 
citrate lyases. The overproduced acetyl-CoA can then be converted into malonyl-CoA by 
the 6-fold upregulated acetyl-CoA carboxylase. Besides acetyl-CoA/malony-CoA, the 
increased dihydroxyacetone phosphate (DHAP) from glycolysis can also be transformed 
into G3P through a 6-fold upregulated G3P dehydrogenase. Overall, mutant mga2 
improves lipogenesis through regulating carbon metabolism genes. In addition, we also 
examined the expression of the glutamate degradation pathway due to its importance in 
the control of the carbon/nitrogen flux distribution and the aforementioned discussion of 
its importance as described in Chapter 5.  We found that all the genes related to glutamate 
degradation exhibit either a downregulation or no significant change, suggesting that 
protein degradation may not be the major source of carbon for lipid biosynthesis in the 
context of this mutation.  
To gain an overall view of transcriptomic changes caused by mutant mga2, we 
performed gene set enrichment analysis with significantly upregulated genes and 
downregulated genes (>1-fold change) (Table 1). Overall, the analysis supported the 
improved lipogenesis phenotype. In particular, fatty acid biosynthesis pathways were 
enriched in upregulated genes and fatty acid metabolisms as well as glycerolipid 
metabolism were enriched in downregulated genes. Interestingly, among the upregulated 
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genes, analysis with INTROPRO suggested the enrichment of mitochondrial substrate 
carrier genes.  Among these, citrate and oxoglutarate carrier protein (YALI0B10736g) 
exhibited a 6.2-fold overexpression, which could be very important as this protein 
functions to export citrate from mitochondria and import oxoglutarate, with a net export 
of NADPH (193).  As a consequence, this gene could supply citrate for acetyl-CoA 
biosynthesis as well as NADPH as cofactor for fatty acid biosynthesis.  Oxaloacetate 
carrier (OAC1, YALI0E04048g) also represents an important link to citrate export: it 
takes in oxaloacetate, which is produced by ATP citrate lyases when converting citrate to 
acetyl-CoA, thus recycling carbon back to the TCA cycle.  Furthermore, one ATP–ADP 
translocase protein (AAC, YALI0A10659g), which is responsible for importing ADP into 
and exporting ATP out of the mitochondria, is also overexpressed.  This protein could 
supply ATP to the ATP citrate lyases for production of acetyl-CoA, as well as supply 
energy to other cellular processes. Among the significantly downregulated genes, we 
found that the fatty acid metabolism pathway (KEGG) was enriched in significantly 
downregulated genes, including POX2 (YALI0F10857g), POX3 (YALI0D24750g), 
POX5 (YALI0C23895g), enoyl-CoA dehydrase (YALI0B10406g) confirming a decrease 
in fatty acid degradation.  We also found that glycerolipid metabolism was enriched, in 
particular DGA1 (YALI0D07986g), a very important lipogenesis enhancer as identified 
in Chapter 4, suggesting that the improvement to lipid accumulation is mainly due to 
initial carbon flux rewiring, further verifying  the previous beneficial results obtained 
from the metabolic engineering of L36. 
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As a transcriptional regulator, this mutant mga2 protein could also regulate the 
expression of other regulators to achieve this complex rewiring of cellular metabolism. 
To understand this process a more deeply, we analyzed the upregulated and 
downregulated genes separately using SCOPE to investigate the enrichment of motifs in 
the promoter region (-800). When comparing the top 10 candidates from both sets to the 
known transcription factor binding sites in S. cerevisiae (194), we found that enriched 
motifs showed similarity to the binding sites of mig1,2,3 proteins (aytttcwgt and thttatta) 
and sko1 protein (tacgtab) in the promoters of upregulated genes, and leu3 protein 
(gttaacd) and azf1 protein (aaaga) in the downregulated genes. These transcription factors 
are closely linked with cellular metabolism, in particular the regulation of carbon and 
nitrogen uptake. Collectively, mutant mga2 improved lipogenesis by rewiring cellular 
metabolism related to carbon flux, fatty acid related biosynthesis and degradation as well 
as other cellular metabolic regulators.    
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Figure 6.4 Differential expression level of genes related to central carbon flux for lipid 
biosynthesis 
 
Differential expression level of genes related to central carbon flux for lipid biosynthesis. PFKM 
change showing as PFKM from PO1f leu2
+
/PFKM from PO1f Δmga2 MGA2 (g1297a) leu+. All 
the changes are significant unless labeled with no (Green: upregulation; Red: downregulation; 
yellow: change cannot be determined). PFKM is from cufflink calculation and statistical analysis 
is using data from edgeR analysis.  
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Table 6.1 Gene set enrichment analysis with significant differential expressed genes from 
RNA-Seq experiments 
 
Upregulated genes Downregulated genes 
  GOTERM 
GO:0018130~heterocyclebiosyntheticpr
ocess 
GO:0030001~metaliontransport 
GO:0016053~organicacidbiosyntheticpr
ocess 
GO:0046942~carboxylicacidtransport 
GO:0046394~carboxylicacidbiosynthetic
process 
GO:0015837~aminetransport 
GO:0008610~lipidbiosyntheticprocess GO:0015849~organicacidtransport 
GO:0044271~nitrogencompoundbiosynt
heticprocess 
GO:0006865~aminoacidtransport 
GO:0055114~oxidationreduction GO:0055114~oxidationreduction 
GO:0042278~purinenucleosidemetaboli
cprocess 
GO:0006812~cationtransport 
GO:0046128~purineribonucleosidemeta
bolicprocess 
GO:0006811~iontransport 
GO:0051188~cofactorbiosyntheticproce
ss 
GO:0000041~transitionmetaliontransport 
GO:0016021~integraltomembrane GO:0006825~copperiontransport 
GO:0031224~intrinsictomembrane GO:0006071~glycerolmetabolicprocess 
GO:0033293~monocarboxylicacidbindin
g 
GO:0019400~alditolmetabolicprocess 
GO:0004806~triacylglycerollipaseactivit
y 
GO:0019751~polyolmetabolicprocess 
GO:0016836~hydro-lyaseactivity GO:0051252~regulationofRNAmetabolicprocess 
GO:0009374~biotinbinding GO:0006355~regulationoftranscription,DNA-
dependent 
  GO:0045449~regulationoftranscription 
  GO:0016021~integraltomembrane 
  GO:0031224~intrinsictomembrane 
  GO:0005576~extracellularregion 
  GO:0046873~metaliontransmembranetransportera
ctivity 
  GO:0046915~transitionmetaliontransmembranetra
nsporteractivity 
  GO:0015171~aminoacidtransmembranetransporter
activity 
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Table 6.1 cont. 
  
 
GO:0005275~aminetransmembranetransporteractiv
ity 
  
   
 
GO:0015082~di-,tri-
valentinorganiccationtransmembranetransporteract
ivity 
  GO:0005375~copperiontransmembranetransportera
ctivity 
  GO:0004175~endopeptidaseactivity 
  GO:0048037~cofactorbinding 
  GO:0004371~glyceronekinaseactivity 
  GO:0004190~aspartic-typeendopeptidaseactivity 
  GO:0070001~aspartic-typepeptidaseactivity 
  GO:0003700~transcriptionfactoractivity 
  GO:0050662~coenzymebinding 
  GO:0046914~transitionmetalionbinding 
  GO:0043167~ionbinding 
  GO:0043169~cationbinding 
  GO:0046872~metalionbinding 
  GO:0070011~peptidaseactivity,actingonL-
aminoacidpeptides 
  GO:0030528~transcriptionregulatoractivity 
KEGG PATHWAY 
yli00061:Fattyacidbiosynthesis yli00071:Fattyacidmetabolism 
  yli00561:Glycerolipidmetabolism 
  yli00650:Butanoatemetabolism 
  yli00410:beta-Alaninemetabolism 
  yli00010:Glycolysis/Gluconeogenesis 
  yli00640:Propanoatemetabolism 
  yli00330:Arginineandprolinemetabolism 
  yli00350:Tyrosinemetabolism 
  yli00280:Valine,leucineandisoleucinedegradation 
  yli00980:MetabolismofxenobioticsbycytochromeP45
0 
INTROPRO 
IPR001993:Mitochondrialsubstratecarri
er 
IPR011701:MajorfacilitatorsuperfamilyMFS-1 
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Table 6.1 cont. 
IPR018108:Mitochondrialsubstrate/soluteca
rrier 
IPR005828:Generalsubstratetransporter 
IPR011701:MajorfacilitatorsuperfamilyMFS-
1 
IPR002293:Aminoacid/polyaminetransporterI 
IPR000873:AMP-
dependentsynthetaseandligase 
IPR004648:Tetrapeptidetransporter,OPT1/isp4 
 
IPR002113:Adeninenucleotidetranslocator1 
IPR004841:Aminoacidpermease-
associatedregion 
IPR003819:TaurinecatabolismdioxygenaseTa
uD/TfdA 
IPR016040:NAD(P)-bindingdomain 
IPR005482:Biotincarboxylase,C-terminal IPR004813:OligopeptidetransporterOPTsuperf
amily 
IPR011764:Biotincarboxylationregion IPR004840:Aminoacidpermease,conservedsite 
IPR013816:ATP-graspfold,subdomain2 IPR018289:MULEtransposase,conserveddomai
n 
IPR002123:Phospholipid/glycerolacyltransfe
rase 
IPR009007:Peptidaseaspartic,catalytic 
IPR006139:D-isomerspecific2-
hydroxyaciddehydrogenase,catalyticregion 
IPR001461:PeptidaseA1 
IPR006140:D-isomerspecific2-
hydroxyaciddehydrogenase,NAD-binding 
IPR003663:Sugar/inositoltransporter 
  IPR002198:Short-
chaindehydrogenase/reductaseSDR 
  IPR000209:PeptidaseS8andS53,subtilisin,kexin,
sedolisin 
  IPR001969:Peptidaseaspartic,activesite 
  IPR001509:NAD-
dependentepimerase/dehydratase 
  IPR002347:Glucose/ribitoldehydrogenase 
  IPR002328:Alcoholdehydrogenase,zinc-
containing,conservedsite 
  IPR015500:PeptidaseS8,subtilisin-related 
  IPR004007:Dakphosphatase 
  IPR004006:Dakkinase 
  IPR007274:Ctrcoppertransporter 
  IPR001092:Basichelix-loop-
helixdimerisationregionbHLH 
  IPR013154:AlcoholdehydrogenaseGroES-like 
  IPR002085:Alcoholdehydrogenasesuperfamily,
zinc-containing 
  IPR013149:Alcoholdehydrogenase,zinc-binding 
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Table 6.1 cont. 
  IPR004843:Metallophosphoesterase 
  IPR013112:FAD-binding8 
  IPR005829:Sugartransporter,conserved site 
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6.4 Discussion and conclusion 
Lipogenesis is a complex and energy-consuming process. Rewiring this process 
usually requires complex cellular metabolic engineering, which is time and labor 
intensive. The mutant mga2 protein conferring improved lipogenesis identified here 
strongly validated the power of transcriptional regulators in altering a complex cellular 
phenotype. Strikingly, when compared to the rational metabolic engineering for high 
lipogenesis in this yeast as presented in Chapter 4, which required a large scale 
exploration of lipogenesis-related targets, this single SNP in the genome placed its de 
novo lipid accumulation on par with the engineered strain (139). The nature of this result 
is characteristic of the gTME (global transcriptional machinery engineering) approach 
(177); single mutations in enzymatic proteins are usually not enough to dramatically 
improve complex cellular phenotypes and sequential beneficial mutations are hard to 
achieve without strong selection pressure.  However, simple mutations to global 
transcriptional regulators can alter the metabolism of the whole cell to a very large extent, 
thus efficiently improving a complex phenotype.  
Although the results of plate assays for the Rag
-
 phenotype resembled those from 
K. lactis and S. cerevisiae, the alterations to the fatty acids profile was different.  In K. 
lacis, there is an increase of C18:1 at the cost of C18:2 and C18:3 (188) while in S. 
cerevisiae, there is reduction of C16:1 and an increase in C18:1 (195). This data suggests 
a difference in mga2’s function in Y. lipolytica. In addition, the changes in UFA with 
mutant mga2 could also explain the detrimental effect of the PEX10 knockout in L36. 
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Moreover, the mga2 knockout strain contained a similar fatty acid profile to the strain 
with mutant mga2, indicating a similar loss of function over the control of OLE1 from 
this mutation. However, the clearly improved lipogenesis as illustrated by the floating 
phenotype and Nile Red staining suggests that the mutant protein functions differently 
than the knockout. Indeed, previous studies also suggested that mga2 could regulate the 
stability of OLE1 mRNA through exosome-mediated mechanisms (182) as well as 
influencing chromatin accessibility (186), presenting the possibility of  an incomplete 
loss of function from the mutation.  
Despite the lack of a conversed domain predicted to contain the mutation, 
alignment of mga2 sequences from different species showed that the mutant position and 
adjacent sequences are actually highly conserved with other yeast species such as S. 
cerevisiae and Scheffersomyces stipitis (196) (Figure 6.5). Interestingly, this conserved 
region in S. cerevisiae (VGLKMNGKLEDAR) has been predicted to be subject to 
ubiquitination on the second lysine (197). A recent study also suggested that the region 
between the IPT domain and the ANK domain are  putative sites of initial degradation 
and processing of mga2 in S. cerevisiae (198). This process is similar to its human 
homolog NFκB (199). However, in Y. lipolytica mga2 as well as in the homologous 
sequences from two other oleaginous yeast sequences Rhodosporidium toruloides (200) 
and Rhodotorula glutinis (201), there is an arginine in the position of lysine, which is 
likely to stop ubiquitination and the resulting degradation. Moreover, in sequence of the 
homologous regulator spt23, there remains a lysine at this position (Figure 6.5). In 
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addition, two lysine residues within membrane-anchored mga2 have also been studied as 
targets of Rsp5p ubiquitination for cleavage (202). These results suggest the possibility of 
multi-step processing of mga2, and hence a complex underlying regulation mechanism. A 
previous study with its human relative, NFκB, indicated the possibility of non-
ubiqutination dependent processing in the conserved region aforementioned (203), raising 
the possibility that due to the level of sequence conservation, processing can occur with 
native mga2 in Y. lipolytica but not the mutant one. As a consequence, mga2G643R does 
not get activated to carry out its full function as a transcriptional factor yet still functions 
in other ways such as improving RNA stability, which could explain both the similarities 
and differences between mga2G643R and mga2 deletion.  
When comparing the differential gene expression data obtained here with that 
obtained from another regulator (SNF1 knockout) for lipogenesis in Y. lipolytica (179), 
out of 49 targets identified for SNF 1 knockout, 32 of these showed differential 
expression in mutant mga2 strain, with 3 out of 8 downregulated genes and 24 out of 41 
upregulated genes overlapping. This suggests there are similar underlying lipogenesis 
rewiring mechanisms shared between the two modifications. However, the large number 
of targets identified through this study may indicate a more complex and complete 
rewiring over cellular metabolism using the mutant mga2 protein, which also led to a 
better lipogenesis phenotype comparing to the SNF1 knockout. Indeed, through the 
promoter motif enrichment analysis, the potential of involvement of several 
transcriptional factors was revealed. Mig1,2,3 proteins have been studied for their role in 
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mediating glucose repression and  sko1 protein has been shown to interact with mig 
proteins as well as to regulate cellular metabolism under oxidative stress (204-205). Leu3 
is a key transcriptional regulator for branched-chain amino acid metabolism in S. 
cerevisiae (206) and azf1 (207) has also been linked with nitrogen assimilation. This 
information indicates a global regulatory change resulting from the mutant mga2 to 
rewire whole cellular metabolism through the glucose repression and nitrogen 
assimilation.  
There is an increased level of unsaturated fatty acids in the mutant strain and the 
mga2 deletion strain.  This increment should result from upregulated desaturase gene 
expression. Desaturases such as OLE1 in yeast and the mammal homolog Stearoyl-CoA 
desaturase-1 (SCD1) have been shown to be functionally important to fatty acid 
biosynthesis. Deletion of OLE1 (ole1Δ/Δ) in Candida parapsilosis severely impaired  
lipid droplet formation inside the cells (208). Furthermore, increases to SCD1 activity in 
CHO cells is sufficient to increase triglyceride accumulation when supplemented with 
exogenous palmitic acid, and this increased triglyceride synthesis associated with SCD1 
overexpression can also protect against lipoapoptosis (209). In addition, SCD in C. 
elegans also showed an ability to regulate fatty acid biosynthesis (184). Unsaturated fatty 
acid biosynthesis is usually tightly regulated due to its importance to membrane fluidity. 
This elevated unsaturated fatty acids level along with improved lipogenesis indicates that 
regulation over UFA biosynthesis could be one of the bottlenecks for improving 
lipogenesis.   
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Lipogenic organisms provide an ideal platform for biodiesel and oleochemical 
production. However, to fully develop a platform for industrial level production, 
understanding the regulatory aspects of lipogenesis can be very beneficial. In this chapter, 
we successfully identified and confirmed a mutant mga2 protein as a novel lipogenesis 
regulator through whole genome sequencing. This mutant mga2 protein leads to a 
superior lipid accumulation phenotype and an elevated unsaturated fatty acids level. 
Through probing the transcriptomic changes associated with the mutant mga2, we were 
able to show that mutant mga2 acts to funnel carbon flux to fatty acid biosynthesis. 
Further metabolic engineering of this mutant strain led to a high lipid producer with a 
titer of 25 g/L. The altered fatty acid profile of this strain makes it a unique starting point 
for downstream engineering for tailored oleochemical production. Collectively, the 
information supplied in this chapter along with the identified mutations and the strains 
could accelerate understanding of the complex regulation of lipogenesis as well as the 
creation of a robust, efficient engineering platform for converting carbon sources into 
value-added oleochemicals and biofuels. 
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Figure 6.5 Illustration of mga2 protein with IPT and ANK domains and sequence 
alignment over mga2 and its homologues 
 
 
Blue indicates transmembrane domain, purple indicates low complexity and grey indicates 
unknown region (illustration made by SMART). Sequence alignment is performed using 
clustralW. 
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 Chapter 7: Major findings and proposal for future work 
7.1 Major findings 
 The experiments described herein had three major goals. The first goal was to 
develop tools for controlling gene expression in Yarrowia lipolytica. We first performed 
hybrid promoter engineering by creating a library of promoters with a 400-fold dynamic 
range based on mRNA expression levels. We then created a set of plasmids with a 
dynamic range of 2.7-fold using different promoters upstream of the centromeric region. 
The results presented in Chapters 2 demonstrated that the hybrid promoter approach is an 
efficient strategy for promoter engineering by fusing a core promoter region with 
upstream activation sequences, and the results presented in Chapter 3 illustrated that 
using a promoter repressed centromere could alter the plasmid copy number and 
expression level to enable an additional layer for controlling gene expression. Both 
methods developed here are based on fundamental molecular biology principles, thus, 
could be easily adapted into other organisms with an ill-defined gene expression toolbox. 
Furthermore, the combination of these two methods would further expand the range of 
expression level. 
 The second goal was to metabolically engineer Y. lipolytica for high lipid 
production. In order to achieve this goal, we employed rational and evolutionary 
metabolic engineering strategies. Rational metabolic engineering efforts included 
combinatorially engineering several targets related to lipogenesis, which successfully 
improved the lipid production in this yeast. The lipid content reached upwards of 90% in 
the engineered strain while the initial strain only amassed up to 10% under the same 
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condition. The engineered strain was able to produce over 25 g/L lipid in a bioreactor 
without requiring nitrogen starvation. By further employing a self-developed 
evolutionary engineering method, the lipid production titer exceeded 40 g/L with both 
increased yield and productivity at the same time. Moreover, unlike other rational 
metabolic engineering cases, this improved lipid production was not accompanied by 
decreased biomass. The results here clearly showed a significant improvement over lipid 
production performance in Y. lipolytica through a combination of rational and 
evolutionary metabolic engineering. The evolutionary metabolic engineering method for 
improving lipid production could be easily applied to other microorganisms to enhance 
lipid production.  
 The third goal was to gain novel understanding over the lipogenesis process in Y. 
lipolytica. Through the engineering experiments and whole genome sequencing efforts, 
we successfully identified several lipogenesis enhancers such as DGA1 overexpression, 
PEX10 knockout, UGA2 mutation/knockout. Leucine biosynthetic capacity was also 
identified as essential for high lipogenesis. These findings supplied clues to the basic 
mechanism of lipid accumulation in this yeast; more specifically, they revealed the 
limiting rate of triacylglycerol biosynthesis, the importance of glutamate degradation, and 
the essence of target of rapamycin pathway (TOR) in lipogenesis process. Transcriptomic 
analysis with the evolved strain confirmed the importance of glutamate degradation and 
further illustrated the potential of DHAP serving as a key molecule to high lipogenesis. In 
addition to the knowledge gained from the strain engineering process, we also identified a 
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mutant mga2 protein functioning as a novel lipid enhancer. Further characterization of 
mga2 protein uncovered its function for regulating unsaturated fatty acid biosynthesis in 
Y. lipolytica. Ultimately, this mutant mga2 protein redirected carbon flux towards fatty 
acid biosynthesis using pyruvate as a key intermediate.  
 Overall, through the experiments described in this work, we employed synthetic 
biology concepts rooted in fundamental molecular biology to gain control over gene 
expression and utilized rational metabolic engineering in combination with evolutionary 
engineering to improve lipid production in Y. lipolytica. In addition, we successfully 
identified and characterized a novel lipogenesis enhancer, a mutant mga2 protein. 
Moreover, we performed genomic and transcriptomic analyses to further explore the 
underlying mechanism that contributed to improved lipogenesis. The resulting strains and 
information would serve as stepping stones for industrial development and production 
studies. A recent study of the oleaginous yeast Lipomyces starkeyi fed with soluble starch 
proposed a biodiesel factory gate price of $2.30 per gallon, which is economically viable 
(210). This study suggests that the Y. lipolytica strain with high lipid production titer, 
yield, and productivity developed in this work could serve as an industrial production 
platform. Since the cost of lipid production was strongly influenced by the cost of 
medium nutrients required for cultivation of cells (50%) and the cost of solvent required 
to extract lipids from biomass (25%), decreases in raw materials cost and engineering 
fatty acid secretion in this organism could improve economic viability (210). Furthermore, 
the methodologies, tools, and information gained in this work could be transferred into 
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other microorganisms in order to engineer them for producing a variety of value-added 
chemicals.   
 
7.2 Proposal for future work 
The research described here represents a metabolic engineering flow for 
engineering high lipid production in a microorganism. Since most of the methods and 
targets used here are based on general biological mechanisms and concepts, it would be 
interesting to apply these similar strategies in order to engineer other organisms for high 
lipid production. Although Y. lipolytica is a very attractive host, there are other natural 
hosts that are amenable to industrial-scale processes and have better alternative carbon 
source utilization (more importantly, different types of biomass), such as other 
oleaginous yeasts like L. starkeyi and Rhodosporidium toruloides (211) as well as non-
oleaginous yeast such as Ustilago maydis (212). Specifically, the evolutionary 
engineering scheme developed in this work could be very effective when applied to other 
organisms. 
The information gained from rational metabolic engineering, especially the 
importance of leucine biosynthetic capacity to high lipogenesis is very interesting. 
Although the studies showed here suggest relation to the TOR pathway, detailed study 
could further reveal its function in lipogenesis. Since rapamycin addition actually 
improved lipogenesis as described in Chapter 4, further engineering of the FK506-
binding protein of 12 kDa (FKBP) that binds rapamycin should impact lipogenesis inside 
the cells (213). In addition, RNA-Seq experiments would be especially helpful to 
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illustrate the changes in lipid accumulation with or without the leucine biosynthesis 
capacity. Furthermore, additional analysis of the RNA-Seq results from the evolved strain 
E26 as well as mutant strain L36 could further supply novel understanding over the 
lipogenesis mechanism in this yeast. The importance of DHAP and glutamate 
degradation pathway can be further studied with metabolic engineering strategies such as 
feeding DHAP and overexpression of the GDH2 (glutamate dehydrogenase 2) to examine 
the lipogenesis changes. Nitrogen starvation is also a very key component for lipogenesis. 
While the studies described here test the effect of nitrogen starvation through optimizing 
the carbon/nitrogen ratio in the medium, more detailed genetic modifications could 
supply better understanding underlying this requirement, such as identifying the resulting 
signaling pathway regulation caused by nitrogen starvation through engineering one of 
the key regulatory knot, the URE2/GLN3 transcriptional regulator pairs (214-215). 
Although we studied and characterized the mutant mga2’s function over lipogenesis, the 
results from sequence alignments and previous studies suggested a complex regulation 
and important function over the identified conserved region. Follow-up studies mixed 
with biochemical characterization to identify different processing events and resulting 
phenotype changes could further explain the function of this regulator. More importantly, 
this study could lead to identification of one of the key factors in creating oleaginous 
yeast.   
While high lipid production has been engineered in Y. lipolytica, their actual use 
for industrial scale production would depend on other factors such as its ability to utilize 
alternative carbon sources (xylose, arabinose, cellulose etc.) in addition to the optimal 
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production medium. Thus, engineering Y. lipolytica for xylose consumption is another 
important task. This can be tackled with overexpressing native genes predicted to code 
for xylose metabolic enzymes and complementing with heterologous genes from other 
xylose metabolizing microorganisms such as Scheffersomyces stipitis (216) and 
Piromyces sp. (217).  Furthermore, micronutrients such as minerals and small molecules 
have been studied as beneficial factors to improve growth and hydrocarbon or lipid 
production in algae (218-219). Similar work has been done with oleaginous yeast such as 
Lipomyces starkeyi to improve lipid production (220).  For Y. lipolytica, a medium 
optimization study was performed to improve its heterologous protein production and 
lipase production (146, 221). Mineral supplementation was also studied in order to 
increase erythritol biosynthesis from glycerol in Y. lipolytica (222). However, the effect 
of micronutrients on lipid accumulation has not been studied in detail. More importantly, 
not only the available study is rather limited but also almost all of those have been carried 
with the wild type strain rather than a metabolic engineered strain for increased lipid 
production. The responses to micronutrients from the genetic engineered strains need to 
be addressed in comparison with the wild type strain in order to fully understand their 
impact on lipogenesis in these strains and to enable their complete and optimal utilization 
during lipid production.  
 Collectively, my research led to successfully improving lipid production in Y. 
lipolytica. In doing so, we developed novel promoter engineering and plasmid 
engineering strategies, and an efficient evolutionary engineering method for increasing 
lipid production. Concurrently, we revealed sufficient knowledge over the lipogenic 
144 
 
pathway in this yeast, such as the importance of leucine biosynthetic capacity and the 
novel functions of a mutant mga2 in lipogenesis.  
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Chapter 8: Materials and methods 
8.1 Common materials and methods 
8.1.1 Strains and media 
E. coli strain DH10β was used for all cloning and plasmid propagation.  DH10β 
was grown at 37
o
C with constant shaking in Luria-Bertani (LB) Broth (Teknova) 
supplemented with 50μg/ml ampicillin for plasmid propagation.  Yarrowia lipolytica 
strain PO1f (ATCC # MYA-2613), a leucine and uracil auxotroph devoid of any secreted 
proteasic activity (82) was used for all studies.  Y. lipolytica PO1f containing plasmid was 
routinely cultivated at 30
o
C with constant agitation in YSC-LEU media consisting of 
20g/L glucose purchased from Fisher Scientific, 0.69g/L CSM-Leucine supplement 
purchased from MP Biomedicals, and 0.67g/L Yeast Nitrogen Base purchased from 
Becton, Dickinson, and Company.  Solid media for E.coli and Yarrowia lipolytica was 
prepared by adding 15g/L agar (Teknova) to liquid media.  
8.1.2 Cloning procedures    
All restriction enzymes were purchased from New England Biolabs and all 
digestions were performed according to standard protocols.  PCR reactions were set up 
with recommended conditions using Phusion high fidelity DNA polymerase (Finnzymes). 
Ligation reactions were performed overnight at 16
o
C using T4 DNA Ligase (Fermentas).  
Gel extractions were performed using the GeneClean gel extraction kit purchased from 
MP Biomedicals.  Purification of small DNA fragments (<200 bp) generated during 
plasmid construction were performed using the MERmaid Spin Kit (Qbiogene).  E. coli 
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minipreps were performed using the Zyppy Plasmid Miniprep Kit (Zymo Research 
Corporation). Y. lipolytica minipreps were performed using Zymoprep Yeast Plasmid 
Miniprep II kit (Zymo Research Corporation).  Transformation of E. coli strains was 
performed using the standard electroporator protocols (223).  Transformation of Y. 
lipolytica was performed using the Zymogen Frozen EZ Yeast Transformation Kit II 
(Zymo Research Corporation).  Genomic DNA was extracted from Y. lipolytica using the 
Wizard Genomic DNA Purification kit (Promega). 
8.1.3 Fatty acid characterization by Nile Red staining 
 Nile Red (MP Biomedicals) is commonly utilized to stain oleaginous cellular 
material and can be coupled with fluorescence flow cytometry to gauge relative lipid 
content (125).  Y. lipolytica strains were routinely inoculated from glycerol stock in 
biological triplicate in appropriate media for 72 hours at 30 
o
C with shaking.  Cell 
concentrations were normalized to a specific OD600 for reinoculation in fresh media and 
further incubation.  For assays in which the effect of media formulation was not being 
investigated, this media contained 0.79 g/L CSM (or 0.69 g/L CSM-Leucine if necessary), 
1.7 g/L Yeast Nitrogen Base w/o amino acid and w/o (NH4)2SO4, 80 g/L carbon source, 
and 5 g/L ammonium sulfate, as this formulation was shown to strongly induce lipid 
accumulation in the highest lipid producing strains .  For large experiments, 2 mL 
cultures were utilized to test large number of cultures and were inoculated to an OD600 
=2.5, and larger volume cultures were inoculated to an OD600 = 0.1.  Cultures were 
incubated for two to eight days at 30 
o
C with constant agitation.  2 mL cultures were 
incubated in a rotary drum (CT-7, New Brunswick Scientific) at speed seven.  Flasks 
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were shaken at 225 rpm in a standing incubator, and bioreactors were agitated by rotor at 
no less than 250 rpm and no more than 800 rpm.  To harvest, one OD600 unit of culture 
was spun down at 1000 x g for three minutes and resuspended in 500 μL Phosphate 
Buffered Saline solution (PBS) (Sigma Aldrich).  6 μL of 1 mM Nile Red (dissolved in 
DMSO) was added, and then cells were incubated in the dark at room temperature for 15 
minutes.  Cells were spun down at 1000 x g for three minutes, resuspended in 800 μL ice 
cold water, spun down again, and resuspended again in 800 μL ice cold water.  300 μL of 
stained cells was added to 1ml ice cold water and tested with a FACS Fortessa (BD 
Biosciences), a voltage of 350, a 10,000 cell count, a forward scatter of 125, a side scatter 
of 125, and the 535LP and 585/42BP filters for fluorescence detection using the GFP 
fluorochrome.  Samples were kept on ice and in the dark during the test and fluorescence 
data was analyzed using FlowJo software (Tree Star Inc., Ashland, OR) to compute mean 
fluorescence values. Day-to-day variability was mitigated by analyzing all comparable 
strains on the same day.  An average fluorescence and standard deviation were calculated 
from the mean values of biological replicates.  Stained cells were routinely examined 
with fluorescence microscopy under a 100X oil immersion objective using the FITC 
channel on an Axiovert 200M microscope (Zeiss). 
8.1.5 Bioreactor fermentations 
Bioreactor fermentations were run in minimal media (described above) as batch 
processes.  All fermentations were inoculated to an initial OD600 = 0.1 in 1.5L of media.  
Dissolved oxygen was maintained at 50% of maximum by varying rotor speed between 
250 rpm and 800 rpm with a constant air input flow rate of 2.5 v/v/m. PH was maintained 
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at 3.5 or above with 2.5M NaOH, and temperature was maintained at 28 
o
C. 10-15 mL 
samples were taken every twenty-four hours. 
8.1.4 Lipid, biomass and glucose quantification from samples 
Lipids from approximate 2mg dry weight culture were extracted following the 
procedure described by Folch et al. (224) and modified for yeast (225). Lipid weights 
were determined through gravity method. For biomass, 500ul culture were washed and 
dried overnight in 65 
o
C until the weight become constant. Glucose concentrations were 
measured with supernant from bioreactor samples using Glucose (HK) Assay Kit (Sigma 
GAHK) following the manufacturer instruction. 
 
8.2 Materials and methods for Chapter 2 
8.2.1 Calculation of codon adaptation index   
Codon Adaption Indices were calculated for the hrGFP, mStrawberry, EGFP, and 
yECitrine genes using the CAIcal server (226) and the codon usage table for Y. lipolytica 
available on the Codon Usage Database(227).   
8.2.2 Plasmid construction  
Detailed information for primers can be found in Table 8.1. 
Construction of endogenous promoter fluorescence cassettes : All plasmids 
employed for gene expression in Y. lipolytica were centromeric, replicative vectors based 
off plasmid pSl16-Cen1-1(227), which was initially modified to include a new 
multicloning site and redubbed pMCSCen1 (85).  The cyc1 terminator (cyc1t) was 
amplified from p416-TEF-yECitrine (16, 228) and inserted into pMCSCen1 with an 
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EcoNI/BlpI digestion to form pMCScyc1t.  Endogenous promoters EXP1, GPAT, GPD, 
TEF, YAT1, FBA and XPR2 were amplified from Yarrowia lipolytica PO1f genomic 
DNA and ligated into pMCScyc1t using XmaI/AscI for FBA and BstBI/AscI for the rest 
to form pMCS-Promoter serial constructs.  Reporter genes including yECitine (16), 
mStrawberry (pmstrawberry, Clonetech), EGFP (229), hrGFP (pIRES-hrGFP, Agilent) 
and lacZ (230) were amplified and inserted into appropriate pMCS-Promoter constructs 
to form different pMCS-Promoter-Reporter constructs. 
Constructions of UAS1B1-Leum through UAS1B32-Leum expression cassettes: 
Leum (minimal leucine promoter) was amplified from Y. lipolytica genomic DNA and 
ligated into pUC19 plasmid using SphI/HindIII.  Following that, serial and reciprocal 
insertions of UAS1B (upstream activating sequence 1B) elements were performed with 
different restriction sites to form pUC-UAS1Bn-Leum plasmids.  UAS1Bn-Leum 
promoter elements were cut out using BstBI/AscI and inserted upstream of hrGFP and 
lacZ reporter genes in pMCS-Promoter-Reporter constructs (pMCS-hrGFP and pMCS-
lacZ).   
Construction of TEF-based promoters and expression cassettes: TEF serial 
truncation promoters, including TEF(1004), TEF(804), TEF(604), TEF(504), TEF, 
TEF(203), TEF(136), were amplified from Yarrowia lipolytica PO1f genomic DNA and 
inserted in the pUC19 vector (pUC-TEF(n)) and further digested with BstBI/AscI and 
ligated into pMCS-hrGFP to form pTEF(n)-hrGFP.  UAS1B8 and UAS1B16 fragments 
were cut out from the appropriate vectors and ligated into pUC19 vectors to form pUC-
UAS1B8/16.  TEF truncation promoters were amplified and inserted into these vectors 
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using HindIII/AscI resulting in pUC-UAS1B8/16-TEF(n) vectors.  UAS1B8/16-TEF(n) 
promoters were cut out and ligated into the pMCS-hrGFP vector to form pUAS1B8/16-
TEF(n)-hrGFP.   
8.2.3 Promoter characterization with flow cytometry 
Y. lipolytica PO1f strains, transformed with different plasmids, were inoculated 
directly from glycerol stock (in biological duplicate or triplicate) in YSC-LEU media for 
48 hours at 30
o
C with shaking, and then normalized to an OD600 of 0.03 in 2ml fresh 
YSC-LEU and incubated for another 48 hours at 30
o
C in a rotary drum (CT-7, New 
Brunswick Scientific) at speed seven.  To harvest, the cultures were spun down at 500g 
for five minutes, washed in cold water, and resuspended in 5ml ice cold water before 
testing with a FACSCalibur (BD Biosciences) using 488nm excitation; FL1 detector; and 
10,000 cell count for hrGFP detection.  Standard, optimized protocols were used for other 
reporter proteins tested in this chapter.  The samples were kept on ice during the test and 
the data was analyzed using FlowJo software (Tree Star Inc., Ashland, OR) to compute 
mean fluorescence values. 
8.2.4 Promoter characterization through β–galactosidase assay  
Y. lipolytica PO1f strains, transformed with different plasmids, were inoculated 
directly from glycerol stock (in biological triplicate) in YSC-LEU media for 48 hours at 
30
o
C in a rotary drum (CT-7, New Brunswick Scientific) at speed seven, and then 
normalized to an OD600 of 0.03 in 2ml fresh YSC-LEU and incubated for another 48 
hours in the same conditions.  The cultures were washed twice in 1ml Z buffer , 
resuspended in 1 ml of Z buffer, and their OD600 readings were recorded (93-94).  β-
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galactosidase assays were performed as described by Miller (93) using 10μl of 
chloroform-permeabilized cells, with a reaction length of 17 minutes.  
8.2.5 Promoter characterization through qRT-PCR  
Y. lipolytica PO1f strains, transformed with different plasmids, were inoculated 
directly from glycerol stock (in biological triplicate) in YSC-LEU media for 48 hours at 
30
o
C with shaking, and normalized to an OD600 = 0.03 in 2ml fresh YSC-LEU media and 
incubated for another 48 hours at 30
o
C in a rotary drum (CT-7, New Brunswick Scientific) 
at speed seven.  The cells were pelleted and total RNA was extracted using the 
RiboPureTM-Yeast Kit (Ambion).  1000ng of RNA from each sample was used for a 
reverse transcription reaction with the High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems).  A 1.2μl sample from each reaction was used to set up a qPCR 
reaction (in triplicate) with FastStart SYBR Green Master (Roche) using primers 5’-
TCAGCGACTTCTTCATCCAGAGCTTC-3’ and 5’-
ACACGAACATCTCCTCGATCAGGTTG-3’ as described in the manual with a non-
template control.  The reactions were run with Applied Biosystems 7900HT Fast Real-
Time PCR System (Applied Biosystems) using fast 96 well plates (Applied Biosystems). 
The data was analyzed with ABI 7900HTsequence detection systems (version 2.4; 
Applied Biosystems). 
8.2.6 Plasmid stability test   
Y. lipolytica PO1f strains containing plasmids pUAS1B12-Leum-hrGFP or 
pUAS1B16-Leum-hrGFP were grown for 48 hours from glycerol stock and thereafter 
subcultured in fresh YSC-LEU media at an OD600=0.01 every 48 hours.  After a total 
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continuous culture time of 192 hours, corresponding to 36 cell doublings, yeast cells were 
miniprepped to extract the plasmid.  Individual plasmids were isolated by transformation 
into E. coli, and sequencing and restriction enzymes digests of isolated plasmids were 
used to confirm the stability of the UAS1B12-Leum and UAS1B16-Leum promoters over 
this timeframe.   
 
Table 8.1 Primers used for Chapter 2 
Primer                                          Sequence (5’-3’) 
JB085           CGGGATCCCCCCCGGGAATTCGAATTGGCGCGCCCCTTAATT 
                     AAGGCACGTGCCTAAAAAAGGCGGACCGGGCTTAGCTTGTTT 
                     AAACAACTGCAGTTTT 
JB088          GGTTCGAAGACGCAGTAGGATGTCCTGCA  
JB089          TTGGCGCGCCGTTGATGTGTGTTTAATTCAAGAATGA 
JB090          GG TTCGAAATAAGTTTGCAAAAAGATCGTATTATAGT 
JB091          TTGGCGCGCCTTGTGAATTAGGGTGGTGAGA  
JB092          TCCCCCCGGGTAAACAGTGTACGCAGTACTATAGA 
JB093          TTGGCGCGCCGGAGAGCTGGGTTAGTTTGT 
JB094          GG TTCGAACAACTTTTCTTGTCGACCTGAGAT  
JB095          TTGGCGCGCCTTAGCGTGTCGTGTTTTTGTTGT  
JB096          GGTTCGAAGGAGTTTGGCGCCCGTTTTT  
JB097          TTGGCGCGCCTGCTGTAGATATGTCTTGTGTGTAAGGG 
JB099           AAAACTGCAGTTGTTTAAACAAGCTAAGCCCGGTCCGCCTT 
                     TTTTAGGCACGTGCCTTAATTAAGGGGCGCGCCAATTCGAA  
                     TTCCCGGGCCGGATCCCG 
JB102          GGCCTAAAAAAGGATCGATACCGTCGACCTCGAG  
JB103           GGGCTTAGCCGAGCGTCCCAAAACCTTCTC 
JB153          TTGGCGCGCCATGGTGAGCAAGGGCGAGGA 
JB155          CCTTAATTAACTACTTGTACAGCTCGTCCATGCC 
JB156          TTGGCGCGCCATGTCTAAAGGTGAAGAATTATTCA 
JB158          CCTTAATTAATTATTTGTACAATTCATCCATACCA  
JB160          TTGGCGCGCCATGGTGAGCAAGCAGATCCTGAAG  
JB161          CCTTAATTAATTACACCCACTCGTGCAGGC 
JB162          ACATGTGCATGCACTGATCACGGGCAAAAGTGCGTATATAT 
JB163          CAACCCAAGCTTTTAGTTTCGGGTTCCATTGTGG 
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JB164          GACACGCGTCGACCTGAGGTGTCTCACAAGTGC 
JB165          GACACATGCATGCCCGGATCGAGGTGGGCGGG 
JB166          GACACATGCATGCGAGCTCCCGGATCGAGGTGGGCGGG   
JB167          CGCGGATCCCTGAGGTGTCTCACAAGTGCC  
JB168          GACACGCGTCGACCCGGATCGAGGTGGGCGGG  
JB169          CACACACGAGCTCCTAGTCTAGACTGAGGTGTCTCACAAGTGCC  
JB170          CGCGGATCCCCGGATCGAGGTGGGCGGG  
JB171          CACACACGAGCTCCTGAGGTGTCTCACAAGTGCC 
JB172          CTAGTCTAGACCGGATCGAGGTGGGCGGG 
JB173          CCGGAATTCCTGAGGTGTCTCACAAGTGCC  
JB174          CACACACGAGCTCCTGAGGTGTCTCACAAGTGC  
JB177           CTGAGGTGTCTCACAAGTGCCGTGCAGTCCCGCCCCCACTT 
                     GCTTCTCTTTGTGTGTAGTGTACGTACATTATCGAGA 
         CCGTTGTTCCCGCCCACCTCGATCCGG 
JB178           CCGGATCGAGGTGGGCGGGAACAACGGTCTCGATAA 
                      TGTACGTACACTACACACAAAGAGAAGCAAGTGGGG 
                      GCGGGACTGCACGGCACTTGTGAGACACCTCAG 
JB249          CATATGCGGTGTGAAATACCGC 
JB250          GGAATTCGGGTACCAACTGCAGTTCGAAACTGGCCGTCGTT 
                     TTACAAC  
JB251          AAGCTTCAGGCGCGCCATCATGGTCATAGCTGTTTCCTG 
JB252          CCCACATGTTCTTTCCTGCGTTATCC 
JB253          GGAATTCAACTGCAGACTGGCCGTCGTTTTACAAC 
JB254          ACATACATGCATGCGGTACCCGGGCAAAAGTGCGTATAT 
                     ATACAA 
JB289          GGAATTCCATATGTGTAAAACGACGGCCAGTTTCGAAGGT 
                     ACCAAGGAAGCATGCCTGCAGAAGCTTGGGAAGA 
JB290           TCTTCCCAAGCTTCTGCAGGCATGCTTCCTTGGTACCT 
                     TCGAAACTGGCCGTCGTTTTACACATATGGAATTCC 
JB311           TTGGCGCGCCATGACCATGATTACGGATTCACTG 
JB312           ACTGTTGGCGCGCCACCATGATTACGGATTCACTGGC 
JB313          CCTTAATTAATTATTTTTGACACCAGACCAACTGG 
LQ9              CCAATTGGTTCGAAATGTCCCAACTTGCCAAATT 
LQ10            CCAATTGGTTCGAAATTGCACCCCAGCCAGACCG 
LQ12            CCAATTGGTTCGAATTGCGTTTCGCTCCCACAC 
LQ13            CCAATTGGTTCGAATCTGTAAAAAGTCTCTACAAG 
LQ14            CCAATTGGTTCGAATTGTGGTTGGGACTTTAG 
LQ15            CCAATTGGTTCGAATTTCTTTGTCTGGCCATC 
LQ16            CCAATTGGTTCGAACCCACACTTGCCGTTAAG 
LQ17            TTAAAGCTTAGAGACCGGGTTGGCG 
LQ18            TATAAGCTTGGCGCGCCTCATTTTGAATGATTCTTATAC 
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LQ19            CCAATTGGTTCGAACGGGCAAAAGTGCGTAT 
LQ20            TTGGCGCGCCTGAAGCTTTTAGTTTCG 
LQ25            CCAATTGGAAGCTTATGTCCCAACTTGCCAAATT 
LQ26            CCAATTGGAAGCTTATTGCACCCCAGCCAGACCG 
LQ28            CCAATTGGAAGCTTTTGCGTTTCGCTCCCACAC 
LQ29            CCAATTGGAAGCTTTCTGTAAAAAGTCTCTACAAG 
LQ30            CCAATTGGAAGCTTTTGTGGTTGGGACTTTAG 
LQ31            CCAATTGGAAGCTTTTTCTTTGTCTGGCCATC 
LQ32            CCAATTGGAAGCTTCCCACACTTGCCGTTAAG 
   
 
8.3 Materials and methods for Chapter 3 
8.3.1 Plasmid construction 
Primer sequences can be found in the primer list in Table 8.2. All plasmids 
employed for gene expression in Y. lipolytica were centromeric, replicative vectors based 
on plasmid pSl16-Cen1-1(227) (85), which was initially modified to pMCSCEN1 (103). 
Promoters with partial open reading frame TEF(404), TEF(272), TEF(136) (primer pair 
LQ105/LQ110, LQ106/LQ110, LQ107/LQ110), GPD (LQ125/LQ126), EXP 
(LQ127/LQ128), POT1 (LQ123/LQ124), CDC2 (LQ172/LQ173), MET2 
(LQ170/LQ171), YOX1 (LQ178/LQ179) were amplified from Y. lipolytica PO1f 
genomic DNA and ligated into pMCSCEN1 by using KpnI/NdeI and then digested out 
Promoter-CEN region with NdeI/BstBI and ligated into pMCSUAS1B16-LeumhrGFP 
(103). CDC2 and POT1-CEN regions were digested out with BglII/XmaI and ligated into 
pMCSUAS1B16-LeumlacZ and pMCSEXPlacZ (103). 
8.3.2 Plasmid characterization with flow cytometry 
Y. lipolytica PO1f strains, transformed with different plasmids, were inoculated 
directly from glycerol stock (in biological triplicate) in YSC-LEU media for 48 hours at 
30
o
C with shaking, and then normalized to an OD600 of 0.03 in 2ml fresh YSC-LEU and 
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incubated for another 48 hours at 30
o
C in a rotary drum (CT-7, New Brunswick Scientific) 
at speed seven. To harvest, the cultures were spun down at 500g for five minutes, washed 
in cold water, and resuspended in 5ml ice cold water before testing with a FACS 
LSRFortessa (BD Biosciences) using 488nm excitation; FL1 detector; and 10,000 cell 
count for hrGFP detection. The samples were kept on ice during the test and the data was 
analyzed using FlowJo software (Tree Star Inc., Ashland, OR) to compute mean 
fluorescence values. The sorting was performed with FACSAria Cell Sorter (BD 
Biosciences) using the same setting to collect 10^6 cells from two subpopulation.  
8.3.3 Plasmid characterization through β–galactosidase assay 
Y. lipolytica PO1f strains, transformed with different plasmids, were inoculated 
directly from glycerol stock (in biological triplicate) in YSC-LEU media for 48 hours at 
30
o
C in a rotary drum (CT-7, New Brunswick Scientific) at speed seven, and then 
normalized to an OD600 of 0.03 in 2ml fresh YSC-LEU and incubated for another 48 
hours in the same conditions. The cells were characterized using Gal-Screen™ β-
Galactosidase Reporter Gene Assay System for Yeast or Mammalian Cells (life 
technologies) following manufacturer’s manual.  
8.3.4 Plasmid copy number characterization through qRT-PCR 
Y. lipolytica PO1f strains, transformed with different plasmids, were inoculated 
directly from glycerol stock (in biological triplicate) in YSC-LEU media for 48 hours at 
30
o
C with shaking, and normalized to an OD600 = 0.03 in 2ml fresh YSC-LEU media and 
incubated for another 48 hours at 30
o
C in a rotary drum (CT-7, New Brunswick Scientific) 
at speed seven. Plasmid copy numbers were quantified using quantitative PCR (qPCR) 
from the total DNA extracts. Total DNA extraction was performed as described 
previously (107). Lyticase from Arthrobacter luteus was purchased from Sigma Aldrich 
(St. Louis, MO). Quantitative PCR was performed on a ViiA7 qPCR system (Life 
Technologies, Carlsbad, CA) using SYBR Green Master Mix from Roche (Penzberg, 
Germany) with primer set 5’-TCAGCGACTTCTTCATCCAGAGCTTC-3’ and 5’-
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ACACGAACATCTCCTCGATCAGGTTG-3’, following the manufacturer's instructions 
with an annealing temperature of 58 °C and 1 μL of total DNA extract per 20-μL reaction 
volume.  
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Table 8.2 Primers used for Chapter 3 
Primer Descriptions Sequences 
LQ105 Translation elongation factor EF-
1α promoter (P-TEF) forward 
primer 
ACTGCATATG AGAGACCGGGTTGGCG 
LQ106 Truncated translation elongation 
factor EF-1α  promoter (P-
TEF(272)) forward primer 
ACTGCATATG CCCACACTTGCCGTTAAG 
LQ107 Truncated translation elongation 
factor EF-1α  promoter (P-
TEF(136)) forward primer 
ACTGCATATG TTGTGGTTGGGACTTTAG 
LQ110 Translation elongation factor EF-
1α promoter (P-TEF) reverse 
primer 
ACTGGGTACC AACGTGAGTCTTTTCC 
LQ123 3-ketoacyl-CoA thiolase, 
peroxisomal promoter (P-POT1) 
forward primer 
GTACATATG GGAGGCGACGTGGCAG 
LQ124 3-ketoacyl-CoA thiolase, 
peroxisomal promoter (P-POT1) 
reverse primer 
TACGGTACC TTGGCGGGGTTCTGCTC 
LQ125 Glyceraldehyde-3-phosphate 
dehydrogenase promoter (P-
GPD) forward primer 
GTACATATG ATGATAGTTGGGGGTGTG 
LQ126 Glyceraldehyde-3-phosphate 
dehydrogenase promoter (P-
GPD) reverse primer 
TACGGTACC GCCTCGACCTTGCCCTTG 
LQ127 Export protein (P-EXP1) forward 
primer 
GTACATATG GGAGTTTGGCGCCCGTT 
LQ128 Export protein (P-EXP1) reverse 
primer 
TACGGTACC GCAAACATGAAAATGAG 
LQ170 homoserine O-acetyltransferase 
possible  transmembrane segment 
(P-MET2) forward primer 
GTACATATG AAACTCGCGAGAAAAAAAG 
LQ171 homoserine O-acetyltransferase 
possible  transmembrane segment 
(P-MET2) reverse primer 
TACGGTACC AGTCCCGAGAAGGGGTTTTC 
LQ172 CDC2 DNA-directed DNA 
polymerase delta catalytic 125 
KD subunit (P-CDC2) forward 
primer 
GTACATATG AAAACAGGAAAAGCGCA 
LQ173 CDC2 DNA-directed DNA 
polymerase delta catalytic 125 
KD subunit (P-CDC2) reverse 
primer 
TACGGTACC ACGTCGTCGCCCGTTCGC 
LQ178 YOX1 homoeodomain protein 
(p-YOX1) forward primer 
GTACATATG GTACAATGATCCGGGCG 
LQ179 YOX1 homoeodomain protein 
(p-YOX1) reverse primer 
TACGGTACC GACGAGGTCTCGTGCTTG 
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8.4 Materials and methods for Chapter 4 
8.4.1 Base strains and media 
 Table 8.3 contains a complete list of PO1f derivatives produced in this chapter.  Y. 
lipolytica was cultivated at 30 
o
C unless otherwise stated with constant agitation.  2 mL 
cultures of Y. lipolytica used in large-scale screens were grown in a rotary drum (CT-7, 
New Brunswick Scientific) at speed seven, and larger culture volumes were shaken in 
flasks at 225 rpm or fermented in a bioreactor. 
YSC media consisted of 20 g/L glucose (Fisher Scientific), 0.79 g/L CSM 
supplement (MP Biomedicals), and 6.7 g/L Yeast Nitrogen Base w/o amino acids 
(Becton, Dickinson, and Company).  YSC-URA, YSC-LEU, and YSC-LEU-URA media 
contained 0.77 g/L CSM-Uracil, 0.69 g/L CSM-Leucine, or 0.67 g/L CSM-Leucine-
Uracil in place of CSM, respectively.  YPD media contained 10 g/L yeast extract (Fisher 
Scientific), 20 g/L peptone (Fisher Scientific) and 20 g/L glucose, and was often 
supplemented with 300 μg mL-1 Hygromycin B (Invitrogen) for knockout selection.  
Lipid accumulation response towards media formulation was investigated by cultivation 
in varying concentrations of glucose and nitrogen.   These media formulations contained 
0.79 g/L CSM, 1.7 g/L Yeast Nitrogen Base w/o amino acid and w/o (NH4)2SO4 (Becton, 
Dickinson, and Company), between 20 g/L and 160 g/L glucose, and between 0.2 g/L and 
5 g/L ammonium sulfate - (NH4)2SO4 (Fisher Scientific) – which corresponds to between 
0.055 g/L and 1.365 g/L ammonium.  Minimal media formulations utilized for bioreactor 
fermentations typically contained 80 g/L glucose and 6.7 g/L Yeast Nitrogen Base w/o 
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amino acids (1.7 g/L YNB and 5 g/L (NH4)2SO4).  When utilizing alternative carbon 
sources, glucose was replaced by 80 g/L arabinose (Fisher Scientific), 80 g/L fructose 
(Alfa Aesar), 80 g/L galactose (Fisher Scientific), 80 g/L glycerol (Fisher Scientific), 80 
g/L mannose (Alfa Aesar), 80 g/L maltose (Acros Organics),  80 g/L ribose (MP 
Biomedicals), 80 g/L sucrose (Acros Organics), or 80 g/L Xylose (Acros Organics).   
Leucine (MP Biomedicals) and isoleucine (Sigma Aldrich) supplementation was used to 
analyze the effect of leucine biosynthetic capacity.  Leucine was added at a concentration 
of 0.8 g/L or 1.6 g/L, while isoleucine was added at concentration of 1.6 g/L.  Inhibition 
of the TOR protein was caused by supplementation with 200 ng/mL rapamycin (LC 
Laboratories).   
Table 8.3 Strain information for Chapter 4 
Host Strain Name Genotype 
Reference or 
Source 
Escherichia coli strains 
DH10B 
F
-
 mcrA Δ(mrr-hsdRMS-mcrBC) 
Φ80dlacZΔM15 ΔlacX74 endA1 recA1 deoR 
Δ(ara,leu)7697 araD139 galU galK 
nupG rpsL λ 
OpenBiosystems 
Yarrowia lipolytica base strains 
PO1f MatA, leucine-, uracil-, xpr2-322, axp1-2 (82) 
pex10 
MatA, leucine-, uracil-, xpr2-322, axp1-2, 
Δmfe1 
(117) 
mfe1 
MatA, leucine-, uracil-, xpr2-322, axp1-2, 
Δpex10 
(117) 
pex10 mfe1 
MatA, leucine-, uracil-, xpr2-322, axp1-2, 
Δpex10, Δmfe1  
This work 
Yarrowia lipolytica overexpression strains 
PO1f background 
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PO1f uracil
+
 MatA, leucine-, uracil+, xpr2-322, axp1-2 
This work 
PO1f leucine
+
 MatA, leucine+, uracil-, xpr2-322, axp1-2 
This work 
PO1f leucine
+
 uracil
+
 MatA, leucine+, uracil+, xpr2-322, axp1-2 
This work 
PO1f leucine
+ 
Epi 
MatA, leucine+, uracil-, xpr2-322, axp1-2 
This work 
PO1f uracil
+
 AMPD 
MatA, leucine-, uracil+, xpr2-322, axp1-2, 
AMPD 
This work 
PO1f leucine
+
 AMPD 
MatA, leucine+, uracil-, xpr2-322, axp1-2, 
AMPD 
This work 
PO1f uracil
+
 MAE 
MatA, leucine-, uracil+, xpr2-322, axp1-2, 
MAE 
This work 
PO1f leucine
+
 MAE 
MatA, leucine+, uracil-, xpr2-322, axp1-2, 
MAE 
This work 
PO1f leucine
+
 uracil
+
 
AMPD MAE 
MatA, leucine+, uracil+, xpr2-322, axp1-2, 
AMPD, MAE 
This work 
PO1f leucine
+
 DGA1 Epi 
MatA, leucine+, uracil-, xpr2-322, axp1-2, 
DGA1 
This work 
PO1f leucine
+
 DGA2 Epi 
MatA, leucine+, uracil-, xpr2-322, axp1-2, 
DGA2 
This work 
PO1f leucine
+
 DGA1 
MatA, leucine+, uracil-, xpr2-322, axp1-2, 
DGA1 
This work 
mfe1 background 
mfe1 uracil
+
 MatA, leucine-, uracil+, xpr2-322, axp1-2, 
mfe1 
This work 
mfe1 leucine
+
 MatA, leucine+, uracil-, xpr2-322, axp1-2, 
mfe1 
This work 
mfe1 leucine
+
 uracil
+
 MatA, leucine+, uracil+, xpr2-322, axp1-2, 
mfe1 
This work 
mfe1 uracil
+
 AMPD 
MatA, leucine-, uracil+, xpr2-322, axp1-2, 
mfe1, AMPD 
This work 
mfe1 leucine
+
 AMPD 
MatA, leucine+, uracil-, xpr2-322, axp1-2, 
mfe1, AMPD 
This work 
mfe1 uracil
+
 MAE 
MatA, leucine-, uracil+, xpr2-322, axp1-2, 
mfe1, MAE 
This work 
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mfe1 leucine
+
 MAE 
MatA, leucine+, uracil-, xpr2-322, axp1-2, 
mfe1, MAE 
This work 
mfe1 leucine
+
 uracil
+
 
AMPD MAE 
MatA, leucine+, uracil+, xpr2-322, axp1-2, 
mfe1, AMPD, MAE 
This work 
mfe1 leucine
+
 uracil
+
 
ACL1 ACL2 
MatA, leucine+, uracil+, xpr2-322, axp1-2, 
mfe1, ACL1, ACL2 
This work 
mfe1 leucine
+
 DGA1 Epi 
MatA, leucine+, uracil-, xpr2-322, axp1-2, 
mfe1, DGA1 
This work 
mfe1 leucine
+
 DGA2 Epi 
MatA, leucine+, uracil-, xpr2-322, axp1-2, 
mfe1, DGA2 
This work 
mfe1 leucine
+
 DGA1 
MatA, leucine+, uracil-, xpr2-322, axp1-2, 
mfe1, DGA1 
This work 
mfe1 leucine
+
 DGA2 
MatA, leucine+, uracil-, xpr2-322, axp1-2, 
mfe1, DGA2 
This work 
pex10 background 
pex10 uracil
+
 MatA, leucine-, uracil+, xpr2-322, axp1-2, 
pex10 
This work 
pex10 leucine
+
 MatA, leucine+, uracil-, xpr2-322, axp1-2, 
pex10 
This work 
pex10 leucine
+
 uracil
+
 MatA, leucine+, uracil+, xpr2-322, axp1-2, 
pex10 
This work 
pex10 uracil
+
 AMPD 
MatA, leucine-, uracil+, xpr2-322, axp1-2, 
pex10, AMPD 
This work 
pex10 leucine
+
 AMPD 
MatA, leucine+, uracil-, xpr2-322, axp1-2, 
pex10, AMPD 
This work 
pex10 uracil
+
 MAE 
MatA, leucine-, uracil+, xpr2-322, axp1-2, 
pex10, MAE 
This work 
pex10 leucine
+
 MAE 
MatA, leucine+, uracil-, xpr2-322, axp1-2, 
pex10, MAE 
This work 
pex10 leucine
+
 uracil
+
 
AMPD MAE 
MatA, leucine+, uracil+, xpr2-322, axp1-2, 
pex10, AMPD, MAE  
This work 
pex10 leucine
+
 DGA1 Epi 
MatA, leucine+, uracil-, xpr2-322, axp1-2, 
pex10, DGA1 
This work 
pex10 leucine
+
 DGA2 Epi 
MatA, leucine+, uracil-, xpr2-322, axp1-2, 
pex10, DGA2 
This work 
pex10 leucine
+
 DGA1 
MatA, leucine+, uracil-, xpr2-322, axp1-2, 
pex10, DGA1 
This work 
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pex10 mfe1 background 
pex10 mfe1 uracil
+
 MatA, leucine-, uracil+, xpr2-322, axp1-2, 
pex10, mfe1 
This work 
pex10 mfe1 leucine
+
 MatA, leucine+, uracil-, xpr2-322, axp1-2, 
pex10, mfe1 
This work 
pex10 mfe1 leucine
+
 
uracil
+
 
MatA, leucine+, uracil+, xpr2-322, axp1-2, 
pex10, mfe1 
This work 
pex10 mfe1 uracil
+
 AMPD 
MatA, leucine-, uracil+, xpr2-322, axp1-2, 
pex10, mfe1, AMPD 
This work 
pex10 mfe1 leucine
+
 
AMPD 
MatA, leucine+, uracil-, xpr2-322, axp1-2, 
pex10, mfe1, AMPD 
This work 
pex10 mfe1 uracil
+
 MAE 
MatA, leucine-, uracil+, xpr2-322, axp1-2, 
pex10, mfe1, MAE 
This work 
pex10 mfe1 leucine
+
 MAE 
MatA, leucine+, uracil-, xpr2-322, axp1-2, 
pex10, mfe1, MAE 
This work 
pex10 mfe1 leucine
+
 
uracil
+
 AMPD MAE 
MatA, leucine+, uracil+, xpr2-322, axp1-2, 
pex10, mfe1, AMPD, MAE 
This work 
pex10 mfe1 leucine
+
 
uracil
+
 ACL1 ACL2 
MatA, leucine+, uracil+, xpr2-322, axp1-2, 
pex10, mfe1, ACL1, ACL2 
This work 
pex10 mfe1 leucine
+
 
DGA1 Epi 
MatA, leucine+, uracil-, xpr2-322, axp1-2, 
pex10, mfe1, DGA1 
This work 
pex10 mfe1 leucine
+
 
DGA2 Epi 
MatA, leucine+, uracil-, xpr2-322, axp1-2, 
pex10, mfe1, DGA2 
This work 
pex10 mfe1 leucine
+
 
uracil
+
 DGA1 Epi 
MatA, leucine+, uracil+, xpr2-322, axp1-2, 
pex10, mfe1, DGA1 
This work 
pex10 mfe1 leucine
+
 
DGA1 
MatA, leucine+, uracil-, xpr2-322, axp1-2, 
pex10, mfe1, DGA1 
This work 
pex10 mfe1 uracil
+
 DGA1 
MatA, leucine+, uracil-, xpr2-322, axp1-2, 
pex10, mfe1, DGA1 
This work 
pex10 mfe1 leucine
+
 
uracil
+
 DGA1 
MatA, leucine+, uracil+, xpr2-322, axp1-2, 
pex10, mfe1, DGA1 
This work 
pex10 mfe1 leucine
+
 
uracil
+
 AMPD DGA1 
MatA, leucine+, uracil+, xpr2-322, axp1-2, 
pex10, mfe1, AMPD, DGA1 
This work 
pex10 mfe1 leucine
+
 
uracil
+
 MAE DGA1 
MatA, leucine+, uracil+, xpr2-322, axp1-2, 
pex10, mfe1, MAE, DGA1 
This work 
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8.4.2 Cloning and transformation procedures 
 All restriction enzymes were purchased from New England Biolabs and all 
digestions were performed according to standard protocols.  PCR reactions were set up 
with recommended conditions using Phusion high fidelity DNA polymerase (Finnzymes), 
or LongAmp Taq DNA polymerase (New England Biolabs).  Ligation reactions were 
performed overnight at room temperature using T4 DNA Ligase (Fermentas).  Gel 
extractions were performed using the Fermentas GeneJET extraction kit purchased from 
Fisher ThermoScientific.  E. coli minipreps were performed using the Zyppy Plasmid 
Miniprep Kit (Zymo Research Corporation).  E. coli maxipreps were performed using the 
Qiagen HiSpeed Plasmid Maxi Kit.  Transformation of E. coli strains was performed 
using standard electroporator protocols (223). Large amounts of linearized DNA (>20 μg), 
necessary for Y. lipolytica PO1f transformation were cleaned and precipitated using a 
standard phenol:chloroform extraction followed by an ethanol precipitation. 
Transformation of Y. lipolytica with episomal expression plasmids was performed 
using the Zymogen Frozen EZ Yeast Transformation Kit II (Zymo Research Corporation), 
with plating on YSC-LEU plates.  Transformation of Y. lipolytica PO1f with linearized 
cassettes was performed as described previously (117), with selection on appropriate 
plates.  Briefly, Y. lipolytica strains were inoculated from glycerol stock directly into 10 
mL YPD media, grown overnight, and harvested at an OD600 between 9 and 15 by 
centrifugation at 1000 x g for 3 minutes.  Cells were washed twice in sterile water.  10
8
 
cells were dispensed into separate microcentrifuge tubes for each transformation, spun 
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down, and resuspended in 1.0 mL 100 mM LiOAc.  Cells were incubated with shaking at 
30 
oC for 60 minutes, spun down, resuspended in 90 μL 100 mM LiOAc, and placed on 
ice.  1-5 μg of linearized DNA was added to each transformation mixture in a total 
volume of 10 μL, followed by 25 μL of 50 mg mL-1 boiled salmon sperm DNA (Sigma-
Aldrich).  Cells were incubated at 30 
o
C for 15 minutes with shaking, before adding 720 
μL PEG buffer (50% PEG8000, 100 mM LiOAc, pH = 6.0) and 45 μL 2M Dithiothreitol.  
Cells were incubated at 30 
o
C with shaking for 60 minutes, heat shocked for 10 minutes 
in a 39 
o
C water bath, spun down and resuspended in 1 mL sterile water.  200 μL of cells 
were plated on appropriate selection plates.  All auxotrophic or antibiotic selection 
markers were flanked with LoxP sites to allow for retrieval of integrated markers with the 
pMCS-UAS1B16-TEF-Cre replicative vector (117).   
8.4.3 Plasmid construction 
 Primer sequences can be found in the Table 8. 4.  All Y. lipolytica episomal 
plasmids were centromeric, replicative vectors derived from  plasmid pSl16-Cen1-1(227) 
(85) after it had been modified to include a multi-cloning site, a hrGFP green fluorescent 
reporter gene (pIRES-hrGFP, Agilent) driven by the strong UAS1B16-TEF promoter 
(103), and a cyc1 terminator (228) to create plasmid pMCS-UAS1B16-TEF-hrGFP.  
Integrative plasmids were derived from plasmids pUC-S1-UAS1B16-Leum or  pUC-S1-
UAS1B16-TEF (117) that contained 5’ and 3’ rDNA integrative sequences surrounding 
the following elements - (from 5’ to 3’) a uracil section marker surrounded by LoxP sites 
for marker retrieval, the strong UAS1B16-Leum or UAS1B16-TEF promoter, AscI and 
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PacI restriction enzyme sites for gene insertion, and a XPR2 minimal terminator.  These 
integrative plasmids were also designed to contain two identical NotI restriction enzyme 
sites directly outside of the rDNA regions so that plasmid linearization would 
simultaneously remove E. coli pUC19-based DNA.  All plasmids containing expression 
cassettes were sequenced confirmed before transformation into Y. lipolytica.    
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Table 8.4 Primers used for Chapter 4 
JB320 actactacgagctcagcggccgcagatcttggtggtagtagcaaa 
JB387 Ttggcgcgccatgccgcagcaagcaatgg 
JB388 Ccttaattaattaaccatgcagccgctcaaac 
JB402 Ttggcgcgccatgtctgccaacgagaacat 
JB403 Ttggcgcgcctctgccaacgagaacatctc 
JB404 Ccttaattaactatgatcgagtcttggccttg 
JB405 Ttggcgcgccatgtcagcgaaatccattcacg 
JB406 Ttggcgcgcctcagcgaaatccattcacgag 
JB407 Ccttaattaattaaactccgagaggagtggaa 
JB862 ccaccgcggataacttcgtataatgtatgctatacgaagttatgagtctttattggtgatgggaaga 
JB863 cggttcgaaataacttcgtatagcatacattatacgaagttatcagtcgccagcttaaagatatcta 
JB911 cattcaaaggcgcgccatgactatcgactcacaatactaca 
JB912 Gcggatccttaattaattactcaatcattcggaactctgg 
JB913 Cattcaaaggcgcgccatggaagtccgacgacgaaa 
JB914 Gcggatccttaattaactactggttctgcttgtagttgt 
AH020 Gactggcgcgccatgttacgactacgaaccatgc 
AH021 Gtccttaattaactagtcgtaatcccgcacatg 
SJB143 Caaagacgggattttgccac 
SJB165 Ggcatgcactgatcacgg 
SJB165 Ggcatgcactgatcacgg 
SJB173 Catggatctggaggatctcat 
SJB205 Ccggtaccgagctccaataa 
SJB206 Accgatggctgtgtagaagta 
SJB234 gattttgccacctacaagcc   
SJB234 gattttgccacctacaagcc   
SJB234 gattttgccacctacaagcc   
SJB249 Gttttgttcgacttggtatg 
SJB250 Gttttggaaacagaaccttc 
SAH001 Cttaatgcagcctgaaatgaggt 
SAH002 Gcacaaatgacgtggcaaac 
SAH003 Tgtatttccgaatgggtgagag 
SAH004 Cgagtgtgatcaagagtgtctg 
SAH019 Acattgactacattgtcgtgactg 
SAH023 Cagtcgccagcttaaagatatcta 
SAH034 Ctaacagttaatcttctggtaagcct 
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8.4.4 Construction of episomal expression cassettes 
 The following genes were PCR amplified from Y. lipolytica PO1f gDNA and 
inserted into vector pMCS-UAS1B16-TEF-hrGFP in place of hrGFP with an AscI/PacI 
digest: AMPD, ACL subunit 1 (ACL1), ACL subunit 2 (ACL2), MAE1, DGA1, and 
DGA2 with primers JB387/388, JB402/404, JB405/407, AH020/021, JB911/912, and 
JB913/914, respectively.  This formed plasmids pMCS-UAS1B16-TEF-AMPD, pMCS-
UAS1B16-TEF-ACL1, pMCS-UAS1B16-TEF-ACL2, pMCS-UAS1B16-TEF-MAE1, 
pMCS-UAS1B16-TEF-DGA1, and pMCS-UAS1B16-TEF-DGA2. 
A leucine marker containing plasmid containing the Cre-Recombinase gene, 
pMCS-UAS1B16-TEF-Cre enables constitutive, high-level Cre expression(117). 
8.4.5 Construction of integrative expression cassettes 
 The following genes were gel extracted from the previously constructed episomal 
expression vectors and inserted into vector pUC-S1-UAS1B16-TEF with an AscI/PacI 
digest: AMPD, ACL subunit 1 (ACL1), ACL subunit 2 (ACL2), MAE1, DGA1, and 
DGA2.  This formed plasmids pUC-S1-UAS1B16-TEF-AMPD, pUC-S1-UAS1B16-TEF-
ACL1, pUC-S1-UAS1B16-TEF-ACL2, pUC-S1-UAS1B16-TEF-MAE1, and pUC-S1-
UAS1B16-TEF-DGA1, and pUC-S1-UAS1B16-TEF-DGA2.  The loxP-surrounded uracil 
marker of these integrative plasmids was replaced with a loxP-surrounded leucine marker 
created by amplification of pMCSCen1 template with primers JB862/863 followed by 
insertion using a BstBI/SacII digest.  These plasmids enabled integrative selection with 
leucine auxotrophy and co-expression of two enzymes without marker retrieval.  These 
leucine marker integrative plasmids were dubbed plasmids pUC-S2-UAS1B16-TEF-
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AMPD, pUC-S2-UAS1B16-TEF-ACL1, pUC-S2-UAS1B16-TEF-ACL2, pUC-S2-
UAS1B16-TEF-MAE1, and pUC-S2-UAS1B16-TEF-DGA1, and pUC-S2-UAS1B16-TEF-
DGA2. ACL1 and ACL2 were similarly inserted into pUC-S1-UAS1B16-Leum with 
primers JB403/404 and JB406/407, respectively, to form plasmids pUC-S1-UAS1B16-
Leum-ACL1 and pUC-S1-UAS1B16-Leum-ACL2.   
8.4.6 Strain construction 
All strains were confirmed through gDNA extraction and PCR.  We previously 
constructed two markerless single-gene deletion strains in the Y. lipolytica PO1f 
background, PO1f-Δmfe1 and PO1f-Δpex10, deficient in their β-oxidation and 
peroxisomal biogenesis capacity, respectively (117).  Following our previous protocol, 
the PEX10 gene was deleted from strain PO1f-Δmfe1 to form the markerless double 
mutant PO1f-Δmfe1-Δpex10.  These four strains, referred to as PO1f, pex10, mfe1, and 
pex10 mfe1 were utilized as backgrounds for single and double overexpression of the 
AMPD, ACL1, ACL2, MAE1, DGA1, and DGA2 proteins, including variation in 
selective marker utilized, i.e., leucine (chromosomal or episomal expression cassette) vs. 
uracil (chromosomal expression cassette).  Integrative cassettes were linearized, 
transformed into the four background strains, and selected for on appropriate dropout 
plates.  Integrative vectors without open reading frames to express, pUC-S1-UAS1B16-
TEF and pUC-S2-UAS1B16-TEF, were utilized to create strains with leucine, uracil, or 
both leucine and uracil prototrophies, but without enzyme overexpression. 
8.4.7 Lipid quantification and fatty acid profile analysis 
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 Lipids from a 500 μL volume of culture, or approximately 1.0 mg dry cell weight, 
were extracted following the procedure described by Folch et al. (224) and modified for 
yeast (231).  Briefly, Y. lipolytica cells were spun down and washed with water twice, 
and then resuspended in a chloroform/methanol solution (2:1) and vortexed on high with 
glass beads for 20 minutes.  The organic solution was extracted and washed with 0.2 
volumes of 0.3% NaCl solution before being dried at 60 
o
C overnight and weighed to 
quantify lipid production.  Lipids in the culture medium were tested for, but no 
extracellular lipids were detected.  Dry cell weight was determined after washing cells 
twice with H2O and drying overnight at 60 
o
C.  The dried lipids were transesterified with 
N-tert-Butyldimethylsilyl-N-methyltrifluoroacetamide (Sigma-Aldrich) following the 
procedure of (Paik et al., 2009), and 2 μL samples were injected into a GC-FID (Agilent 
Technologies 6890 Network GC System) equipped with an Agilent HP-5 column (5% 
phenyl-95% methylsiloxane - product number 19091J-413) to analyze fatty acid fractions.  
Briefly, the following settings were used: Detector Temp = 300 
o
C, He Flow = 1.0 mL 
min
-1
, Oven Temp = 80 °C for 2 min, increased at 30 °C min
-1
 to 200 °C, increased at 
2 °C min
-1
 to 229 °C, increased at 1 °C min
-1
 to 232 °C, increased at 50 °C min
-1
 to 
325 °C.  Fatty acid standards for C16:0 palmitic acid, C16:1(n-7) palmitoleic acid, C17:0 
heptadecanoic acid, C18:0 stearic acid, C18:1(n-9) oleic acid, and C18:2(n-6) linoleic 
acid were purchased from Sigma-Aldrich, transesterified, and analyzed by GC to identify 
fatty acid peaks.  Similarly, C16:1(n-9) palmitoleic acid was purchased from Cayman 
Chemical and used a standard.  GC-MS confirmation of fatty acid type was performed 
with a Thermo Scientific TSQ Quantum Triple Quad using chemical ionization and a 1.5 
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mL min
-1
 flow rate.  Lipid quantification obtained using both methods converge within an 
error of less than 20%; thus, we determine both methods are suitable for quantifying lipid 
levels in the cells. 
8.4.8 Citric acid quantification 
 A 2 mL culture sample was pelleted down for 5 minutes at 3000 x g, and the 
supernatant was filtered using a 0.2 mm syringe filter (Corning Incorporated).  Filtered 
supernatant was analyzed with a HPLC Ultimate 3000 (Dionex) and a Zorbax SB-Aq 
column (Agilent Technologies).  A 2.0 μL injection volume was used in a mobile phase 
composed of a 99.5:0.5 ratio of 25 mM potassium phosphate buffer (pH=2.0) to 
acetonitrile with a flow rate of 1.25 mL min
-1
.  The column temperature was maintained 
at 30 
o
C and UV–Vis absorption was measured at 210 nm.  A citric acid standard (Sigma-
Aldrich) was used to detect and quantify citric acid production. 
8.4.9 Ammonium quantification 
 1 mL of culture was heated to 80 
o
C for 15 minutes, and then centrifuged at 
17,900 x g for 3 minutes.  Supernatant was stored at 4 
o
C for less than 1 week, and 
ammonium concentration was determined using the R-Biopharm Ammonium Assay kit 
following the manufacturer’s instructions.  Ammonium Assay kit accuracy was assessed 
by measuring ammonium concentration in solutions with varying concentrations of Yeast 
Nitrogen Base w/o amino acids.  Minor necessary adjustments were made using the 
resulting standard curve.   
8.4.10 Bioreactor fermentations 
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 Typically, bioreactor fermentations were run in minimal media (described above) 
as batch processes.  However, one fermentation included a spike of an additional 80 g/L 
glucose at the 72 hour timepoint, and another had a doubled media formulation that 
contained 160 g/L glucose and 13.4 g/L YNB w/o amino acids.  All fermentations were 
inoculated to an initial OD600 = 0.1 in 1.5 L of media.  Dissolved oxygen was maintained 
at 50% of maximum by varying rotor speed between 250 rpm and 800 rpm with a 
constant air input flow rate of 2.5 v v
-1
 min
-1
 (3.75 L min
-1
).  PH was maintained at 3.5 or 
above with 2.5 M NaOH, and temperature was maintained at 28 
o
C.  10-15 mL samples 
were taken every twelve hours, and fermentations lasted 6-7 days.  We ran several 
fermentations with suboptimal conditions before settling on the above parameters.  
Supernatant was diluted 1:10 and glucose concentration was quantified using a YSI Life 
Sciences Bioanalyzer 7100MBS. 
8.4.11 Transesterification 
 Y. lipolytica lipid reserves were transesterified using acid-promoted direct 
methanolysis of cellular biomass (232).  1L of pex10 mfe1 leucine
+
 uracil
+
 DGA1 
fermented in a bioreactor for seven days as described above was washed twice in 400 mL 
water.   Cells were dried on a hotplate at 140 
o
C for 3 hours.  The dried cell mass was 
transesterified with 2% w v
-1
 H2SO4 in 200 mL methanol at a fast boil with reflux and 
constant agitation for 72 hours.  The reaction mixture was centrifuged to remove cellular 
debris.  FAMEs were extracted from the supernatant by adding 0.2 volumes water, 
mixing, centrifuging, and removing the polar phase.  Additional FAMEs were extracted 
172 
 
in the polar phase with a second extraction using 0.4 volume of water.  FAMEs were 
washed in 1 volume of water and analyzed with TLC and GC.    
8.4.12 Protein extraction 
Protein content from 0.5 to 1.0 mL of culture was extracted using the Pierce BCA 
Protein Assay Kit following the manufacturer’s instructions.  Protein concentration (mg 
mL
-1
) was normalized per mL of culture and per culture OD600 to normalize to the 
individual cellular level.  PO1f leucine
+
 uracil
+
 and pex10 mfe1 leucine
+
 uracil
+
 DGA1 
strains were analyzed in this manner after fermentation in a bioreactor.  
 
8.5 Material and Method for Chapter 5 
8.5.1 Culture media 
For testing growth with GABA as a nitrogen source, 1 g/L GABA were added in 
place of ammonia sulfate. Lipid accumulation was promoted by cultivation in media with 
high glucose, containing 80 g/L glucose, 0.79 g/L CSM supplement, 6.7 g/L Yeast 
Nitrogen Base w/ ammonia sulfate w/o amino acid. Minimal media formulations utilized 
for bioreactor fermentations contained 160 g/L glucose and 13.4 g/L Yeast Nitrogen Base 
w/ ammonia sulfate w/o amino acids (3.4 g/L YNB and 10 g/L (NH4)2SO4). Solid media 
for E. coli and Y. lipolytica were prepared by adding 15 g/L agar (Teknova) to liquid 
media formulations. Nile Red plates were made by adding 1mM Nile Red (MP 
biomedicals) stock solution dissolved in DMSO (Fisher Scientific) to a final 
concentration of 1µM.  
8.5.2 Transformation procedures 
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Transformation of Y. lipolytica PO1f with linearized cassettes was performed as 
described previously (233), with selection on appropriate plates. All auxotrophic or 
antibiotic selection markers were flanked with LoxP sites to allow for retrieval of 
integrated markers with the pMCS-UAS1B16-TEF-Cre replicative vector (103).   
8.5.3 Plasmid construction 
Primer sequences can be found in the Table 8.5. All Y. lipolytica episomal 
plasmids were centromeric, replicative vectors derived from plasmid pSl16-Cen1-1(227) 
(85) as described in (103). Integrative plasmids were derived from plasmids pUC-S1-
UAS1B16-TEF as described in (139). All plasmids containing expression cassettes were 
sequence-confirmed before transformation into Y. lipolytica. 
 
Table 8.5 Primers used for Chapter 5 
LQ379 YLUGA2up ACTGGGCGCGCC GTCAGATGGCAGCCCTACATGACG
LQ380 YLUGA2up ACTGGCGGCCGC TGTGTGTGAGAAGGTGCTTACAGAG
LQ381 YLUGA2do ACTGGGCCGGCC GCAAAAATGAGTAGTTTCAAGATT
LQ382 YLUGA2do ACTGGTTTAAAC CAAATATAGATAATAATATAATGTCCGTGA
LQ361 UGA2 for ACTGGCGCGCC ATGTTGCGAGCCCTGAATACCGTC
LQ362 UGA2 rev ACT TTAATTAA GATTAAGGCTGAATGTGGGGCTCGAC
LQ363 YOX1 for ACT CCGCGG ATGGATCTGGCGAAAATCACCGA
LQ364 YOX1 rev ACT TTAATTAA TTACCATCGTCCTCCGTTTCGAA
LQ365 OSH6 for ACT GGCGCGCC ATGCACCACCACCTCAACCCCAA
LQ366 OSH6 rev ACT TTAATTAA CTACTGGGCGTCGTGGAACTCGT
Primers
 
 
8.5.4 EMS mutagenesis and high lipid population enrichment 
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The EMS mutagenesis procedures were performed following the protocol 
described by Winston (234). Briefly, an overnight culture was cultivated to OD around 
10. Cells were then harvested, washed and suspended with 0.1M sodium phosphate 
buffer (pH=7). 30µl of EMS was added and incubated along with an unmutagenized 
control for 1 hour at 30°C, with agitation. The cells were then washed with 5% sodium 
thiosulfate and prepared for serial transfer experiments to enrich the high lipid population. 
The EMS treated cells and unmutagenized cells starting OD approximately equals 
5 were first cultured YSC media for 72 hours and then cultured in high glucose media 
(containing 80 g/L glucose, 0.79 g/L CSM supplement, 6.7 g/L Yeast Nitrogen Base w/ 
ammonia sulfate w/o amino acid) for 144 hours. High glucose media has been used here 
to induce lipid accumulation in Y. lipolytica (235). The cells were centrifuged down with 
100 x g for 2 minutes, the unclear supernatant, which contains enhanced lipogenesis 
strains, was used as seed for another round of cultivation after pellet down with starting 
OD approximately equals 0.1. After five rounds of transfer, the cells were plated on Nile 
Red YSC plate to isolate of high lipid production strains. Individual colonies were picked 
from the EMS treated cells as well as the unmutagenized but serial transferred cells 
(spontaneous mutagenesis) for characterization. First round of evolution was performed 
in 15ml culture tubes with 2ml media with starting OD equals 2.5 and the second round 
was done in 500ml flask with 100ml media with starting OD equals 0.1. 
8.5.5 Whole genome sequencing and small nucleotide variation analysis 
Next generation sequencing platform Illumina paired ended sequencing PE 
2X100 were performed with genomic DNA extracted from strain E26 and E13 by 
175 
 
Genomic Sequencing and Analysis Facility in The University of Texas at Austin. 
6,424,381 reads for strain E26 and 6,565,093 reads for strain E13 were collected from 
Illumina HiSeq, which lead to a coverage approximately 65X. The illumina reads were 
mapped to the CLIB122 genome using BWA (236) and analyzed with Samtools (156) 
and BEDTools (157). The SNPs identified were then filtered with SnpSift with 
QUAL >= 30 (237). The SNPs identified from PO1f , EMS26 and EMS13 were 
compared to extract the authentic SNPs in EMS26 and EMS13. The identified SNPs were 
then visualized in the IGV genome visualization software to validate as well as study the 
location of the SNPs in the genome due to the high false error rate in SNP calling process 
(238).  
8.5.6 RNA preparation, sequencing and analysis 
Samples were taken at the early stationary phase of strain PO1f ura+ leu+ and 
E26 (evolved from strain Δpex10, mfe DGA1 ura+ leu+) when growing in with 100ml in 
500ml flask (~48 h). Total RNA was extracted by ™ RNA Purification Kit, yeast (Life 
technologies) according to the manufacturer’s instructions. The RNA quality and quantity 
were determined using Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, 
USA). The RNA integrity number (RIN) of all RNA samples used for sequencing was 
more than 7.0. The RNA samples were then sent to Genomic Sequencing and Analysis 
Facility at The University of Texas at Austin for library preparation and sequencing. The 
sequencing experiments were performed with using illumina Hiseq single end 100bp 
(1X100) platform.  
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The sequence files in FASTQ format were first groomed with FastQC (239). The 
RNA-seq single-end reads were analyzed with TopHat and Cufflinks (240). The reads 
were mapped into transcripts using TopHat by setting the reference genome as Y. 
lipolytica (CLIB122) (65). 18,948,539/19,943,689/18,170,124 reads from triplicates of 
strain E26 and 18,322,608/20,708,616/18,393,515 reads from triplicates of strain PO1f 
ura
+
 leu
+
 were successfully mapped to the reference sequences.  The mapped reads were 
then analyzed by bedtools (157) and edgeR (192) to identify differentially expressed 
genes. The differentially expression were further filtered with log2 > 1 (overexpression) 
or log2 < -1 (downregulation). The gene ontology analysis was performed using DAVID 
(241) with background setting as Y. lipolytica.  
 
8.6 Material and Method for Chapter 6 
8.6.1 Culture media 
YSC media was used for starting cultures, consisted of 20 g/L glucose (Fisher 
Scientific), 0.79 g/L CSM supplement (MP Biomedicals), and 6.7 g/L Yeast Nitrogen 
Base w/ ammonia sulfate w/o amino acids (Becton, Dickinson, and Company). YSC-
LEU media contained 0.69 g/L CSM-Leucine in place of CSM, respectively. Lipid 
accumulation was promoted by cultivation in media with high glucose, containing 80 g/L 
glucose, 0.79 g/L CSM supplement, 2 g/L ammonia sulfate and 1.7 g/L Yeast Nitrogen 
Base w/o ammonia sulfate w/o amino acid for strains with leu
+ 
and ura
+
  and 160 g/L 
glucose, 0.79 g/L CSM supplement, 0.2 g/L ammonia sulfate and 1.7 g/L Yeast Nitrogen 
Base w/o ammonia sulfate w/o amino acid for strains with leu
+
. YPD media contained 10 
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g/L yeast extract (Fisher Scientific), 20 g/L peptone (Fisher Scientific) and 20 g/L 
glucose, and was often supplemented with 300 μg/ml Hygromycin B (Invitrogen) for 
knockout selection. GAA media is the same to YPD media except 50g/L glucose with 
5µM antimycin A (Sigma-Aldrich). The unsaturated fatty acids (UFAs) – oleic (Fisher 
Scientific) and palmitoleic acids (Sigma-Aldrich) – were used at a final concentration of 
0.5mM each. Minimal media formulations utilized for bioreactor fermentations contained 
80 g/L glucose and 3.4 g/L Yeast Nitrogen Base w/o ammonia sulfate w/o amino acids 
and 4 g/L (NH4)2SO4 with another 80g glucose fed at day 3 time point. Solid media for E. 
coli and Y. lipolytica were prepared by adding 15 g/L agar (Teknova) to liquid media 
formulations. Nile Red plates were made by adding 1mM Nile Red (MP biomedicals) 
stock solution dissolved in DMSO (Fisher Scientific) to a final concentration of 1µM.  
8.6.2 Plasmid construction 
Primer sequences can be found in the Table 8.6. Y.lipolytica integrative/knockout 
related plasmids for DGA1 overexpression and PEX10 knockout were described in (117). 
The knockout plasmid for MGA2 was constructed with as described in (117). 
Mga2G643R were cloned with primer pair which including 1500 bps upstream to the 
start codon to keep its native regulation in plasmids pMCSUAS1B16-TEF as described in 
(103) and digested with NdeI/ BamHI to linearized the plasmid for integration. All 
plasmids containing expression cassettes were sequence-confirmed before transformation 
into Y. lipolytica. 
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Table 8.6 Primers used for Chapter 6 
Primer name Sequences
LQ313 mga2KO upf ACTGGGCGCGCC gaaaaggaggtggatcgggtatcg
LQ314 mga2KO upr ACTGGCGGCCGC acacgaacaagcggaagaagtctg
LQ315 mga2KO downf ACTGCCCGGG ctgtgttaggtcctggtgctggag
LQ316 mga2KO downr ACTGGTTTAAAC tgaggttgctgtgtatcgcgacc
LQ331 ProMga2 f ATCG CCCGGG atttctcggacgacaagtcgactagc
LQ309 Mga2 r ACTGTTAATTAA tcatgcagcctgggcctgg  
 
8.6.3 Whole genome sequencing and small nucleotide variation analysis 
Next generation sequencing platform Illumina paired ended sequencing PE 
2X100 were performed with genomic DNA extracted from strain L36 by Genomic 
Sequencing and Analysis Facility in The University of Texas at Austin. 4,706,014 pair-
end reads were collected from Illumina HiSeq, which lead to a coverage approximately 
47X. The illumina reads were mapped to the CLIB122 genome using BWA (236) and 
analyzed with Samtools (156) and BEDTools (157). The SNPs identified were then 
filtered with SnpSift with QUAL >= 30 (237). The SNPs identified from PO1f (242) and 
L36 were compared to extract the authentic SNPs in strain L36. The identified SNPs 
were then visualized in the IGV genome visualization software to validate as well as 
study the location of the SNPs in the genome due to the high false error rate in SNP 
calling process (238).  
8.6.4 RNA-Seq and gene differential expression analysis 
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Total RNA was extracted from triplicates from strains PO1f leu
+
 and PO1f Δmga2 
MGA2g1927a leu+ using RiboPure™ RNA Purification Kit for yeast (life technologies) 
at 36 hour time point with starting OD equals 0.1 in media with 160 g/L glucose, 0.79 g/L 
CSM-LEU supplement and 6.7 g/L Yeast Nitrogen Base w/o amino acid. The polyA 
mRNA capture and sequential RNA-Seq library construction and next generation 
sequencing platform Illumina paired ended sequencing PE 2X100 were performed by 
Genomic Sequencing and Analysis Facility in The University of Texas at Austin. The 
sequence files in FASTQ format were first groomed with FastQC (239). The reads were 
analyzed with TopHat and Cufflinks (240). 8,194,962/13,338,379/14,861,420 reads of the 
triplicates from PO1f leu+ and 12,077,107/6,210,940/13,192,029 reads of the triplicates 
from PO1fΔmga2 MGA2(g1927a) leu+ were mapped into transcripts using TopHat by 
setting the reference genome as Y. lipolytica (CLIB122) (65). The transcripts were 
assembled and the FPKM (fragments per kilobase of exon per million fragments mapped) 
were estimated using Cufflinks with the default parameter settings, followed by 
transcripts merge using Cuffmerge. The assembled transcripts between control group and 
experimental group were compared using Cuffdiff. The differential gene expressions 
were analyzed with bedtools (157) and edgeR (192) for significant expression with output 
bam files from TopHat. The differentially expression were further filtered with log2 > 1 
(overexpression) or log2 < -1 (downregulation) with p-value and FDR both < 0.05. The 
promoter motifs were analysis with SCOPE (243) and the identified motifs were then 
compared with transcriptional factor binding sites sequences in YEASTRACT database 
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(194). The reference sequences and annotation filed were downloaded from Ensembl 
Genomes.  
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